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Abstract 
 
Adequate amounts of copper in milk are critical for normal neonatal 
development, however the mechanisms regulating copper supply to milk 
have not been clearly defined. The mammary gland is an unusual organ as it 
expresses three copper efflux molecules; ATP7A, ATP7B and ceruloplasmin 
(Cp). Analysis of mammary epithelial cells provides the opportunity to 
investigate their interactions. PMC42-LA cell cultures representative of the 
resting (no hormones), lactating (2.7 ng/mL β-estradiol, 157 ng/mL 
progesterone, 1 μg/mL dexamethasone 0.6 μg/mL insulin and 200 ng/mL 
prolactin) and suckled mammary epithelium (similar to the lactating model, 
but with 800 ng/mL prolactin) were used to investigate the role of copper 
transporting proteins in copper homeostasis and to provide insights into the 
delivery of copper to milk. 
 
The addition of copper to cultured mammary epithelial cells reduced the 
presence of CTR1 at the cell membrane and increased the dispersion of 
ATP7A and ATP7B throughout the cells. The dispersion of ATP7A correlated 
with an increase in ATP7A at the plasma membrane, while ATP7B was not 
detected at the membrane in any conditions. These responses to 
extracellular copper suggest that the cells balance cellular copper levels by 
reducing uptake and increasing efflux. Elevated copper conditions also 
augmented the level of the ferroxidase form of Cp which is important in iron 
metabolism. When exposed to high copper levels, the cells did not effectively 
efflux all of the absorbed copper and it accumulated within the cells. 
Expression of metallothionein (MT) correlated with the intracellular copper 
levels, consistent with its role as a metallochaperone 
 xviii 
 
 
Lactational hormones increased the presence of CTR1 at the plasma 
membrane. This correlated with an increased level of copper within the cells. 
ATP7A responded becoming more dispersed, consistent with its role in 
trafficking copper across the basolateral membrane when copper levels are 
elevated. This may be a defensive mechanism to protect a suckling infant 
from receiving too much copper in the milk. However Cp levels are also 
increased which would promote copper secretion into the milk. Increased 
transport of copper across the membranes due to changes in protein 
expression and localisation may enable the cells to easily and quickly redirect 
copper where required, whether across the apical membrane into the milk or 
across the basolateral membrane away from the milk. Syncrotron X-ray 
fluorescence and AAS revealed that the organoids grown in culture 
representing the mammary gland lobules, secrete copper into the lumen of 
the organoid. This effect was enhanced in the presence of lactational 
hormones, reflecting the in vivo conditions of the mammary gland lobules 
during lactation. 
 
ATP7A, a copper efflux protein, was overexpressed in PMC42-LA cells to 
obtain insight into its role in lactation. The impact of this homeostatic 
disturbance on the other copper transporting molecules was investigated. 
The overexpression of ATP7A caused an increase in CTR1 and ATP7B in 
the presence of hormones, responses thought to counteract additional 
movement of copper across the basolateral membrane. Increasing CTR1 and 
ATP7B levels stimulates the movement of copper towards the apical 
membrane for secretion into the milk, thus preventing the secretion of copper 
 xix 
 
deficient milk. Copper levels also regulated ATP7B expression. Most notably 
in the ATP7A overexpressing cells treated with lactational hormones, ATP7B 
levels were reduced in response to high copper levels. This is thought to 
regulate the efflux of copper across the apical membrane into the milk. The 
levels of β2-microglobulin (β2M), a protein involved in iron uptake, increased 
in response to ATP7A overexpression, as did Cp, indicating that 
overexpressing ATP7A not only disturbed copper homoestasis, but also 
impacted upon iron pathways. 
 
A soluble secreted form of Cp as well as membrane bound 
glycosylphosphatidylinositol-linked Cp (GPI-Cp) were detected in the 
PMC42-LA cells. The GPI-Cp expression was unaffected by copper or 
lactational hormones, but increased with ATP7A overexpression similar to 
the secreted Cp. Additionally, an interaction between ATP7B and Cp was 
confirmed, suggesting that Cp receives its copper from ATP7B. No 
interaction between ATP7A and Cp was identified. 
 
In summary, these data highlight the important roles that CTR1, ATP7A, 
ATP7B, Cp and MT play in maintaining copper homeostasis. Additionally, 
they demonstrate the interactions between ATP7A, ATP7B and Cp, that 
control copper efflux across the apical and basolateral membranes to ensure 
safe copper levels within the cells and to provide an adequate supply of 
copper into milk. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
 
Introduction 
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1.1 Copper in biological systems 
Copper is a trace element required for cellular growth and development. It is 
incorporated into a number of enzymes with a multitude of biochemical 
functions (Linder, 1991). Copper binding proteins facilitate strict regulation of 
copper homeostasis by taking up, distributing, storing or effluxing copper as 
required (La Fontaine and Mercer 2007). Imbalances to copper homeostasis 
can have dramatic effects upon cellular functions. Excess copper can be 
detrimental due to its redox properties. Unbound ionic copper can produce 
free radicals in cells, leading to damage of lipids, proteins, RNA and DNA. 
Excess copper can also displace other metal ions from their enzymes leading 
to altered function or inactivation of these enzymes. Copper deficiency can 
lead to the inactivation of copper dependent enzymes. For example, 
inactivation of copper dependent enzymes like Cu/Zn superoxide dismutase, 
a free radical scavenger, can lead to increased oxidative damage. Whereas 
disruption to cytochrome c oxidase due to copper depletion can reduce ATP 
levels which can affect metabolic activity (Pena et al., 1999). 
  
1.2 Copper in humans 
Copper is available to humans through diet, with seafood, meat and seeds 
being the richest sources of copper and to a lesser extent fruit and 
vegetables (Linder and Hazegh-Azam, 1996). Approximately 2.5 mg per day 
is the recommended daily intake with about 75% being absorbed by the 
intestine (Lutsenko et al., 2007a, Vonk et al., 2008), however it has been 
shown that copper uptake is regulated according to body copper 
concentration. Mammals absorb more when their body is deficient and 
absorb less when the body concentrations are sufficient or in excess (Linder, 
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1991, Turnlund, 1998). Copper is absorbed across the intestinal epithelium 
into the portal blood stream where it is transported to the liver (Kuo et al., 
2006, Monty et al., 2005, Nose et al., 2006, Ravia et al., 2005). Before 
entering the portal bloodstream, it is bound to copper chaperone proteins 
including albumin and α2-macroglobulin (Linder et al., 1998, Moriya et al., 
2008). The delivery of copper to these chaperones is critical to prevent the 
toxic effects of its ionic form. Copper is absorbed from the portal vein by the 
liver which is the main regulator of copper homeostasis in the body. When 
required, copper is transferred from liver cells into the main circulatory 
system of the body (Linder et al., 1998). Excess amounts of copper are 
excreted from the body via the biliary canaliculus into the bile and expelled in 
the faeces (Linder et al., 1998, Terada et al., 1999). Bile is the main form of 
copper excretion from the body with 98% of total copper lost through this 
pathway (Wijmenga and Klomp, 2004). Before entering the blood stream 
from the liver, copper is incorporated into ceruloplasmin (Cp) (Linder and 
Hazegh-Azam, 1996, Linder et al., 1998, Terada et al., 1998). While 
circulating around the body, copper is absorbed by cells and incorporated 
into cuproenzymes, enabling their activity (Vonk et al., 2008). Copper within 
cells exists bound to metallochaperones like metallothionein, glutathione, 
ATOX1, CCS and COX17 (Amaravadi et al., 1997, Culotta et al., 1997, 
Ferreira et al., 1993, Freedman et al., 1989a, Freedman et al., 1989b, 
Glerum et al., 1996, Klomp et al., 1997, Lin et al., 1997, Sturtz et al., 2001). 
Binding copper to chaperones prevents copper from creating reactive oxygen 
species which cause damage to cells. 
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In humans, there are a number of enzymes and cellular processes that 
require copper for efficient function. Copper dependent enzymes include: 
lysyl oxidase, which is involved in the cross linking collagen and elastin; 
tyrosinase, which helps in the formation of melanin; cytochrome c oxidase, 
which is involved in the electron transport chain; peptidylglycine α amidating 
monooxygenase, which is involved in the processing of neuropeptides; 
superoxide dismutase which scavenges free radicals; cross-linkase, which 
cross-links keratin; dopamine β hydroxylase, which helps to produce 
catecholamine; and finally Cp, which is a multicopper ferroxidase, oxidises 
Fe (II) to Fe (III) (Giraud et al., 1992, Kagan and Li, 2003, Matoba et al., 
2006, Osaki et al., 1966, Peterson et al., 1998, Richardson et al., 1975, Rush 
and Geffen, 1980, Sato and Gitlin, 1991, Tsukihara et al., 1995). Disruption 
to the function of these enzymes as a result of copper deficiency can have 
dire consequences. 
 
1.3 Copper deficiency 
Copper homeostasis must be tightly regulated as imbalances in copper levels 
can have a great impact on the quality and length of life. In a copper deficient 
environment, the activity of copper dependent enzymes is reduced or 
completely abated. Impeded function of lysyl oxidase and cross-linkase, 
prevents the cross linking of collagen, elastin and keratin, causing problems 
in connective tissue leading to loose skin and joints, and brittle hair. Deficient 
activity of tyrosinase leads to hypopigmentation of the skin. Dopamine β 
hydroxylase deficiency can lead to hypothermia, hypotension, dehydration 
and somnolence as a result of hypothalamic imbalance. Widespread 
disturbances caused by malfunctioning peptide hormones are thought to 
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occur due to copper-dependent peptidylglycine α amidating monooxygenase 
inactivity, however specific details are yet to be elucidated. Copper depleted 
Cp has an impact upon iron metabolism and can lead to anemia (Mercer, 
2001, Peterson et al., 1998). 
 
It has been demonstrated that the average western diet contains less copper 
than the recommended daily average. This is leading to a higher prevalence 
of copper deficiency in the community (Klevay, 2011, Sánchez et al., 2010). 
Copper deficiency has been associated with diseases including abdominal 
aortic aneurysm, Alzheimer’s disease, coronary artery disease, coronary 
heart disease, ischemic heart disease and osteoporosis, all of which are 
becoming more prevalent in modern society. It is not yet clear whether 
copper deficiency has a role in the etiology of the disorders (Klevay, 2011). 
However, compelling evidence suggests that copper deficiency influences 
the onset of osteoporosis, cardiomyopathy and hypertension (Allen et al., 
1982, Chiplonkar et al., 2004, Conlan et al., 1990, Kawada et al., 2006, 
Klevay, 1998, Saari et al., 2007).  
 
Menkes disease is an X-linked recessive genetic disorder that causes 
general copper deficiency in the body (Danks et al., 1972, Menkes et al., 
1962). The disease can be identified by a number of symptoms including 
kinky/steely depigmented hair, loose skin with no pigment, loose skeletal 
joints, neurological degeneration and retardation, seizures and growth 
retardation (Danks et al., 1972, Menkes et al., 1962). Patients usually show 
symptoms of Menkes disease by 2-3 months of age and if untreated, can 
cause death by the age of three years. Patients also exhibit low copper 
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concentrations in the blood as well as low Cp levels (Danks et al., 1972, 
Menkes et al., 1962). The milder form of Menkes disease displays similar 
symptoms, however the neurological degeneration is far less severe or 
nonexistent which prolongs the life of the patient (Danks,1988, Kaler et al., 
1994, Procopis et al., 1981). 
 
Menkes disease arises due to various mutations in the ATP7A gene (Chelly 
et al., 1993, Mercer et al., 1993, Vulpe et al., 1993). Over 200 different 
mutant variations have been described, including missense and nonsense 
mutations as well as insertions, deletions and splice site mutations (Tumer et 
al., 1999, Hsi and Cox, 2004). The effects of mutations can range in severity 
and three types of Menkes disease have been described; classical Menkes 
disease, mild Menkes disease and Occipital Horn Syndrome (Danks, 1995). 
Mutations to the ATP7A gene can inhibit the function of the protein by 
preventing ATP binding due to an altered protein structure. ATP7A is then 
incapable of functioning and so copper cannot be transported through the 
protein pore. Nonsense mutations can cause ATP7A transcription to 
terminate prematurely, preventing the full transcription of the protein. 
Mutations can also cause improper trafficking and mislocalisation of the 
ATP7A protein. ATP7A mutations can cause the protein to be unresponsive 
to copper and remain in the trans-Golgi network (TGN) when intracellular 
copper concentrations increase. In other instances ATP7A can remain near 
the plasma membrane when copper levels are reduced. Some mutations can 
also cause ATP7A to mislocalise to the endoplasmic reticulum. Trafficking 
irregularities and mislocalisation all inhibit copper efflux from cells. In milder 
forms of Menkes disease, ATP7A retains some capacity to function although 
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it is less effective at effluxing copper (Bertini and Rosato, 2008, de Bie et al., 
2007, Kim et al., 2003, Voskoboinik et al., 2003). 
 
Copper deficiency caused by Menkes disease arises due to copper 
homeostatic disturbances in the intestine. Intestinal enterocytes take up 
copper from the digested food in the gut, however in Menkes disease 
patients, copper transfer to the bloodstream is inhibited (Kodama et al., 1999, 
Kuo et al., 2006, Monty et al., 2005, Nose et al., 2006, Ravia et al., 2005). 
This causes a build up of copper in the enterocytes leading to toxicity, 
however the rest of the body remains copper deficient as there is little copper 
in the blood (Cheng and Bayliss, 2008). No effective cure is available for 
Menke’s Disease, however the addition of copper into the bloodstream in the 
form of copper-histidine can impede the progression of symptoms and 
prolong the patient’s life expectancy. Patients with residual ATP7A activity 
have been shown to respond better to treatments than those without. Copper 
supplementation also appears to be more effective against the development 
of neurological symptoms than some of the other symptoms like the skeletal 
defects (Komada et al,. 2012, Tumer and Moller, 2010). 
 
1.4 Copper toxicity 
In addition to the problems encountered when copper levels are deficient, 
excess copper can also be detrimental to health. Ionic copper is toxic and in 
high doses can produce reactive oxygen species that cause damage to cells. 
Long term exposure to high levels of reactive oxygen species in humans can 
lead to diseases like cancer, stroke, myocardial infarction and diabetes 
(Karthikeyan et al., 2011). Acute exposure to high levels of copper induces 
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nausea, vomiting, diarrhea, and abdominal pain (Araya et al., 2001). There 
have also been instances where infants exposed to drinking water 
contaminated with high copper levels from copper piping, developed liver 
failure, occasionally leading to their death (Schramel et al., 1988, Walker, 
1999). Copper can also enter the body via routes other than ingestion. It was 
shown that vineyard workers using copper based fungicide sprays had up to 
10 fold high levels of copper in buccal cells compared to non exposed 
controls (Thompson et al., 2012). Lifestyle factors can also contribute to an 
elevation in copper levels in the body. Studies have shown that smoking and 
also low levels of activity leads to increased copper levels (Sánchez et al., 
2010). 
 
Copper toxicity is not limited to environmental factors. Wilson’s disease is an 
autosomal recessive genetic disorder which leads to copper toxicity. Clinical 
markers of Wilson’s disease include a build up of copper in the cornea of the 
eye (Kayser-Fleischer rings), excess copper in the urine, low copper levels in 
the bile, low Cp levels, neurological symptoms like depression and 
schizophrenia, and hepatic symptoms like jaundice, hepatitis or cirrhosis 
(Mak and Lam, 2008). 
 
Wilson’s disease symptoms can manifest themselves at various ages, 
ranging from two to over forty years of age (Mercer, 2001). Wilson’s disease 
is only fatal if left untreated, usually as a result of liver failure (Ala et al., 
2007). Organ damage can be avoided if the disease is identified early and 
treatment is administered (Mak and Lam, 2008). While the greatest impact of 
copper toxicity is on the liver, other organs like the brain are also subjected to 
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damage. Neurological symptoms are present in Wilson’s disease 
approximately 50% of the time (Vonk et al., 2008). Damage occurs mainly 
due to release of reactive oxygen species caused by copper accumulation 
(Sokol et al., 1994). Copper toxicity in the liver arises from the inability of 
ATP7B to excrete copper into the biliary canaliculus (Roelfosen et al., 2000, 
Schaefer et al., 1999).  
 
The abnormal copper status of Wilson’s disease patients is due to mutations 
in the ATP7B gene which inhibit ATP7B’s ability to bind ATP and also to 
traffic properly causing an accumulation of copper in the liver. Over 250 
different genetic mutations of the ATP7B gene are known, most of which are 
missense mutations, although some are the result of small insertion or 
deletion mutations (Cox and Moore, 2002, Hsi and Cox 2004). Mutations that 
disrupt trafficking can render the protein unresponsive to copper causing it to 
remain localised in the TGN in all copper conditions. Mutations can also 
cause the mislocalisation of ATP7B where it remains in the endoplasmic 
reticulum (de Bie et al., 2007, Forbes and Cox, 1998, Forbes and Cox, 2000). 
All known mutations cause varying degrees of Wilson’s disease. The severity 
and type of symptoms differ greatly, even between patients, with the same 
genetic mutation (Riordan and Williams, 2001). 
 
Copper is incorporated into Cp from ATP7B in the liver and then the copper 
loaded Cp is dispersed into the blood for transport around the body (Linder 
and Hazegh-Azam, 1996, Linder et al., 1998, Terada et al., 1998). When 
ATP7B is defective, less copper is incorporated into Cp (Scheinberg and 
Gitlin, 1952, Sternlieb et al., 1973, Terada et al., 1998). This leads to reduced 
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Cp levels, as copper free Cp degrades more rapidly than the copper loaded 
form (Gitlin and Janeway, 1960, Matsuda et al., 1974, Sternlieb et al., 1961). 
 
1.5 The mammary gland 
The maternal milk secreted from the mammary gland is an important source 
of nutrition for neonates. The mammary gland is made up of lobular 
structures surrounded by adipose and connective tissue. Each lobule is 
made up of 10-100 alveoli which are lined with epithelial cells surrounding a 
central lumen. Mammary epithelial cells are polarised cells with microvilli on 
the apical membrane. Junctions between cells include adherens junctions, 
desmosomes, tight junctions and gap junctions (Lanigan et al., 2007, 
Ozzello, 1971, Tannenbaum et al., 1969). Mammary epithelial cells have 
certain distinct features including the presence of lipid granules, large 
secretory vacuoles, swollen endoplasmic reticulum and basally located nuclei 
(Ackland et al., 2001, Ackland et al., 2003, Monaghan et al., 1985, 
Whitehead et al., 1983a, Whitehead et al., 1983b). The epithelial cells of the 
alveoli are surrounded by contractile myoepithelial cells, which are 
themselves surrounded by a basement membrane (Lanigan et al., 2007). 
The alveoli are connected to ducts, which converge to form larger ducts that 
transport the milk to the nipple, enabling an infant to feed (Geddes, 2007) 
(Fig 1.1). 
 
Until pregnancy, mammary epithelial cells remain dormant. Hormonal 
changes in pregnancy play an important role in modification of the mammary 
gland, initiating growth and proliferation of both the ducts and the alveoli, 
increasing the number of secretory cells available (Lamote et al., 2004). 
  
 
Figure 1.1 Structure of the mammary gland 
A cross-section of the human breast shows the lobes, ducts and surrounding 
tissues. The magnified image shows the arrangement of cells at the terminal 
region of the ducts called the alveolus. 
 11 
 
 
 
 
 
 
 
 
 12 
 
Hormones including estrogen, progesterone, prolactin and insulin are 
important in ductal development and alveolus formation (Hovey et al., 2002). 
By mid-pregnancy, the mammary epithelial cells begin to secrete colostrum 
(Geddes, 2007). Withdrawal of estrogen and progesterone from the 
circulation helps initiate the secretion of milk at the beginning of lactation 
(Neville et al., 2002, Pang and Hartmann, 2007, Rillema, 1994). Prolactin and 
insulin are important in the synthesis and secretion of milk from mammary 
epithelial cells (Hovey et al., 2002). Insulin may also play a role in providing 
nutrients to the mammary gland which are then used for milk production 
(Neville et al., 2002). Suckling initiates the release of oxytocin from the 
posterior pituitary gland, causing contraction of the myoeplithelial cells 
surrounding the mammary gland. This contraction squeezes the milk out of 
the lobules and along the ducts. Suction from the infant also aids the removal 
of milk from the mammary gland (Geddes, 2007). Glucocorticoids similar to 
dexamethasone also perform roles in the differentiation of mammary glands 
and the induction of lactation (Neville et al., 2002). 
 
1.6 Copper in lactation 
Copper levels in the milk must be adequate for the growth and development 
of the infant shortly after birth. The importance of copper in milk is clearly 
illustrated by the toxic milk (tx) mutant mouse model, in which a defective 
ATP7B protein impedes the supply of copper into the dam’s milk causing the 
suckling pups to develop symptoms of copper deficiency leading to their 
death after approximately two weeks (Michalczyk et al., 2000, Rauch, 1983). 
Copper levels fluctuate greatly in the mother’s blood during gestation and 
lactation compared to normal levels. While unaffected by dietary intake, milk 
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copper levels change with progression of lactation (Dorea, 2000). During 
lactation, the rate of copper uptake by the mammary gland is increased 20-
fold in rats (Donley et al., 2002). Milk copper concentrations are highest after 
birth (0.4–0.6 mg/L in humans, 3.2-6.4 mg/L in rodents), but decrease as 
lactation progresses both in humans (0.2–0.3 mg/L) and rodents (0.9-2.1 
mg/L) (Friel et al., 1999, Kelleher and Lonnerdal, 2006, Linder et al., 1998, 
Lonnerdal, 1996, Perrone et al., 1993, Salmenpera et al., 1986, Tsymbalenko 
et al., 2009, Wooten et al., 1996). Copper transport and secretion into milk 
has also been shown to be stimulated by suckling (Kelleher and Lonnerdal, 
2006). During lactation, it is vital that copper is secreted into milk at a rate 
that will not expose the suckling infant to excess or deficient copper levels, 
thus causing harm to the neonate, which could affect its growth and 
development. 

1.7 Copper homeostasis in mammary epithelial cells 
Copper homeostasis in the mammary gland is controlled by a small number 
of influx and efflux proteins. The current model suggests that CTR1 brings 
copper from the blood plasma into the mammary epithelial cells across the 
basolateral membrane (Kelleher and Lonnerdal, 2003, Kelleher and 
Lonnerdal, 2006, Llanos et al., 2008). ATOX1 then delivers the copper to 
either ATP7A or ATP7B in the TGN (Banci et al., 2007, Banci et al., 2009, 
Strausak et al., 2003, Tanchou et al., 2004, van Dongen et al., 2004). The 
efflux of copper from the cells is accomplished by translocating ATP7A to the 
basolateral membrane where it is released back into the maternal circulation 
(Kelleher and Lonnerdal, 2006, Llanos et al., 2008), while ATP7B traffics 
copper towards the apical membrane where it is thought to deliver copper to 
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Cp which is then secreted into the milk (Kelleher and Lonnerdal, 2006, 
Platonova et al., 2007, Tsymbalenko et al., 2009). It is also likely that ATP7B 
delivers copper to the membrane bound glycosylphosphatidylinositol 
anchored form of Cp (GPI-Cp). The majority of copper found in milk is bound 
to the Cp secreted from the mammary epithelial cells (Platonova et al., 2007, 
Tsymbalenko et al., 2009). Metallothionein, a copper storage protein, 
sequesters excess copper in the cell when copper levels are elevated (Mehta 
et al., 2006, Sutherland and Stillman, 2011, Urani et al., 2003) (Fig 1.2). 
 
1.8 CTR1 
In humans CTR1 has not been linked to any diseases, although when 
knocked out in mice, it has been shown to be embryonically lethal, indicating 
the importance of the protein in copper homeostasis (Kuo et al., 2001, Lee et 
al., 2001). CTR1 is a 190 amino acid protein (Zhou and Gitschier, 1997) 
which, once glycosylated, is approximately 35 kDa in size (Klomp et al., 
2002). CTR1 has three transmembrane domains with the N-terminus on the 
extracellular side and the C-terminus on the cytosolic side (Klomp et al., 
2003). Electron crystallography showed that three CTR1 proteins bind 
together to form a radially symmetrical conical shaped channel which is 
widest on the cytoplasmic side. It has been shown that the N-terminal region 
is important in accepting Cu (II) from the external environment. Once bound, 
Cu (II) is converted to Cu (I) enabling it to be transported passively through 
the protein channel to the C-terminal region that makes copper available to 
copper chaperones like ATOX1. The yeast ATOX1 homologue protein ATX1 
was demonstrated to accept copper (I) from the C-terminal domain of CTR1 
(de Feo et al., 2009, Eisses and Kaplan, 2005, Ferruzza et al., 2000, Hill and 
  
 
Figure 1.2 The molecular interactions maintaining copper homeostasis 
in mammary epithelial cells 
This is a schematic diagram of copper transporting proteins in mammary 
epithelial cells. The diagram shows the localisation of proteins with regard to 
the apical and basolateral membranes of mammary epithelial cells. Arrows 
identify known and possible pathways of copper movement through cells. 
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Link, 2009, Howell et al., 2010, Lee et al., 2002b, Puig et al., 2002, Xiao and 
Wedd, 2002). 
 
The mechanism by which copper influx is regulated is quite contentious. A 
number of research groups suggested that CTR1 binds copper and the 
protein is then internalised into cellular vesicles and degraded (Guo et al., 
2004a, Guo et al., 2004b, Holzer and Howell, 2006, Holzer et al., 2004a, Liu 
et al., 2007, Petris et al., 2003), on the other hand it has been proposed that 
the mechanism could be due to internalisation and recycling of the CTR1 
complex back to the membrane (Molloy and Kaplan, 2009), while another 
group has demonstrated CTR1 degradation without internalisation (Safaei et 
al., 2009). Finally, it has even been reported that there is no degradation of 
the protein nor removal from the cell membrane in response to copper and 
that there may be another mechanism in place that regulates the influx of 
copper (Eisses et al., 2005, Wu et al., 2009). 
 
1.9 ATOX1 
ATOX1 is a small 7 kDa protein, classified as a copper chaperone. It is most 
commonly known for its role in delivering copper to either of ATP7A or 
ATP7B in the TGN, where its interaction with the metal binding domains of 
these ATPases has been confirmed (Banci et al., 2007, Banci et al., 2009, 
Strausak et al., 2003, Tanchou et al., 2004, van Dongen et al., 2004). There 
have only been a small number of studies analysing ATOX1 responses to 
copper and these studies showed ATOX1 to be unaffected (Andersen et al., 
2007, Gambling et al., 2004). Most research on ATOX1 was carried out on 
ATOX1 knockout mice. ATOX1 has proven to have a great impact upon 
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mouse survival, with only 55% of ATOX1 -/- mice surviving past weaning. 
The low rate of survival is due to the impact ATOX1 has on regulating copper 
efflux. Without ATOX1, copper efflux is restricted as copper does not reach 
ATP7A or ATP7B which are able to remove excess copper from cells. As a 
result, these mice showed symptoms of copper deficiency, similar to Menkes 
disease, including restricted growth, loose skin, hypopigmentation and 
seizures (Hamza et al., 2001, Hamza et al., 2003). ATOX1 may have 
additional functions including the unbiquitination of CTR1, targeting it for 
degradation. It is also thought that ATOX1 may have a role in the nucleus as 
a transcription factor, influencing cellular proliferation (Itoh et al., 2008, Muller 
and Klomp, 2009). ATOX1 expression levels have also been shown to be 
tightly linked with SOD3 expression, indicating it may have some role in 
relieving oxidative stress (Jeney et al., 2005). 
 
1.10 ATP7A 
ATP7A is a P-type ATPase that exports copper across the basolateral 
membrane in most cell types except hepatocytes (Vulpe et al., 1993). Human 
ATP7A protein has a number of important functional regions. These include 
eight transmembrane domains that cross the lipid bilayer, forming a 
cylindrical channel. The N-terminal region contains six metal binding sites 
that are specific for copper binding prior to its transport through the pore 
formed by the trans-membrane domains. One of the cytoplasmic loops also 
contains an ATP binding domain which provides energy for the copper ions 
to be moved through the protein pore once ATP is bound (Lutsenko and 
Kaplan, 1995). 
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The localisation of ATP7A within cells is influenced by copper (Petris et al., 
1996). The mechanism behind ATP7A trafficking is not clear; however it is 
evident that this process is important in maintaining copper homeostasis of 
the cell. Basal and low copper conditions in non-polarised cells cause ATP7A 
to reside in the TGN where it can receive copper from ATOX1. ATP7A makes 
copper available to copper dependent enzymes like lysyl oxidase, where it is 
incorporated into the enzyme structure enabling it to function (Kagan and Li, 
2003, Tchaparian et al 2000). Most intracellular copper is recycled and not 
often excreted back into the blood from cells unless in excess (Tapiero et al., 
2003). Exposure to high copper concentrations induces movement of ATP7A 
from the TGN towards the plasma membrane of the cell. This response is 
indicative of a protein that exports or facilitates the export of excess copper 
(Ackland et al., 1997, La Fontaine et al., 1998a, La Fontaine et al., 1998b, 
Petris et al., 1996). Copper excretion was proposed to occur by two methods, 
exocytosis, which involves ATP7A moving copper into vesicles and the 
vesicular transfer of copper across the plasma membrane, or by ATP7A 
incorporating itself into the membrane and directly transporting copper out of 
the cell. (Cobbold et al., 2003, Lane et al., 2004, Nyasae et al., 2006, Petris 
et al., 1998, Petris and Mercer, 1999, Strausak et al., 1999, Voskoboinika et 
al., 1998). 
 
Experiments in non-polarised cells show trafficking of ATP7A to all parts of 
the plasma membrane of the cell, however trafficking is more complicated in 
polarised cells. ATP7A has been detected in many types of epithelial cells 
which have an apical side (which faces the lumen) and a basolateral side 
(which faces the basement membrane). Limited research has been 
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performed on ATP7A localisation in polarised cells; however based on the 
vectorial transport of copper, it is hypothesised that it would reside on the 
basolateral side of the epithelium (Greenough et al., 2004, Hardman et al., 
2007, Llanos et al., 2008). 
 
ATP7A has been observed in epithelial cells of lactating and non-lactating 
mammary gland tissue (Ackland et al., 1999, Kelleher and Lonnerdal, 2006, 
Llanos et al., 2008). It was demonstrated that ATP7A trafficking is induced 
during lactation with the protein residing in the TGN in the non-lactating 
mammary epithelial cells and dispersing towards the plasma membrane 
during lactation (Ackland et al., 1999). ATP7A was shown to be clearly visible 
at the basolateral membrane of lactating mammary epithelial cells (Kelleher 
and Lonnerdal, 2006, Llanos et al., 2008). These data fit the current model, in 
which copper enters the mammary epithelial cells via CTR1 and is delivered 
to ATP7A or ATP7B in the TGN. ATP7A is then able to make copper 
available for other copper dependent enzymes like lysyl oxidase, or efflux 
any unnecessary copper back across the basolateral membrane to the 
maternal blood stream, thus protecting a suckling infant from obtaining 
excessive amounts of copper. One study also observed ATP7A to localise 
towards the apical membrane in response to suckling (Kelleher and 
Lonnerdal, 2006). This does not fit with the current model which proposes the 
ATP7B and Cp are the key components involved in delivering copper across 
the apical membrane into milk. Unless ATP7A is also involved in delivery of 
copper to Cp in situations where demand is very high. It has been shown 
previously in the brain and in macrophages that ATP7A can be used to 
 20 
 
deliver copper to Cp when ATP7B is not present (Barnes et al., 2005, White 
et al., 2009a). 
 
1.11 ATP7B 
ATP7B is a P-type ATPase found predominantly in the liver. In the mammary 
gland, placenta, kidney, brain, heart and lungs, ATP7B is expressed along 
with ATP7A (Bull et al., 1993, La Fontaine and Mercer, 2007). ATP7B has 
two main functions in the liver; firstly, it moves copper into the biliary 
canaliculi, where it is incorporated into bile and excreted from the body via 
the faeces (Linder et al., 1998, Terada et al., 1999); secondly, ATP7B in liver 
cells loads Cp with copper which enables copper to be safely transported 
around the body in the blood (Linder and Hazegh-Azam, 1996, Linder et al., 
1998, Terada et al., 1998).  
 
ATP7B has 67% similar amino acid sequence to ATP7A, and like ATP7A has 
eight transmembrane domains which form a pore through which ATP 
catalyses the transport of copper. ATP7B also contains six copper binding 
sites at the N-terminal region like ATP7A (Bull et al., 1993). Similar to 
ATP7A, ATP7B’s trafficking is also dependent on intracellular copper 
concentrations. ATP7B resides in the TGN under basal and copper depleted 
conditions where it predominantly facilitates the incorporation of copper into 
Cp (Cater et al., 2004, Forbes and Cox, 2000, Hung et al., 1997, La Fontaine 
et al., 1998b, Linder and Hazegh-Azam, 1996, Linder et al., 1998, Terada et 
al., 1998). When copper concentrations increase, ATP7B begins to traffic 
towards the cell membrane with the intention of transporting excess copper 
out of the cell. ATP7B does not travel directly to the membrane. It was 
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proposed that ATP7B delivers copper to vesicles, possibly late endosomes, 
which then efflux copper from the cell via exocytosis (Cater et al., 2006, 
Harada et al., 2005). In polarised cells, ATP7B traffics towards the apical side 
of the cells, as opposed to ATP7A which traffics towards the basolateral side 
(Bartee and Lutsenko, 2007, Guo et al., 2005, Kelleher and Lonnerdal, 
2006). It was suggested that the 63 amino acid sequence that is present in 
ATP7B and not in ATP7A is responsible for the trafficking of ATP7B in the 
opposite direction to ATP7A (Guo et al., 2005). 
 
The importance of ATP7B in delivering copper from the mammary epithelium 
into milk has been clearly demonstrated with the toxic (tx) mutant mouse 
model. The tx mouse has a defective ATP7B gene, rendering the protein 
incapable of proper function. The dams produce copper deficient milk 
causing suckling neonates to develop symptoms of copper deficiency. This 
can lead to death of the pups within two weeks (Michalczyk et al., 2000, 
Rauch, 1983). Immunolocalisation analysis of ATP7B in resting and lactating 
mammary epithelial cells shows a similar pattern to ATP7A. Trafficking of 
ATP7B appeared to increase in response to lactation (Michalczyk et al., 
2008). ATP7B has demonstrated apical localisation, consistent with ATP7B’s 
role in delivering copper to milk (Kelleher and Lonnerdal, 2006), however it is 
not known whether ATP7B directly transports copper across the membrane 
or facilitates efflux via vesicles, but it has been shown that Cp contains a high 
proportion of copper in milk and so it is likely that ATP7B plays a vital role in 
loading copper onto Cp for secretion into milk. (Platonova et al., 2007, 
Tsymbalenko et al., 2009). 
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1.12 Ceruloplasmin 
Ceruloplasmin (Cp) has been found expressed in the liver, macrophages, 
lymphocytes, choroid plexus, yolk sac, placenta, uterus, testis, lung, heart, 
kidney and the mammary gland; from which it had been found to be secreted 
into the milk (Cerveza et al., 2000, Tsymbalenko et al., 2009, Wooten et al., 
1996, Yang et al., 1990). Cp is known to have a number of roles in the 
human body which may include copper transport. Cp is secreted from the 
liver and circulates in the blood carrying up to 60-95% of serum copper. The 
remaining copper in the blood is bound to albumin and low molecular weight 
complexes (Cerveza et al., 2000, Jaeger et al., 1991, Lockhart and Mercer, 
1999, Wooten et al., 1996). A lack of disturbance to copper levels in systemic 
tissues in the genetic disorder aceruloplasminemia and also in Cp knockout 
mice, suggested that Cp is not an essential component of copper distribution 
around the body (Meyer et al., 2001, Miyajima, 2003, Miyajima et al., 1987, 
Waggoner et al., 1999). However, other research has suggested it is a key 
component in copper uptake in rats and cultured cells (Bae and Percival, 
1994, Campbell et al., 1981, Davidson et al., 1994, Lee et al., 1993, Linder, 
1991, Linder et al., 1998, Owen, 1971, Percival and Harris, 1990). Contrary 
to this, aceruloplasminemia patients and Cp knockout mice have 
demonstrated disturbances to iron metabolism. When Cp is absent, iron 
accumulates in liver, pancreas, retina and brain (Patel et al., 2002, Xu et al., 
2004). This occurs because copper bound Cp has ferroxidase activity and is 
able to oxidise Fe (II) to Fe (III) (Osaki et al., 1966, Sato and Gitlin, 1991). 
Converting the more toxic Fe (II), to the more inert Fe (III) form of iron, not 
only protects cells from oxidative damage, it also allows iron to bind to 
proteins like transferrin (which only binds Fe (III)), making it mobile and 
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available for circulation around the body (Chen et al., 2003, Collins et al., 
2010, Hellman and Gitlin, 2002, Rathore et al., 2008). There are also other 
transferrin like proteins, which are similar in structure and also bind Fe (III), 
one of which, lactoferrin, interacts with Cp and is found to be a major iron 
transporter in the milk (Dorea, 2000, González-Chávez et al., 2009, Ha-
Duong et al., 2010, Kawakami et al., 1990, Sabatucci et al., 2007, Sokolov et 
al., 2006, Zakharova et al., 2000). Cp is involved in the uptake (Chang et al., 
2007) and efflux (de Domenico et al., 2007, Harris et al., 1999) of iron from 
cells. Along with its ferroxidase capability, Cp has also been shown to oxidise 
amines and low-density lipoproteins (Boivin et al., 2001, Mazumder and Fox, 
1999, Tapryal et al., 2009). 
 
The tx mutant mouse which has a defective ATP7B gene has around 22% of 
the normal level of copper in the secreted milk (Rauch, 1985). It has been 
shown that Cp contains up to 85% of copper in milk and so it is likely that 
ATP7B is responsible for the incorporation of all the copper into Cp 
(Platonova et al., 2007, Tsymbalenko et al., 2009). It has been suggested the 
remaining fraction of copper in milk may be bound to other soluble copper 
dependent enzymes like superoxide dismutase (Tsymbalenko et al., 2009). 
Copper levels in milk have been shown to decline with the progression of 
lactation; a trend followed by Cp suggesting that milk copper levels are 
dependent on to the Cp levels in the milk (Albera and Kankofer, 2009, 
Cerveza et al., 2000, Keen et al., 1982, Platonova et al., 2007, Tsymbalenko 
et al., 2009).  
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An alternate, membrane bound form of Cp (GPI-Cp) is also expressed in 
most tissues (Banha et al., 2008, Fortna et al., 1999, Kono et al., 2010, Mittal 
et al., 2003, Mostad and Prohaska, 2011, Patel and David, 1997) and is 
linked to the plasma membrane by a glycosylphosphatidylinositol anchor 
(GPI-Cp) (Patel and David, 1997). GPI-Cp has also been implicated in iron 
oxidation and efflux from cells, though not in iron uptake (Chang et al., 2007, 
Jeong and David, 2003, Kono et al., 2006a). 
 
1.13 Metallothionein 
There are four known types of metallothionein; MT-1, MT-2, MT-3 and MT-4 
(Margoshes and Vallee, 1957, Quaife et al., 1994, Thirumoorthy et al., 2011, 
Uchida et al., 1991). MT-1 and MT-2 are ubiquitously expressed, while MT-3 
and MT-4 have been found in CNS and squamous epithelial cells 
respectively (Masters et al., 1994, Miles et al., 2000, Quaife et al., 1994). 
MTs have roles in metal homeostasis and detoxification, free radical 
scavenging and protection against oxidative stress, and have also been 
implicated in antiapoptotic defence mechanisms and neuroprotection 
(Penkowa et al., 2006, Sato and Bremner 1993). MTs have 20 cysteine 
residues which are important in the binding of metals (Sutherland and 
Stillman, 2011). MT-1 and MT-2 have been shown to bind and respond to 
metal ions of cadmium, copper and zinc (Nielson et al., 1985, Vasak and 
Meloni, 2011). MT binds cadmium more strongly than zinc, while copper has 
a higher affinity to MT than both cadmium and zinc, however zinc has greater 
influence upon MT expression levels (Sutherland and Stillman, 2011, Urani et 
al., 2003). Research has also shown that MT can bind to metals like 
antimony, bismuth, cobalt, indium, iron, lead, mercury, nickel, osmium, 
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palladium, platinum, rhenium, rhodium, silver, technetium and thallium (Good 
and Vasak, 1986, Morelock et al., 1988, Nielson et al., 1985, Ngu et al., 
2010). 
 
1.14 Copper and iron homeostatic association 
Copper and iron homeostasis are linked, with the levels of one metal being 
affected inversely to the other. In cultured hepatocarcinoma cells, it was 
shown that increases in copper levels, decreased iron levels (Fosset et al., 
2009). The opposite effect was observed in rats fed Cu deficient diets where 
iron levels were raised significantly in the liver and intestine, however the 
spleen, kidney and bone had less iron (Chen et al., 2006). Supporting the 
copper-iron relationship in living organisms, rats fed high iron diets had lower 
copper levels than rats fed low iron diets (Gambling et al., 2004). These 
changes may be mediateld by altered Cp activity. Increasing copper 
concentration allows ferroxidase active Cp to metabolise more iron from Fe 
(II) to Fe (III) enabling it to become more mobile and be effluxed from cells; 
the opposite applies during copper deficiency (Chen et al., 2006, Fosset et 
al., 2009). 
 
1.15 Transferrin receptor, β2-microglubulin and iron uptake 
The main iron uptake pathway in cells is via transferrin receptor 1 (TfR) which 
binds iron-loaded transferrin and is then endocytosed (Bhatt et al., 2010, 
Enns, 2001). β2-microglobulin (β2M) plays an important role in TfR iron 
uptake by creating a complex with HFE, a protein that binds to TfR and 
inhibits its capacity to accept transferrin. When β2M interacts with HFE it 
prevents its inhibitory action on TfR allowing this protein to freely bind 
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transferrin (Bhatt et al., 2009, Bhatt et al., 2010, Enns, 2001, Vecchi et al., 
2010). The stability of β2M is affected by the presence of Cu (II) (Deng et al., 
2006). In situations where copper status is altered, β2M protein can be 
affected. It has been shown that cells overexpressing β2M increase their 
uptake of iron (Waheed et al., 2002). 
 
1.16 PMC42-LA mammary epithelial cell line 
In this study, the PMC42-LA cultured human mammary epithelial cell line was 
used to analyse copper transporting proteins and the mechanisms controlling 
copper homeostasis. The PMC42 cell line was originally derived from the 
pleural effusion fluid of a woman who had metastatic breast cancer. The 
PMC42 cells were originally grown in suspension and also as a surface 
monolayer of cells. Eight different morphological cell types were identified in 
the culture which included undifferentiated stem cells, spindle shaped cells, 
syncytium forming cells, large cells and small epithelial cells with differing 
intracellular characteristics. These observations led the authors to believe 
that the PMC42 cells originated from a tumorous breast stem cell (Whitehead 
et al., 1983a, Whitehead et al., 1983b). Initial characterisation of the PMC42 
cells also revealed that they contain receptors for estrogen, progesterone 
and dexamethasone and that the cells responded to all of these hormones. 
Other mammary epithelial cells lines have failed to respond to these 
hormones giving the PMC42 cells line a distinct advantage in analysing the 
effects of lactation which requires hormonal stimulation (Whitehead et al., 
1984). 
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A major difference between lactating mammary tissue and cultured 
mammary cells is the degree of cellular differentiation. Previous studies 
showed that PMC42-LA cells grown on plastic have some breast-specific 
features including lipid granules, swollen endoplasmic reticulum and large 
secretory vacuoles (Whitehead et al., 1983a, Whitehead et al., 1983b). 
However, when grown on EHS matrix coated permeable membranes, 
PMC42-LA cells form organoids similar to the alveolar structures of the 
mammary gland where cells are arranged around a central lumen. These 
cells develop a phenotype more representative of differentiated luminal 
epithelial cells, including the presence of tight junctions and microvilli, basally 
located nuclei and the presence of lipid granules (Ackland et al., 2001). 
PMC42-LA cells also express proteins found in milk. The iron transporting 
milk protein lactoferrin has been detected in cells grown on plastic and on 
EHS matrix coated membrane. However, upon differentiation, the milk 
protein β-casein is also expressed, but only in the presence of lactational 
hormones. β-casein has often been used as a marker of fully differentiated 
lactating mammary epithelial cells. Lactation is induced with the addition of 
estrogen and progesterone for three days following a week of culturing. 
These hormones are then removed and replaced with prolactin, insulin and 
dexamethasone (Ackland et al., 2001, Ackland et al., 2003, Michalczyk et al., 
2008). As in physiological conditions, the withdrawal of estrogen and 
progesterone has a role in initiating the milk secretion process, while 
prolactin, insulin and glucocorticoids like dexamethasone are key to 
maintaining the synthesis and secretion of milk from mammary epithelial cells 
(Hovey et al., 2002, Neville et al., 2002, Pang and Hartmann, 2007, Rillema, 
1994). 
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1.17 Hypotheses 
The following research is based on hypotheses that copper transport proteins 
which are the subject of the thesis, have specific roles in the movement of 
copper into the milk during lactation. These hypotheses are based on data 
describing the functions of the molecules in other cells/tissues. CTR1 is 
proposed to be the first point of contact, bringing copper into the mammary 
epithelial cells from the blood stream. Once inside the cells ATOX1 is 
hypothesised to deliver copper to the TGN to the ATPases ATP7A and 
ATP7B. ATP7A and ATP7B are copper efflux proteins predicted to export 
copper from the mammary epithelial cells across the basolateral and apical 
membranes respectively. ATP7B is proposed to deliver copper to the mulit-
copper ferroxidase ceruloplasmin, which is then secreted via the apical 
membrane into the milk. The milk is then ejected from the mammary gland to 
feed a suckling infant. Lactational hormones including estrogen, 
progesterone and prolactin that are known to regulate milk section from the 
mammary gland and these hormones are hypothesised to influence the 
movement of copper into mammary epithelial cells and then into the secreted 
milk. 
 
1.18 Aims 
The following research, analyses the activity of CTR1, ATOX1, ATP7A, 
ATP7B and Cp in the PMC42-LA cell line in relation to copper transport in 
lactation. To commence the project, the PMC42-LA cells were used in their 
non-differentiated state. The cells were then differentiated and lactation was 
induced by treatment with lactational hormones to attain a more accurate 
understanding of the mechanisms involved in vivo. In addition to the non-
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hormonally treated resting model and the hormonally treated lactation model, 
a third model was created with a higher concentration of prolactin to simulate 
suckling conditions. To gain further insight into copper transport homeostasis, 
ATP7A was overexpressed in PMC42-LA cells. Copper transporters in both 
the undifferentiated and differentiated cells were investigated. The 
differentiated ATP7A overexpressing cells were also treated with lactational 
hormones to simulate lactation and suckling. These studies enabled the 
analysis of a potential copper depletion caused by a homeostatic disruption 
in a system containing three copper efflux proteins; ATP7A, ATP7B and Cp. 
 
PMC42-LA cells were exposed to two different copper treatments. The levels 
used were similar to those found in the blood during lactation and non-
lactational periods. This was studied to gain insight into the copper 
transporter responses that occur solely as a result of the variable copper 
levels found in the blood during these periods. Additionally, copper chelators 
were also used to identify the responses due to copper deficiency. 
 
The overall objective of this research was to increase the current knowledge 
of the roles that copper transporting proteins play in delivering copper to milk. 
By observing changes of the proteins involved in copper uptake and efflux 
from mammary epithelial cells in response to altered copper status and 
fluctuations in hormonal levels, a greater understanding of the processes 
involved in maintaining an adequate, non-toxic supply of copper into milk 
which provides nutrition for suckling neonates, can be obtained. 
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1.19 Approach 
A key approach to this research is the use of the the PMC42-LA mammary 
epithelial cells that can be induced to form a 3D organoid. This organoid is a 
model representative of the lobules of the mammary gland. The treatment of 
cells with lactational hormones induces the secretion of the milk protein β-
casein, a key marker of lactation. Hormone-treated PMC42 cells exposed to 
hormones thus provide a model of the lactating human gland. Treatment of 
cells with variable copper levels will allow the replication of the physiological 
conditions encountered in the mammary gland during lactation. mRNA and 
protein analysis and protein localisation of the copper transporting proteins 
by qRT-PCR, Western blot and fluorescence confocal microscopy 
respectively will provide crucial information about the function of the copper 
transporters. Trace metal levels and localisation determined by atomic 
absorption spectroscopy and X-ray fluorescence microscopy will provide 
insights into the link between copper molecules and transport of copper. This 
approach will enable analysis of the behaviour of the copper transporting 
proteins during lactation compared to non-lactational periods, identifying how 
changes in copper homeostasis affects the intracellular copper levels and the 
potential effects this may have on the copper levels secreted into milk. It will 
also shed light on interactions between the different copper transport 
molecules within the mammary gland. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
 
Materials and Methods 
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2.1 Plasmid preparation and cell transfection 
A previously developed ATP7A overexpression plasmid, pCMB344 (Ke et al., 
2006) was used to transfect PMC42-LA using polyethylenimine solution (Shin 
et al., 2005). Specifically, 20 μg plasmid DNA was diluted in 150 mM NaCl to 
a concentration of 10 μg/mL. 4.2 mg/mL polyethylenimine (MR 2000) pH 5.0 
was added to DNA/NaCl solution to a final concentration of 0.813 mg/mL. 
The mixture was vortexed for 10 sec and incubated for 30 min at room 
temperature. The mixture was added to 15 mL RPMI 10% FBS and added 
overnight to a 75 cm2 culture flask containing PMC42-LA cells that were 75% 
confluent. Transfected cells were selected using 500 μg/mL G418 (Sigma-
Aldrich; Sydney, Australia) in RPMI 10% FBS medium. Fresh medium with 
antibiotics were added every three days. 
 
2.2 Cell culture 
The breast adenocarcinoma cell line PMC42-LA, a variant of the PMC42 line, 
originally derived from a pleural effusion (Whitehead et al., 1983a), was 
cultured in RPMI 1640 culture media (Thermo Fisher Scientific; Melbourne, 
Australia) supplemented with 10% FBS (Bovogen; Melbourne, Australia) at 
37ºC in 5% CO2. The cells were passaged when confluent using 0.05% 
trypsin-EDTA solution in PBS (Sigma-Aldrich; Sydney, Australia). Cells were 
grown in 75 cm2 culture flasks (Nunc; NY, USA) for Western blot, 
Quantitative Real Time PCR and AAS analysis, 6-well plates (Nunc; NY, 
USA) for biotinylation or on glass coverslips for immunofluorescent analysis. 
Cells were treated with a combination of 200μM bathocuproine disulfonate 
(BCS) (Sigma-Aldrich; Sydney, Australia) and 200μM D-penicillamine (DPen)
(Sigma-Aldrich; Sydney, Australia) to deplete the available pool of copper, 
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while 5 μM CuCl2 (Sigma-Aldrich; Sydney, Australia) was added to simulate 
basal serum conditions and be used as a control treatment. 50 μM CuCl2 was 
added to analyse the effect of surplus copper on the cells, similar to 
conditions reported in vivo during lactation. All treatments were for three 
days. To identify whether iron influenced Cp levels, cells were treated with 
0μM (control), 100μM, 300μM, 500μM and 1000μM FeCl3 for three days then 
processed for Western blot analysis 
 
To induce cellular differentiation, PMC42-LA cells were grown on porous 
Transwell filters (BD Falcon; Sydney, Australia) coated with a thin layer of 
undiluted extracellular matrix gel from Engelbreth Holm-Swarm mouse 
sarcoma (Sigma-Aldrich; Sydney, Australia) (EHS matrix). Differentiated 
PMC42-LA cells were treated with lactogenic hormones to obtain a cellular 
model of lactating epithelia as we previously described (Ackland et al., 2001, 
Ackland et al., 2003, Michalczyk et al., 2008). Cells were grown for seven 
days and then treated with 2.7 ng/mL β-estradiol (Sigma-Aldrich; Sydney, 
Australia) and 157 ng/mL progesterone (Sigma-Aldrich; Sydney, Australia) 
for three days, followed by a three day treatment of 1 μg/mL dexamethasone 
(Sigma-Aldrich; Sydney, Australia), 0.6 μg/mL insulin (Sigma-Aldrich; 
Sydney, Australia), and 200 ng/mL prolactin (Jomar Diagnostic; Melbourne, 
Australia). The cells grown on the porous Transwell filters were processed for 
immunofluorescence or harvested for protein, mRNA or trace metal analysis. 
Regular suckling causes constantly elevated plasma levels of prolactin 
(Neville et al., 2002). To create a model representative of the mammary 
gland during suckling, the cells were treated the same as the lactating model 
except 800 ng/mL prolactin was added instead of 200 ng/mL for the final 
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three days. No hormones were added to the model that simulates the resting 
breast. Copper treatments were also carried out during the last three days as 
described above. 
 
2.3 Antibodies  
A polyclonal rabbit anti-human CTR1 antibody was raised to the first 98 
amino acids and affinity purified using an AminoLink Plus Immobilization Kit 
(Thermo Fisher Scientific; Melbourne, Australia) (Hardman et al., 2006, Ke et 
al., 2008, Llanos et al., 2008). A polyclonal sheep anti-human ATP7A (R17) 
antibody was raised and affinity purified as previously described (Ke et al., 
2006). Antibodies to ceruloplasmin (Dako; Melbourne, Australia – CAT 
#A0031), ATP7B (Saphire Bioscience; Sydney, Australia - CAT# PAB12477), 
Na/K ATPase (Thermo Fisher Scientific; Melbourne, Australia – CAT# sc-
48345), ATOX1 (Abnova; Taipei City, Taiwan – CAT# H00000475-M01), MT 
(Dako; Melbourne, Australia – CAT # M0639), β2-microglobulin (Saphire 
Bioscience; Sydney, Australia – CAT# ab75853), transferrin receptor 
(Saphire Bioscience; Sydney, Australia – CAT# NB100-92243) and β-actin 
(Sigma-Aldrich; Sydney, Australia – CAT# A5441) were purchased 
commercially. 
 
2.4 Immunocytochemistry 
PMC42-LA cells, grown on coverslips or on undiluted EHS matrix coated, 
porous Transwell cell culture inserts and following treatment were fixed in 4% 
paraformaldehyde (Sigma-Aldrich; Sydney, Australia) for 10min, 
permeabilized with 0.1% Triton X-100 (Sigma-Aldrich; Sydney, Australia) (3% 
for cells on matrix) in PBS (Amresco; Ohio, USA) for 10 min, and blocked 
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with 1% BSA (Sigma-Aldrich; Sydney, Australia) in PBS for 10 min (3% BSA 
in PBS for 1 h for cells on matrix). Primary antibody diluted in 1% BSA in 
PBS (ATP7A 1/4000; ATP7B 1/1000; CTR1 1/3000; Cp 1/1000) was applied 
to cells overnight at 4 °C. For immuno-colocalisation ATP7A antibody was 
added in combination with Cp antibody. Following PBS washes, a secondary 
antibody, AlexaFluor 488 chicken anti-rabbit (Molecular Probes; Melbourne, 
Australia) (ATP7B, CTR1, Cp) or AlexaFluor 488 donkey anti-sheep 
(Molecular Probes; Melbourne, Australia) (ATP7A) diluted 1/2000 in 1% BSA 
in PBS, was applied for 2hr at room temperature. AlexaFluor 488 donkey 
anti-sheep and  AlexaFluor 594 donkey anti-rabbit were used in combination, 
diluted 1/2000 for immuno-colocalisation. After washing off excess secondary 
antibody with a 10 min PBS wash, ethidium bromide (Sigma-Aldrich; Sydney, 
Australia) (1 μg/mL) was added to cells for 45 sec to enable visualization of 
the nuclei (this was not done for immuno-colocalisation). The cells were then 
washed three times quickly to remove any excess ethidium bromide, followed 
by two more 10 min PBS washes. Coverslips and filters were then mounted 
on glass slides in ProLong Gold antifade reagent (Invitrogen; Melbourne, 
Australia). Confocal images were collected using a Leica confocal 
microscope system TCS SP2 (Leica; Melbourne, Australia). Image J co-
localisation software was used to determine Pearson’s co-localisation 
coefficient for co-localisation analysis. Statistical significance is indicated by 
p<0.05. 
 
2.5 Western blot analysis – whole cells 
PMC42-LA cells grown in 75 cm2 culture flasks were collected by 
trypsinisation and washed three times in PBS. Lysates were prepared using 
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500 μL of 1% (w/v) SDS (Sigma-Aldrich; Sydney, Australia) in 10 mM Tris-
HCl (pH 7.5) (Sigma-Aldrich; Sydney, Australia) lysis buffer whereas PMC42-
LA cells grown on filters were collected from the Transwell cell culture inserts 
after exposure to 250 μL of 2% (w/v) SDS in 10 mM Tris-HCl (pH 7.5) lysis 
buffer for 5 min. Lysates were homogenised by repeatedly passing the lysate 
through a 21-gauge needle followed by sonication (15 pulses, 40% power 
output, 30% duty cycles; Microson XL2000 Ultrasonic Cell Disruptor, Misonix, 
Farmingdale, NY, USA) on ice in 1x EDTA-free inhibitor cocktail (Roche 
Diagnostics; Melbourne, Australia). The total protein content of cell extracts 
was measured using the BCA Protein Assay Kit (Pierce; Melbourne, 
Australia) calibrated against BSA standards. 60 μg of lysates were 
fractionated by SDS-PAGE on 7.5% (ATP7A, ATP7B, Cp, TfR), 12% (CTR1) 
or 15% (ATOX1, MT, β2M) gels and transferred to nitrocellulose membranes 
(Whatman; Dassal, Germany). Membranes were then stained with 0.1% 
Ponceau S (Sigma-Aldrich; Sydney, Australia). Ponceau S stain was 
removed with 0.1% NaOH (Sigma-Aldrich; Sydney, Australia). After 1 h 
blocking in 5% (w/v) milk powder in TBS at room temperature, membranes 
were exposed overnight at 4 °C to primary antibody diluted in TBS: ATP7A 
1/4000; ATP7B 1/1000; CTR1 1/3000; Cp 1/1000; ATOX1 1/500; MT 1/50; 
β2M 1/10000; TfR 1/500. Membranes were washed four times for 10 min in 
TBS and antibodies were detected using 1/2000 dilution of horseradish 
peroxidase–conjugated goat anti-rabbit (ATP7B, CTR1, Cp, β2M, Tfr), 
donkey anti-sheep (ATP7A) or goat anti-mouse (ATOX1, MT) secondary 
antibody (Millipore; Melbourne, Australia) in TBS for 45 min at room 
temperature. After removal of excess secondary antibody, membranes were 
rinsed twice in TBS for 10 min and then twice more in TBS with 0.1% Tween 
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20 (Sigma-Aldrich; Sydney, Australia). Proteins were detected by enhanced 
chemiluminescence (Immobilon Western Chemiluminescent HRP Substrate; 
Millipore; Melbourne, Australia) and a LAS-3000 FujiFilm Lumino-Image 
Analyzer (Fuji Photo Film; Tokyo, Japan). Blots were stripped for 5-10 min 
using Reblot Plus Strong (Millipore; Melbourne, Australia) solution and then 
reprobed with β-actin monoclonal antibody diluted 1/5000 or Na/K ATPase 
antibody diluted 1/1000 followed by goat anti-mouse secondary antibody to 
determine the protein loading for lysates and biotinylation respectively. 
Densitometry to quantify results was performed using Fuji Film Multi Gauge 
V3.0 computer software, and ratios for protein levels were calculated relative 
to β-actin or Na/K ATPase. 
 
2.6 Western blot analysis – cell secretions 
At the completion of each cell culture experiment, the remaining growth 
medium was collected and spun at 10,000 xg for 10 min to remove any 
suspended cells. The supernatant was collected and protein concentration 
estimated as was done for the cells. 60μg of protein was fractionated by 
SDS-PAGE on a 7.5% gel and transferred to nitrocellulose membranes 
(Whatman; Dassal, Germany) and probed for Cp as stated above. Images of 
the Ponceau S stain were taken using LAS-3000 FujiFilm Lumino-Image 
Analyzer and were used to determine the loading of the growth medium. 
Densitometry to quantify results was performed using Fuji Film Multi Gauge 
V3.0 computer software, and ratios for protein levels were calculated relative 
to the Ponceau S image. 
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2.7 Quantitative real time PCR (qRT-PCR) 
PMC42-LA cells grown in 75 cm2 culture flasks were collected by 
trypsinisation and washed three times in PBS. PMC42-LA cells grown on 
filters were collected from the Transwell cell culture inserts using 1mL of 
5mg/mL dispase (Gibco; Melbourne, Australia) dissolved in PBS. The 
dispase was left on the cells for 45 min until all cells detach from the EHS 
matrix. Cells were processed using an RNeasy Mini Kit (QIAGEN; 
Melbourne, Australia) following manufacturer’s protocol. Total RNA was 
purified by DNase1 treatment following the manufacturer’s protocol of the 
DNA-free kit (Ambion; Melbourne, Australia). RNA concentrations were 
determined using a Nanodrop 100 spectrophotometer (Thermo Fisher 
Scientific; Melbourne, Australia). Once quantified, RNA was converted to 
cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems; Melbourne, Australia) following the manufactures protocol. 
Quantitative Real Time PCR was performed using 7500 Real Time PCR 
system (Applied Biosystems; Melbourne, Australia) with 20 μl sample 
volumes containing 8 μl SYBR green mastermix (Applied Biosystems; 
Melbourne, Australia), 0.3 μM of both forward and reverse primers (Table 1) 
and 20 ng cDNA. The PCR reaction was performed at 50ºC 2 min, 95ºC 10 
min (1 cycle), 95ºC 15 sec, 60ºC 1 min (40 cycles). Relative mRNA 
expression was determined by comparing the expression of the target gene 
(ATP7A, ATP7B, CTR1, Cp, ATOX1, β2M) with housekeeping control (β-
actin) using the equation 2-ΔΔCT ± SD, where ΔΔCT was the difference between 
the control ΔCT and the treatment ΔCT. 
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Table 1.1 Real Time PCR Primers 
 
Gene 
 
Forward Primer 5’-3’ 
 
Reverse Primer 5’-3’ 
 
ATP7A 
 
GCTACCTTGTCAGACAACGAATGAC 
 
TCTTGAACTGGTGTCATCCCTTT 
 
ATP7B 
 
CCAGCAAAGCCCTTGTTAAGTT 
 
CACGAAAGCCAATTTCCTCAAT 
 
CTR1 
 
ACTCCAACAGTACCATGCAACCT 
 
AGTTCCACATTCTTAAAGCCAAAGTAG 
 
Ceruloplasmin 
 
GACACCATCAGAGTAACCTTCCATAA 
 
CCCCAATCGGCTCAATACTG 
 
ATOX1 
 
GCTTGGAGGAGTTAAGTATGACATTG 
 
TTTCTTCAGGGTTGCAAGCA 
 
β2-microglobulin 
 
AGCGTACTCCAAAGATTCAGGTT 
 
ATGATGCTGCTTACATGTCTCGAT 
 
β-actin 
 
GACAGGATGCAGAAGGAGATTACT 
 
TGATCCACATCTGCTGGAAGGT 
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2.8 Reverse transcription PCR (RT-PCR) 
RNA was extracted from PMC42-LA cells, purified and converted to cDNA as 
specified for qRT-PCR. PCR was performed using GoTaq Flexi Kit 
(Promega; Sydney, Australia) as per manufacturer’s instructions, using 
primers and thermocycling conditions as specified by Banha et al. (2008). 
PCR products were separated on a 1.5% Agarose (Amresco; Ohio, USA) in 
TAE buffer. 
 
2.9 Surface biotinylation 
Cells were grown in 6-well plates or on EHS matrix coated Transwell filters. 
Following treatment cells were placed on ice and allowed to cool to 4ºC. All 
buffers were also cooled to 4ºC before use. Growth medium was removed 
and cells were washed three times with PBS wash buffer supplemented with 
0.1 mM CaCl2 (Sigma-Aldrich; Sydney, Australia) and 1.0 mM MgCl2 (Sigma-
Aldrich; Sydney, Australia). EZ-Link Sulfo-NHS-SS-biotin (Pierce; Melbourne, 
Australia) was dissolved in biotinylation buffer (10 mM triethanolamine 
(Sigma-Aldrich; Sydney, Australia), pH 7.5, 2 mM CaCl2, 150 mM NaCl 
(Sigma-Aldrich; Sydney, Australia)) to a concentration of 0.77 mg/mL. 400 μl 
of Biotin was added per well and incubated for 25 min on ice while rocking. 
Biotin was removed and cells were washed once with quenching buffer (PBS 
with 0.1 mM CaCl2, 1.0 mM MgCl2, 100 mM Glycine (Sigma-Aldrich; Sydney, 
Australia)), then incubated in quenching buffer for 20 min on ice while 
rocking. This step was repeated once more. Lysis buffer (1% Triton X-100, 
150 mM NaCl, 5mM EDTA, 1x protease inhibitor cocktail (Roche; Melbourne, 
Australia), 50 mM Tris-HCl, pH 7.5) was added and incubated for 2 h at 4ºC, 
rotating end-over-end. The lysate was then centrifuged at 10,000 xg for 10 
 41 
 
min. The supernatant was transferred along with 0.15 volume of 
Streptavadin-agarose (Pierce; Melbourne, Australia) into a fresh tube and 
incubated at 4ºC overnight, rotating end-over-end. Samples were then 
centrifuged at 500 xg for 5 min and the supernatant aspirated using a 23-
guage needle bent into a z shape near the tip. The resin was then washed 
with lysis buffer (1% Triton X-100, 150 mM NaCl, 5 mM EDTA, 50 mM Tris-
HCl, pH 7.5) three times, salt wash buffer (0.1% Triton X-100, 500 mM NaCl, 
5 mM EDTA, 50 mM Tris-HCl, pH 7.5) two times and no salt buffer (10 mM 
Tris, pH 7.5) once. The resin was then centrifuged after the final wash at 
10,000 xg for 10 min. Protein was eluted from the streptavadin agarose resin 
using 40 μl of SDS-PAGE lysis buffer (1% SDS, 300 mM DTT, Tris-HCl, pH 
7.5). Protein was quantified and separated by SDS-PAGE. 
 
2.10 Co-immunoprecipitation 
PMC42-LA cells grown in 75 cm2 culture flasks were collected by 
trypsinisation and washed three times in PBS. The pellet was incubated in 
100 μl of lysis buffer (150 mM NaCl, 1.0% NP-40 (Sigma-Aldrich; Sydney, 
Australia), 50 mM Tris (pH 8.0)) on ice for 30 min with occasional mixing. The 
sample was then spun at 10,000 xg for 10 min at 4ºC. The supernatant was 
transferred to a fresh tube and combined with 2 μg of ATP7B or ATP7A 
antibody and incubated for 1 h on ice. The mixture was then combined with 
100 μl of Immobilized protein G (Pierce; Melbourne, Australia) and rotated 
end-over-end at room temperature for 2 h. Protein G beads were pelleted 
from solution by centrifugation at 1000 xg for 1 min and washed 5 times for 
5min with 1mL lysis buffer at room temperature. Proteins bound to protein G 
beads were removed by heating to 85ºC for 10 min in 40 μl 1% (w/v) SDS in 
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10 mM Tris-HCl (pH 7.5) lysis buffer with 100 mM DTT. The sample was then 
spun at 10,000 xg for 1 min and the supernatant collected for processing by 
Western blot and probed with the Cp antibody. 
 
2.11 Atomic absorption spectroscopy 
PMC42-LA cells grown as stated above in 75 cm2 culture flasks were 
collected by trypsinisation and washed three times in PBS. PMC42-LA cells 
grown on EHS matrix coated Transwell filters were collected using 1 mL of 5 
mg/mL dispase and washed three times in PBS. Cells were then centrifuged 
at 600 xg for 5 min and resuspended in 2 mM EDTA in PBS (pH 8.0) and 
treated for 30 min at 37ºC. Cells were washed three times in PBS then 
collected, lysed and quantifed as for Western blot analysis. Lysates were 
then dried for seven days at 85ºC. Once dry, samples were resuspended in 
500 μl concentrated Suprapur Nitric Acid (Merck; Melbourne, Australia), 
vortexed briefly then incubated at room temperature for 1 h. The samples 
were then incubated at 65ºC for 3 h, opening the tube cap every half an hour 
to release the build up of gas. Following the incubation, samples were 
vortexed briefly while still hot and then 2.5 mL (1 mL for Transwell filters) 
ElgaQ water was added, vortexed again and then left until ready for AAS 
analysis. Samples were analysed by electrothermal graphite furnace atomic 
absorption spectrometry, using a Varian GTA 100 spectrophotometer 
(Varian; Melbourne, Australia). 
 
2.12 Liquid-chromatography mass-spectrometry 
BCS/DPen treated cells grown in a 75 cm2 flask of cells were pelleted, lysed 
and sonicated as specified previously, then separated on 7.5% and 12% 
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SDS-PAGE gels. Gels were stained with Coomassie Brilliant Blue R-250 
(Biorad; Sydney, Australia) (0.1% Coomassie, 50% Methanol (Merck; 
Melbourne, Australia), 10% acetic acid (Merck; Melbourne, Australia)) for 
liquid-chromatography mass-spectrometry (LCMS) or transferred to 
nitrocellulose and processed by Western blot to confirm immunoreactivity of 
bands. Coomassie stained bands were excised from the gel in 1mm cubes 
and destained with 10 mM ammonium bicarbonate (Sigma Aldrich; Sydney, 
Australia) in 50% acetonitrile (Sigma Aldrich; Sydney, Australia). Sample was 
shaken on a variable speed mixer for 10 min. This process was repeated 
three times until the gel was visibly less stained. Reducing buffer (10mM DTT 
(Sigma Aldrich; Sydney, Australia), 10 mM ammonium bicarbonate) was 
added to gel and incubated at 60ºC for 1 h. Reaction mixture was cooled to 
room temperature then reducing buffer was discarded. Alkylation buffer (50 
mM iodoacetamide (Sigma Aldrich; Sydney, Australia), 10 mM ammonium 
bicarbonate) was added to sample and incubated at room temperature for 1 
h. The gel was washed with 10 mM ammonium bicarbonate for 10 min on 
variable speed mixer and then the liquid was removed from the gel and 
discarded. This wash was repeated twice more. Acetonitrile (100%) was 
added to the gel and incubated for 10 min at room temperature on a variable 
speed mixer to dehydrate the gel. The acetonitrile treatment was repeated 
twice more. Samples were left to air dry for 5 min. Samples were rehydrated 
with sequencing grade trypsin (Sigma Aldrich; Sydney, Australia) (0.02 μg/μl 
trypsin, 10 mM ammonium bicarbonate, 10% acetonitrile) and incubated at 
37ºC for 6-10 h. The supernatant was collected and mixed with 2% formic 
acid (Sigma Aldrich; Sydney, Australia), shaken and then spun down. 
Extraction buffer (50% acetonitrile, 2% formic acid) was added to the gel and 
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shaken for 30 min on a variable speed mixer. The liquid containing the 
extracted peptides was transferred to another tube and the process repeated 
once more, pooling the liquid. The peptide mixture was dried by vacuum 
centrifugation for 30 min at 35ºC. Once dried, 1% formic acid was added to 
the dried tube and redissolved by vortexing for 1-2 min. Samples were then 
processed by liquid-chromatography mass-spectrometry. 
 
2.13 Synchrotron X-ray fluorescence 
PMC42-LA cells were grown on ethanol sterilised 4mm silicon nitride 
windows (Melbourne Centre for Nanofabrication; Melbourne, Australia) or on 
EHS matrix coated Transwell filters as described in section 2.2. Following 
treatment, cells were rinsed twice in PBS then incubated in 2 mM EDTA in 
PBS (pH 8.0) for 5 min. Cells were rinsed three times in PBS and then fixed 
in 4% paraformaldehyde for 10 min. Cells were rinsed twice in PBS, then 
three times in ultrapure water (Sigma Aldrich; Sydney, Australia) and then air 
dried. EHS matrix coated filters with differentiated organoids were cut to an 
appropriate size and stuck to the silicon nitride windows with tape. At the 
Australian Synchrotron, the KB mirror microprobe with a spot size of 2x2 μm 
was used in conjunction with the 384-element silicon array Maia detector 
arranged in 180 degree backscatter geometry on the X-ray Fluorescence 
Microscopy beamline (Australian Synchrotron; Melbourne, Australia). This 
experiment used an X-ray energy level of 14.5KeV to excite secondary X-ray 
emissions from the K-shells of the first row of transition metals. Samples 
were scanned 10 mm from the detector, with each 2x2 μm spot being 
analysed for 62.5 ms. Scans covered areas of 200x200 μm. GeoPIXE 
version 6.3r (Library 27w32) software (CSIRO; Melbourne, Australia) was 
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used to compile and visualise the 2D X-ray fluorescence maps and to 
determine the localisation and levels of copper through traverse sections of 
the organoids. Quantitation of copper and iron levels was achieved by 
calibrating the secondary X-ray emission of a Pt standard reference foil using 
the GeoPIXE software. 
 
2.14 Statistical analysis 
All experiments were repeated in triplicate, and values expressed as means 
± SD. Probability plots (P-P plots) were produced for all data sets to test for 
normal distribution. One-way analysis of variance and Tukey’s honest 
significant difference test was used to determine statistical variation between 
treatments using the statistical software SPSS version 17; p<0.05 was 
considered significant. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
Copper and lactational hormones 
influence the CTR1 copper transporter in 
the PMC42-LA mammary epithelial cell 
culture model 
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3.1 Introduction 
 
Copper is an essential dietary component. Neonates rely heavily on maternal 
milk for their daily dietary needs and so maintaining adequate copper levels 
in milk is highly important. Milk is secreted from mammary epithelial cells in 
the mammary gland. For copper to be secreted into the milk, it must first be 
absorbed into the mammary epithelial cells from the maternal bloodstream.  
 
CTR1 plays an important role in copper uptake into cells. Thought to be the 
primary copper influx protein, it is important for CTR1 to be able to regulate 
copper uptake to protect cells from the toxic effects of copper (Eisses et al., 
2005, Lee et al., 2002b). CTR1 may also be important in mammary epithelial 
cells in enabling adequate uptake of copper for sufficient secretion of copper 
into milk to nourish a suckling infant. Studies have revealed a basolateral 
localisation of CTR1 in the mammary gland which is consistent with the 
model in which CTR1 enables the uptake of copper from the maternal 
bloodstream into the mammary epithelial cells (Kelleher and Lonnerdal, 
2003, Kelleher and Lonnerdal, 2006, Llanos et al., 2008). Little work has 
focussed on responses of CTR1 to lactation and suckling in humans; 
however the work that has been done suggests that in mice CTR1 moves 
towards the membrane during lactation and suckling. Increased levels of 
CTR1 at the plasma membrane would enable more copper to enter the 
mammary epithelial cells which in turn would facilitate secretion of copper 
into milk. 
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Metallothionein 1 and 2 (MT), are metal ion chaperones which play a role in 
the prevention of cellular toxicity by sequestering excess copper in the cells 
(Coyle et al., 2002, Mehta et al., 2006, Prohaska and Gybina, 2004, 
Sutherland and Stillman, 2011). In the mammary gland, MT could act in a 
protective way, not only inhibiting the toxic effects of copper by sequestering 
it within the mammary epithelial cells, but also preventing the secretion of 
excess copper into milk. 
 
It is hypothesised that CTR1 plays a key role in the uptake of copper into 
mammary epithelial cells during lactation. This research aims to identify the 
responses to CTR1 to changing copper and lactational hormone levels, like 
the variations experienced between non-lactating and lactating periods, to 
understand how CTR1 may influence copper levels in the mammary gland.  
In the current study the differentiated PMC42-LA cell culture models 
representing the resting and lactating mammary gland have been utilised. 
The lactating model has also been further developed to mimic the conditions 
encountered by the mammary epithelial cells while an infant is suckling by 
increasing the concentration of prolactin in the culture. The 50 μM copper 
treatment also represents the maternal blood copper level in the mammary 
gland that is elevated in pregnancy and lactation. Using this culture system, 
CTR1, MT and copper levels and localisation were analysed. Total and 
plasma membrane bound CTR1 levels increase with the addition of 
hormones, which was accompanied by the accumulation of copper within the 
cells as well as induced secretion of copper into the lumen of the organoids. 
It is proposed that this mechanism may aid the movement of copper from the 
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maternal blood stream into milk secretions to sustain the rapid growth of a 
breast-fed neonate. 
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3.2 Results 
 
3.2.1 CTR1 and MT protein in undifferentiated PMC42-LA cells was 
influenced by copper, while CTR1 mRNA remained unaltered 
Undifferentiated PMC42-LA cells were grown in culture flasks and treated 
with varying concentrations of copper to determine the effect on CTR1 
expression. A concentration of 5 μM copper was used in the growth medium 
to match the normal concentration of exchangeable copper in blood plasma 
which is in the range of 2.7 and 7.7 μM (Linder, 1991, Linder, 2002). We 
treated PMC42-LA cells with 50 μM copper to simulate the maternal plasma 
copper concentration during lactation. Copper concentrations during lactation 
vary widely among reports, however the upper limit is approximately 50 μM 
(Dorea, 2000). Copper chelators were added to determine the effect of 
copper deficiency in the mammary gland models. Quantitative Real Time 
PCR analysis determined that there was no significant difference (p>0.05) in 
CTR1 mRNA levels between cells grown in low (BCS/DPen, 103.9 ± 19.2%), 
basal (5 μM copper, 100.0 ± 13.2%) or high (50 μM copper, 107.6 ± 15.1%) 
levels of copper (Fig 3.1a). 
 
Analysis of protein by Western blot revealed bands at approximately 105kDa 
and also 35kDa which were detected with all three treatments purportedly 
correlating to the trimeric and monomeric forms of CTR1, however the 
fluctuations between the two bands in response to copper were inconsistent. 
This led us to question whether the 105kDa band was in fact the trimeric form 
of CTR1. Using liquid-chromatography mass-spectrometry (LCMS) to 
analyse the 105kDa protein, CTR1 could not be identified among the top 67 
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abundant proteins within the molecular weight range of 15-30 kDa (covering 
the 22 kDa native CTR1 protein). Considering the intensity of the band 
detected by Western blot in this region, this strongly suggests that this is non-
specific immunoreactivity, rather than the CTR1 trimer, thus the following 
research focuses solely on the monomeric CTR1 band. 
 
The level of the 35 kDa monomeric CTR1 form was influenced by varying 
copper treatments. CTR1 exhibited a significant decrease in expression in 
response to increasing copper levels (50 μM copper treated cells; 67.1 ± 
12.2%), and a significant increase (p<0.05) in response to copper chelation 
(BCS/DPen treated cells; 239.6 ± 25.9%) compared to the 5 μM copper 
treated PMC42-LA cells used as a control (100.0 ± 15.1%) (Fig 3.1b).  
 
MT sequesters copper when high copper levels are present. Western blot 
analysis of MT revealed it to be present only in the 50 μM copper treated 
cells. MT was not detected in the BCS/DPen or 5 μM copper treated cells 
(Fig 3.1b). 
 
Surface biotinylation was used to determine the amount of CTR1 located at 
the plasma membrane when cells were exposed to varying concentrations of 
copper. CTR1 protein was identified at the plasma membrane in all 
treatments. The BCS/DPen treated cells had significantly more protein (541.4 
± 188.1%) (p<0.05) compared to the 5 μM copper basal conditions (100.0 ± 
18.7%), which in turn was significantly higher than the levels detected in the 
50 μM copper treated cells (37.6 ± 16.0%) (p<0.05) (Fig 3.1c).  
 
 52 
 
To determine the effect of copper on CTR1 localisation, PMC42-LA cells 
were grown on glass coverslips and analysed by immunofluorescence 
confocal microscopy. CTR1 showed a granular distribution throughout the 
cytoplasm of cells. This staining pattern did not vary between any of the 
copper conditions (Fig 3.1d). 
 
3.2.2 Intracellular copper levels increased upon exposure to high 
copper 
Atomic absorption spectroscopy (AAS) was used to identify whether the 
observed changes to CTR1 protein in cells exposed to varying copper 
concentrations affected cellular copper accumulation. Low levels of copper 
were detected in BCS/DPen treated cells (32.9 ± 7.0 ng Cu/mg protein). 
Surprisingly, they were not significantly different from copper levels in the 5 
μM copper treated cells (27.4 ± 6.7 ng Cu/mg protein), however the addition 
of  50 μM copper to the cells resulted in a significant rise in intracellular 
copper levels (586.9 ± 33.3 ng Cu/mg protein) (p<0.05) (Fig 3.2a). 
 
X-ray fluorescent microscopy (XFM) was used to determine whether the 
changes observed in copper levels correlated with a change in distribution of 
copper within the cells. No copper was detected in the BCS/DPen treated 
cells, however a faint signal was observed in the 5 μM copper treated 
samples suggesting that the levels of copper in these cells was bordering the 
detection limit of this technique. The copper in the 50 μM treated cells was 
clearly visible and localised in the centre of the cells rather than the 
periphery, possibly in the TGN and nucleus (Fig 3.2c). Zinc was detected in
  
 
Figure 3.1 CTR1 and MT in response to copper treatments in 
undifferentiated PMC42 cells 
(a) Relative CTR1 mRNA levels of 50 μM copper and BCS/DPen treatments 
compared to that of the 5 μM copper treatment. The bar graph shows mRNA 
mean percentages ±SD from three independent experiments normalised 
against β-actin obtained by qRT-PCR. (b) Representative CTR1 and MT 
Western blot analysis of 60μg of undifferentiated PMC42-LA cell extracts. 
Lane 1, BCS/DPen treatment; lane 2, 5 μM copper treatment; lane 3, 50 μM 
copper treatment. β-actin was used as a loading control. Desitometric 
analysis of CTR1 band intensity are expressed as a mean percentage of 
arbitrary units ±SD compared to the 5 μM copper treated sample and 
normalised against β-actin. This figure shows representative results of three 
independent experiments. Asterisk indicates significant difference between 
samples (p<0.05). (c) Surface biotinylation of CTR1. The graph indicates 
densitometric values obtained from Western blot analysis of biotinylated 
CTR1 protein bands in response to BCS/DPen (lane 1), 5 μM copper (lane 2) 
and 50 μM copper (lane 3). Values are expressed as a mean percentage of 
arbitrary units ±SD compared to the 5 μM copper treated sample normalised 
against Na/K ATPase. Results are representative of three independent 
experiments. Asterisk indicates significant difference between samples 
(p<0.05). (d) Immunolocalisation of CTR1 (green) in PMC42-LA cells treated 
with BCS/DPen (i), 5 μM copper (ii) and 50 μM copper (iii). Nuclei were 
stained with ethidium bromide (red). Scale bar = 10 μm. 
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all samples and was used in this analysis to indicate the position of each cell 
(Fig 3.2c). Analysis of the images using GeoPIXE software revealed that the 
scanned cells had an average copper concentration of 27.8 ± 4.3 ppm within 
them when treated with 50 μM copper. This was 7 fold higher than the cells 
treated with 5 μM copper (4.1 ± 1.0 ppm) (Fig 3.2b). This trend reflected the 
data obtained by AAS analysis.  
 
3.2.3 CTR1 mRNA levels were not influenced by copper or lactational 
hormones in differentiated PMC42-LA cells 
In the current study, the previously characterised PMC42-LA models of 
resting and lactating mammary glands were used (Ackland et al., 2001, 
Ackland et al., 2003, Michalczyk et al., 2008). An additional model 
representing the sucked mammary gland was developed to further 
characterise the involvement of CTR1 in transporting copper into milk. For 
this, PMC42-LA cells were grown on EHS matrix coated Transwell filters and 
treated with lactational hormones together with a higher concentration of 
prolactin than was used in the lactating model. This mimics the physiological 
conditions of mammary cells during suckling where plasma prolactin levels 
are increased in response to mechanical stimuli and can be maintained at an 
elevated level if breast-feeding occurs frequently (Neville et al., 2002, Pang 
and Hartmann, 2007, Rhoads and Grudzien-Nogalska, 2007). The copper 
concentration of 50 μM represented the high maternal blood serum copper 
levels during early lactation, while the 5 μM copper treatment represented the 
non-lactating blood serum levels. 
 
 
  
 
Figure 3.2 PMC42-LA intracellular copper levels in response to copper 
chelation and copper treatment 
(a) The graph shows average values of copper levels in PMC42-LA cells 
treated with BCS/DPen, 5 μM copper and 50 μM copper as determined by 
AAS. Asterisk indicates significant difference (p<0.05). (b) Analysis of the 
XFM images using GeoPIXE software revealed the levels of copper in the 
cells of each treatment. (c) XFM analysis showing the localisation of copper 
and zinc in PMC42-LA cells treated with BCS/DPen (i and iv), 5 μM copper (ii 
and v) and 50 μM copper (iii and vi). The colour scale bar shows the relative 
levels of copper from lowest (black) to highest (white). Length scale bar = 
30μm. 
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Quantitative Real Time PCR was performed on differentiated PMC42-LA 
cells to identify whether mRNA levels were influenced by treatment with 
lactational hormones in combination with varying copper levels. No significant 
effect on the expression levels of CTR1 in PMC42-LA cells was observed in 
the resting model (BCS/DPen – 93.5 ± 13.7%, 5 μM copper – 100.0 ± 13.4% 
and 50 μM copper – 93.9 ± 10.3%), lactating model (BCS/DPen – 110.9 ± 
14.2%, 5 μM copper – 111.2 ± 12.5% and 50 μM copper – 98.4 ± 13.4%) or 
suckled model (BCS/DPen – 106.0 ± 22.5%, 5 μM copper – 106.7 ± 17.9% 
and 50 μM copper – 98.4 ± 13.3%) (p>0.05) (Fig 3.3a).  
 
3.2.4 CTR1 and MT total protein levels altered in response to copper 
and lactational hormones 
To identify whether protein levels reflected that of the mRNA, total protein 
lysates were analysed by Western blot. The observed trends in response to 
copper were consistent across all three models. Densitometric analysis 
revealed that the BCS/DPen treated samples had significantly higher CTR1 
protein levels (resting – 350.5 ± 44.0%, lactating – 397.3 ± 32.4%, suckled – 
439.4 ± 33.6%) than the 5 μM copper treated cells (resting – 100.0 ± 14.6%, 
lactating – 139.9 ± 30.7%, suckled – 170.5 ± 5.2%) and 50 μM copper 
treated cells (resting – 71.1 ± 11.0%, lactating – 100.7 ± 6.1%, suckled – 
125.6 ± 10.7%) (p<0.05). While the 50 μM copper treated samples 
consistently proved to have less CTR1 protein that the 5 μM copper treated 
samples in all three models, the reduction was not statistically significant 
(p>0.05). 
 
 57 
 
Comparison of the hormonal treatments in the PMC42-LA cell line revealed 
that the resting model cells had less CTR1 protein levels in each respective 
copper treatment compared to those of the lactating model. The levels in the 
lactating model were lower than those of the suckled model. These data 
show that there is statistically more CTR1 protein in each of the copper 
treatments of the suckled model compared to the resting model (p<0.05), 
however the differences between the resting model and lactating model and 
between the lactating and suckled model showed no statistical differences 
(p>0.05) despite the consistently increasing protein levels in response to 
elevated levels of prolactin (Fig 3.3b).  
 
In the differentiated cells, MT was present only in the 50 μM copper treated 
cells similar to undifferentiated cells, however the levels also increased in 
response to hormones. The lactating (211.1 ± 45.7%) and suckled (325.3 ± 
52.3%) models had significantly more MT than in the resting model (100.0 ± 
7.8%) (p<0.05). MT levels were slightly elevated in the suckled model 
compared to the lactating model, however this difference was not significant 
(p>0.05) (Fig 3.3b). No MT was detected in the BCS/DPen or 5 μM copper 
treated cells for any of the three models.  
 
3.2.5 Plasma membrane bound CTR1 levels decreased in response to 
copper, but increased in the presence of lactational hormones 
The amount of CTR1 protein detected at the plasma membrane by 
biotinylation was similar to that observed in the total CTR1 protein levels (Fig 
3.3b). Copper chelation increased the amount of CTR1 protein present at the 
plasma membrane, while the addition of copper diminished its presence. This 
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trend was consistent in all three models. The protein levels in response to 
BCS/DPen (resting – 381.4 ± 123.6%, lactating – 1705.7 ± 200.5%, suckled 
– 3303.6 ± 576.6%) were significantly higher than those levels detected in 
response to both 5 μM (resting – 100.0 ± 27.5%, lactating – 249.8 ± 53.8%, 
suckled – 379.6 ± 124.0%) and 50 μM copper (resting – 92.7 ± 17.1%, 
lactating – 210.5 ± 45.7%, suckled – 346.9 ± 106.8%) (p<0.05). Like the total 
protein levels, no statistically significant difference was observed between the 
5 μM and 50 μM copper treated samples; however each model clearly 
showed a trend indicating there was less CTR1 protein at the membrane with 
the addition of 50 μM copper. 
 
The total CTR1 protein changes observed in response to the addition of 
lactational hormones was similarly reflected in the levels of CTR1 protein 
found at the plasma membrane. Levels increased in response for hormones 
in each respective copper treatment with the changes between the resting 
and suckled models being significantly different (p<0.05) (Fig 3.3c). The 
differences between the resting and lactating values were only significant for 
the BCS/DPen treated cells; this was also the case when comparing the 
lactating and suckled models.  
 
3.2.6 No change in CTR1 localisation was observed in PMC42-LA cells 
treated with copper and lactational hormones 
Immunofluorescence confocal microscopy was used to visualise the 
localisation of CTR1 protein within the organoidal structures of the 
differentiated PMC42-LA cultures. Analysis revealed no obvious variations in 
CTR1 localisation between any of the copper or hormonally treated cultures 
  
 
Figure 3.3 The copper and hormonal responses of CTR1 and MT in 
differentiated PMC42-LA cells 
(a) Relative mRNA levels of CTR1 in response to copper and hormones 
obtained by qRT-PCR. The bar graph indicates the mean percentage 
difference ±SD compared to the 5 μM copper treated cells of the resting 
model. CTR1 mRNA levels were normalised against β-actin. B = BCS/DPen, 
5 = 5 μM copper, 50 = 50 μM copper (b) Representative Western blots of 
60μg of protein extract showing the CTR1 and MT bands in the resting breast 
model, lactating model and suckled model treated with BCS/DPen, 5 μM 
copper and 50 μM copper. The β-actin blot demonstrates relative loading of 
samples. The CTR1 densitometry graph bar show mean intensity of CTR1 
bands expressed as a percentage of arbitrary units ±SD compared to the 5 
μM copper treatment of the resting model. The MT densitometry graph 
shows values relative to the 50 μM copper treated resting model. 
Densitometric analysis of CTR1 and MT bands were normalised against β-
actin. (c) This representative Western blot of extracellularly biotinylated 
protein extract shows the CTR1 band in the resting breast model, lactating 
model and suckled model treated with BCS/DPen, 5 μM copper and 50 μM 
copper. Densitometric analysis shows mean intensity of CTR1 bands 
expressed as a percentage of arbitrary units ±SD compared to the 5 μM 
copper treatment of the resting model. Densitometric analysis of CTR1 bands 
were normalised against the Na/K ATPase. All blots are representative of 
four independent experiments. Statistical variation is indicated by different 
letters and asterisk above graph bars, whereas the same letters represent no 
significant difference (p<0.05).  
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(Fig 3.4). The labelling of CTR1 appeared punctate and evenly distributed 
throughout the cell. It was difficult to determine whether this labelling was 
cytoplasmic, membrane or a combination of both. X-Z section analysis 
indicated that labelling was predominantly basolateral. 
 
3.2.7 Intracellular copper levels of differentiated PMC42-LA cells were 
influenced by copper and lactational hormone treatment 
Variations in copper and hormonal treatments influenced the intracellular 
copper levels of differentiated PMC42-LA cells. Copper levels in the resting 
model determined by AAS, showed no difference between the BCS/DPen 
(54.3 ± 23.0 ng Cu/mg protein) and 5 μM copper (61.4 ± 10.5 ng Cu/mg 
protein) treated cells (p>0.05). However the levels observed in the 50 μM 
copper treated cells (165.5 ± 14.7 ng Cu/mg protein) were significantly higher 
(p<0.05). This trend was replicated the lactating model (BCS/DPen – 40.4 ± 
9.8 ng Cu/mg protein, 5 μM copper – 58.8 ± 16.9 ng Cu/mg protein, 50 μM 
copper – 520.3 ± 75.8 ng Cu/mg protein) and also the suckled model 
(BCS/DPen – 41.0 ± 18.4 ng Cu/mg protein, 5 μM copper – 59.0 ± 23.7 ng 
Cu/mg protein, 50 μM copper – 622.6 ± 78.7 ng Cu/mg protein) (p<0.05). 
Between the models, there was no difference in cellular copper accumulation 
in the BCS/DPen or 5 μM copper treatments (p>0.05). However there was a 
significant difference between the metal accumulation of the 50 μM copper 
treated resting model cells compared to the lactating and suckled models 
(p<0.05). This indicates that hormones were having an effect on the 
accumulation of copper in the cells, although the difference was not 
statistically significant between the levels of copper in the lactating and 
suckled models (p>0.05) (Fig 3.5). 
  
Figure 3.4 CTR1 localisation in differentiated PMC42-LA cells following 
copper and hormonal treatment 
Localisation of CTR1 (green) in the resting breast cell model in response to 
BCS/DPen, 5 μM copper and 50 μM copper (a, b and c). CTR1 protein 
localisation in the lactating breast cell model in response to BCS/DPen, 5 μM 
copper and 50 μM copper (d, e and f). CTR1 localisation within the suckled 
breast cell model in response to BCS/DPen, 5 μM copper and 50 μM copper 
(g, h and i). Image i of each sub-figure is a transverse section through the top 
of the organoid. Image ii and iii show y-z and x-z sagittal sections 
respectively, cutting through the centre of the organoid. Nuclei were stained 
with ethidium bromide (red). Scale bar = 20 μm. 
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Figure 3.5 The intracellular copper levels of differentiated PMC42-LA 
cells treated with copper and lactational hormones 
AAS analysis of copper levels within the PMC42-LA cells in response to 
BCS/DPen, 5 μM copper and 50 μM copper treatments for each of the 
resting, lactating and suckled models. Statistical variation is indicated by 
different letters above graph bars (p<0.05). 
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3.2.8 The level and localisation of copper within PMC42-LA organoids 
was affected by copper and lactational hormone treatment 
XFM analysis of PMC42-LA organoids revealed that the organoids 
accumulated copper more than the surrounding monolayer of cells. This was 
particularly evident in the lactating (Fig 3.6e and f) and suckled models (Fig 
3.6h and i) treated with 5 μM and 50 μM copper, however less obvious in the 
resting model (Fig 3.6b and c). Copper was not detected in any of the 
BCS/DPen samples, similar to the undifferentiated cells (Fig 3.6a, d and g). 
Each copper distribution image is accompanied by a corresponding total 
fluorescence image showing the cells of the monolayer and the structure of 
the organoid. 
 
The graphs in figures 3.6j-r represent the levels of copper in the traverse 
regions defined by the green boxes shown on the images of figures 3.6a-i. 
There was a distinct correlation between copper levels and organoid 
localisation. The graphs of the 5 μM copper treated samples (Fig 3.6k,n and 
q) indicated low levels of copper (<5 ppm) in the monolayer region of cells, 
whereas in the presence of an organoid, the maximum levels rose to around 
15-35 ppm for all models. The trend was similar in the 50 μM treated 
samples with the monolayer of the resting model giving readings no higher 
than 5 ppm (Fig 3.6l), however the lactating and suckled models (Fig 3.6o 
and r) had slightly higher levels in the monolayer (between 10-20 ppm) than 
the resting model. This level of copper is similar to the undifferentiated 
PMC42-LA cells and is consistent with the AAS data which showed that the 
levels in the 50 μM copper treated cells of the lactating and suckled models 
were similar to those of the undifferentiated cells, whereas the levels in the 
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resting model were much lower. Like the 5 μM copper treated samples, 
levels rose significantly in the location of an organoid reaching 40 ppm in the 
resting model, 120 ppm in the lactating model and 85 ppm in the suckled 
model. The copper graphs of the BCS/DPen treated samples barely peaked 
above 0 ppm (Fig 3.6j, m and p). 
 
To determine whether the accumulation within the organoid was copper 
specific, other elements were examined. Zinc showed little variation between 
monolayer and organoid giving readings of around 40-50 ppm. Similarly, iron 
was present in approximately 140-150 ppm for organoid and monolayer cells 
(data not shown). While there appears to be some regions of elevated zinc in 
the traverse region graphs (Fig 3.6j-r), these increases correspond to “hot 
spots” on the images and did not follow a trend consistent with accumulation 
specifically within an organoid or within the monolayer region. 
 
  
 
Figure 3.6 Copper levels and localisation within differentiated PMC42-
LA organoids 
X-ray fluorescence images show the location of copper within the BCS/DPen 
(a, d and g), 5 μM copper (b, e and h) and 50 μM copper (c, f and i) treated 
cells in each of the resting (a, b and c), lactating (d, e and f) and suckled 
models (g, h and i). Total X-ray fluorescence images accompany the XFM 
copper images to show the position of each of the organoids. The colour 
scale bar shows the relative levels of copper from lowest (black) to highest 
(white). Length scale bar = 30 μm. The green line on each XFM image 
indicates the position of the traverse section displayed in figures 3.6 j-r. Metal 
levels within this traverse line are plotted on line graphs. Traverse sections 
through the organoids reveal the change in copper levels between the 
monolayers of cells and organoidal structures found in differentiated PMC42-
LA cells. For each cell model treated with BCS/Dpen (j, m and p), 5 μM 
copper (k, n and q) and 50 μM copper (l, o and r), the graphs show the levels 
of copper and zinc, through each point of the traverse line shown in the 
copper images of figures 3.6 a-i. The x-axis shows distance along the 
traverse line in micrometers and the y-axis shows the levels of each element 
in ppm. 
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3.3 Discussion 
 
Copper is an essential component of milk, yet little is known about how this 
element is taken up by the mammary epithelial cells. There have been few 
reports on the regulation of CTR1 in the mammary gland in response to 
lactation. This research utilises previously developed cell culture models of 
the resting and lactating mammary gland in conjunction with a newly created 
suckled model to gain insight into the regulation of CTR1 and its involvement 
in the delivery of copper into the milk during the periods of lactation and 
suckling when copper and hormone levels fluctuate dramatically. As CTR1 is 
postulated to mediate copper absorption from the maternal bloodstream into 
the mammary epithelium for its incorporation into the milk and subsequent 
secretion, this work focuses on analysis of CTR1 protein expression in 
mammary epithelial cells in different lactational states. 
 
Synchrotron X-ray fluorescence data revealed that the organoidal structures, 
which have been previously shown to contain mammary gland specific 
features including lipid granules, swollen endoplasmic reticulum and large 
secretory vacuoles (Ackland et al., 2001), accumulated copper, and this 
accumulation increased with the addition of lactational hormones in the 
representative lactating and suckled models. A 5-25 fold increase in copper 
was detected when comparing the highest levels in the central regions of the 
organoids to those of the surrounding monolayers. This increase is not due to 
the difference in thickness between the organoid and monolayer of cells. 
Organoids contain either two or three layers of cells and should not result in 
an increase greater than 2-3 fold depending on the organoid’s thickness, or 
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possibly no detectable change at all, as was shown by the zinc and iron 
analysis. The copper localisation data suggest that the accumulation in the 
organoids is not an accumulation of copper within the cells, rather an 
accumulation of secreted copper within the lumen of the organoid. The AAS 
data indicated that there was no difference in copper levels between the cells 
treated with BCS/DPen and 5 μM copper for any of the differentiated models. 
In contrast, the XFM data showed the 5 μM copper treated organoid to be 
loaded with copper, whereas the BCS/DPen treated organoids had no 
observable copper. The monolayer areas of the BCS/DPen and 5 μM copper 
treated cultures had undetectable levels or in some cases barely detectable 
levels of copper; similar to the undifferentiated cells which also showed no 
difference in copper accumulation when analysed by AAS. Thus, the copper 
detected in the organoid is not accumulating in the cells, but concentrated 
within the lumen of the organoid. This copper would not be detected by AAS 
as it would be washed away during sample preparation in contrast to XFM 
sample preparation which maintains the organoid structures. The reason no 
copper was detected in the lumen of the BCS/DPen organoids, despite the 
fact that AAS analysis determined the levels to be equivalent between the 
BCS/DPen and 5 μM copper treated cultures, may be that the BCS/DPen 
samples would have a limited capacity to deliver copper into the lumen of the 
organoid as the majority of copper would be bound to the chelators and not 
biologically available for proteins to transport. The 50 μM copper treated 
cultures had more copper in the lumen and also in the cell monolayers than 
the 5 μM copper and BCS/DPen treated samples. This trend was reflected in 
the undifferentiated cells. The addition of lactational hormones to the 50 μM 
copper treated cultures increased cellular copper accumulation. Hormonally 
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treated samples also appear to have more copper in the lumen of the 
organoid compared to the resting model, while there was no significant 
difference between the lactating and suckled models. This indicates that the 
hormones are inducing the secretion of copper into the lumen of the 
organoids and similarly may mediate the movement of copper into the milk of 
a lactating mammary gland. This is consistent with the physiological 
observations described in rodents during lactation where copper is 
preferentially directed towards the mammary gland, presumably to be 
secreted into the milk to feed a suckling pup (Donley et al., 2002). The 
organoid data is also consistent with physiological observations that show 
copper levels in the milk alter in conjunction with circulating hormone levels 
during lactation. It was shown that when prolactin levels are elevated during 
early lactation, copper levels are high in the milk and gradually decrease as 
lactation progresses and circulating prolactin levels reduce (Kelleher and 
Lonnerdal, 2006). 
 
Metallothionein 1 and 2 (MT) levels strongly correlated with the copper levels 
within the cells, being highest in cells containing high levels of copper in both 
the differentiated and undifferentiated cells. This is consistent with previous 
research that shows MT is regulated by copper and is elevated in conjunction 
with copper levels (Armendariz et al., 2004, Coyle et al., 2002, Prohaska and 
Gybina, 2004, Urani et al., 2003). It is also consistent with MT’s role as a 
metallochaperone which sequesters excess metal ions like copper, zinc and 
cadmium within cells (Mehta et al., 2006, Sutherland and Stillman, 2011, 
Urani et al., 2003). The elevation of MT following hormone treatment is likely 
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a result of the additional copper found within the hormonally treated cells 
rather than a direct influence of the hormones themselves. 
 
Using differentiated culture models it was shown that lactational hormones 
increased the total, as well as the plasma membrane bound CTR1 protein 
levels. It was evident in cells exposed to 50 μM copper, similar to the levels 
found in the lactating mammary gland, that the increased CTR1 protein 
caused by lactational hormones correlated with increased intracellular copper 
levels. The levels of CTR1 protein increased further in the suckled model 
compared to the lactating model suggesting that prolactin plays a role in 
CTR1 regulation. It has been shown previously that the monomeric form of 
CTR1 is responsive to hormones, with reduction in the Jeg-3 placental cell 
line upon exposure to progesterone, estrogen and insulin (Hardman et al., 
2006). While this response appears to contradict the PMC42-LA cell culture 
data, it can be explained by understanding the copper fluxes in placenta 
(Hardman et al., 2006). In the mammary gland, copper moves from the 
maternal bloodstream towards the milk facilitated by CTR1 protein present at 
the basolateral membrane. In the placenta, the main movement of copper is 
from the maternal bloodstream to the foetal bloodstream, however in this 
instance, CTR1 is on the foetal side of the placenta (Hardman et al., 2006). 
Reduced CTR1 levels due to lactational hormones, as demonstrated in Jeg-3 
cells, would decrease the amount of copper leaving the foetal bloodstream 
helping to drive the copper flow towards the growing foetus. CTR1 may have 
a protective role in this instance, removing excess copper from the foetal 
circulation back to the maternal bloodstream.  
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The CTR1 mRNA results showed no changes in response to hormones or 
depleted or elevated copper levels. There have been few reports on the 
mRNA levels of CTR1 in cultured cells, however experiments on 
differentiated intestinal Caco2 cells showed no response to changing copper 
levels (Bauerly et al., 2004, Tennant et al., 2002), while work with yeast and 
a small cell lung carcinoma cell line has shown that CTR1 mRNA expression 
is influenced by changing copper levels (Kirchman and Botta, 2007, Song et 
al., 2008). In the latter research, total and membrane protein levels in these 
cells were not analysed. If the mechanisms controlling copper influx by CTR1 
are cell type specific as suggested by Molloy and Kaplan, (2009), then 
perhaps it is possible that some cells regulate CTR1 by controlling 
transcription. In agreement with our findings, mice studies have shown that 
changes in circulating prolactin and copper concentration have no impact on 
the levels of CTR1 mRNA in mice mammary glands (Gambling et al., 2004, 
Kelleher and Lonnerdal, 2006), also dietary copper intake has shown to have 
no impact on the CTR1 mRNA levels in rat pups’ small intestines (Bauerly et 
al., 2005). 
 
The research presented in this chapter suggests that the changes in protein 
levels in response to copper and hormones may be a result of post 
translational CTR1 degradation as the transcription levels of this transporter 
was unaltered in any of the cell treatments. Degradation of endogenous 
CTR1 protein in response to copper has been reported a number of times 
(Holzer and Howell, 2006, Holzer et al., 2004a, Safaei et al., 2009) while it 
has also been shown that exogenously expressed, myc or GFP tagged CTR1 
protein follows the same trend (Guo et al., 2004a, Guo et al., 2004b, Liu et 
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al., 2007, Petris et al., 2003). CTR1 is important for copper uptake and is 
possibly the primary copper influx protein in human cells (Eisses et al., 2005, 
Lee et al., 2002b), therefore down-regulating the levels of CTR1 in response 
to elevated copper may be essential to prevent cellular copper toxicity. This 
is clearly demonstrated by the results showing that the total CTR1 protein 
levels were reduced along with the levels of CTR1 protein at the plasma 
membrane. The addition of hormones seems to impede this degradation 
process, leading to the observed increase in CTR1 protein. Reduced 
degradation would enable more CTR1 to be retained at the membrane 
allowing more copper to enter the cells for transfer into the milk. CTR1 
degradation has been reported previously in MDCK, HeLa and HepG2 cells 
in response to copper. HEK293 cells also showed a reduction in CTR1 
protein at the plasma membrane, however this was not due to degradation of 
total CTR1 protein, rather a result of the internalisation of the protein complex 
into the cells by endocytosis (Molloy and Kaplan, 2009). Contrary to this 
T47D cells did not show a reduction in protein levels at the membrane in 
response to copper suggesting that the mechanism involved in controlling 
influx via CTR1 may be cell type specific (Molloy and Kaplan, 2009). 
Internalisation of CTR1 has been reported a number of times (Guo et al., 
2004a, Guo et al., 2004b, Holzer and Howell, 2006, Holzer et al., 2004a, Liu 
et al., 2007, Petris et al., 2003) and is a logical process in the prevention of 
copper uptake into cells. CTR1 protein analysis data obtained from whole cell 
lysates and biotinylated plasma membrane fractions suggest that there may 
be some internalisation of CTR1 in addition to its degradation. The 
observation was made that the difference between the levels of CTR1 at the 
membrane in the BCS/DPen and 5 μM copper treated cells was far greater 
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than the difference between the total CTR1 levels of the same treatments. 
This was observed in undifferentiated cultures as well as the differentiated 
models. The same trend was also observed between the 5 μM copper and 
50 μM copper treatments of the undifferentiated cells. These data indicate 
that when cells are depleted of copper, there is a higher proportion of the 
total CTR1 protein present at the membrane which is available for copper 
uptake. In the presence of copper, CTR1 protein is degraded, but 
internalisation also takes place. 
 
Immunolocalisation studies revealed a membrane and cytoplasmic/vesicular 
pattern of CTR1 labelling. This is consistent with previous observations 
where researchers have shown that CTR1 predominantly localises at the 
plasma membrane (Eisses and Kaplan, 2002, Hardman et al., 2006, Holzer 
et al., 2004b, Kelleher and Lonnerdal, 2006, Klomp et al., 2003, Klomp et al., 
2002, Lee et al., 2002a, Maryon et al., 2007, Petris et al., 2003) with some 
groups also reporting perinuclear (Eisses and Kaplan, 2002, Klomp et al., 
2002) and cytoplasmic/vesicular (Guo et al., 2004b, Holzer et al., 2004a, 
Kelleher and Lonnerdal, 2006, Klomp et al., 2002, Safaei et al., 2009) 
distribution, however the localisation observed between cells lines seems to 
vary widely (Klomp et al., 2002). While the biotinylation and whole cell lysate 
data suggest some internalisation of CTR1 protein from the membrane, 
immunofluorescent staining of CTR1 did not reveal differences following 
treatment with copper and hormones, a trend also observed in Jeg-3, HeLa, 
Caco2, HEK293 cells (Eisses et al., 2005, Hardman et al., 2006, Klomp et al., 
2002) and in mammary gland tissues between early and late lactation when 
copper and hormone levels differ greatly (Kelleher and Lonnerdal, 2006). 
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Several studies have reported internalisation of CTR1 from the membrane 
following copper treatment (Guo et al., 2004a, Guo et al., 2004b, Liu et al., 
2007, Molloy and Kaplan, 2009) by clathrin dependent macropinocytosis 
(Holzer and Howell, 2006, Petris et al., 2003) which preceeds proteosomal 
degradation (Holzer and Howell, 2006, Jandial et al., 2009, Liu et al., 2007). 
CTR1 internalises from the membrane into cytoplasmic vesicles (Guo et al., 
2004a) in which it has been shown to co-localise with transferrin receptor in 
endosomes (Bauerly et al., 2004, Eisses et al., 2005, Kelleher and 
Lonnerdal, 2006, Petris et al., 2003). Such slight movements from plasma 
membrane to endosomal compartments upon treatment with copper would 
be indistinguishable using single labelled fluorescence microscopy. 
 
X-Z sections produced by confocal microscopy revealed that CTR1 localised 
towards the basolateral side of the cells in PMC42-LA organoid structures. 
Studies on polarised MDCK, OK and Caco2 cultured cells have identified 
CTR1 at the basolateral membrane using biotinylation (Molloy and Kaplan, 
2009, Zimnicka et al., 2007). This is consistent with mouse tissues that have 
shown CTR1 to be basolaterally localised in the mammary gland (Kelleher 
and Lonnerdal, 2003, Kelleher and Lonnerdal, 2006, Llanos et al., 2008) and 
placenta (Hardman et al., 2006). 
 
In the lactating cells treated with 50 μM copper, there was a higher level of 
copper in the cells compared to the resting model. CTR1 may be mediating 
additional copper uptake that is not balanced by efflux from the cells resulting 
in an increase in intracellular copper, reminiscent of the elevated copper 
levels observed in lactating mammary epithelial cells. In the suckled model a 
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further up-regulation of CTR1 levels was observedl. It is possible that 
prolactin has also facilitated greater efflux of copper from the apical 
membrane of the epithelial cells. 
 
It is proposed that the increase in CTR1 induced by exposure to hormones 
increases the flux of copper through the cell into the milk. This may be in 
conjunction with ATP7B, reported to be a key protein involved in delivery of 
copper into milk (Michalczyk et al., 2000, Rauch, 1983). ATP7B has been 
shown to traffic towards the lumen of the organoids in response to hormones 
in the same PMC42-LA mammary culture models (Michalczyk et al., 2008). 
This would assist the copper taken up by CTR1 to be moved across the 
apical membrane. 
 
Suckling and hyperprolactinemia stimulated copper transport into the milk of 
rodents by moving more CTR1 protein to the basolateral membrane (Kelleher 
and Lonnerdal, 2006). This, along with the data presented in this chapter, 
suggest that the elevation of prolactin causes an increase in copper transport 
through the mammary epithelial cells. 
 
Cultured HC11 mammary epithelial cells showed no change in the levels of 
CTR1 protein in response to 1 μg/mL prolactin (Kelleher and Lonnerdal, 
2006), however this could be a result of the cells being undifferentiated. It 
has been shown that copper transporting proteins, like ATP7A, can be 
unresponsive to hormones in undifferentiated cells (Ackland et al., 1997), 
while being influenced in differentiated cells (chapter 6) and tissues (Ackland 
et al., 1999).  
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3.4 Conclusion 
 
The development of a differentiated mammary gland model (PMC42-LA) that 
mimics the human breast epithelium during lactation and periods of suckling, 
has enabled the investigation of copper and hormonal regulation of CTR1 
and has provided evidence that CTR1 plays a role in copper homeostasis in 
breast epithelial cells. This work on the cell culture models representing three 
different physiological states has shown that hormones, specifically prolactin, 
influence the total and membrane bound CTR1 protein levels. This is 
associated with an increase in intracellular copper levels. Synchrotron X-ray 
fluorescence analysis revealed that copper is secreted into the lumen of the 
organoids as it is in the alveolar lumen of the mammary gland; an effect that 
was enhanced by the addition of lactational hormones. It is proposed that 
while extracellular copper concentrations regulate the levels of CTR1 through 
degradation, the addition of lactational hormones, most likely prolactin, 
initiates mechanisms that inhibit the degradation of CTR1 allowing greater 
uptake of copper into the cells thus enabling more copper to be secreted into 
milk to feed and nourish the suckling infant. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
 
The expression and secretion of 
ceruloplasmin protein is influenced by 
copper and lactational hormones in 
PMC42-LA human breast cells 
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4.1 Introduction 
 
The study presented in chapter 3 focused on the uptake of copper into the 
mammary epithelial cells by CTR1. This shed light on the processes involved 
in copper uptake as a means of regulating the delivery of copper into milk to 
nourish a suckling neonate. While it is important to understand how copper 
uptake into the mammary epithelial cells is regulated through CTR1, it is also 
important to understand the processes involved in directly delivering copper 
into the secreted milk. 
 
Ceruloplasmin (Cp) has roles in copper transport and iron oxidation. There 
are two forms of Cp that have been identified; a secreted (sCp) and a 
membrane bound glycosylphosphatidylinositol-linked (GPI-Cp) form (Hellman 
et al., 2002b, Kono et al., 2006b, Mittal et al., 2003, Patel et al., 2000, 
Platonova et al., 2007, Terada et al., 1995). Each of these forms exist in two 
states; copper bound feroxidase active holo-Cp and copper depleted 
ferroxidase inactive apo-Cp (Hellman et al., 2002a, Hochstrasser et al., 2005, 
Kim et al., 2009, Kono et al., 2006a, Kono et al., 2010, Sato and Gitlin, 1991, 
Terada et al., 1995, Zaitseva et al., 1996). Cp that is secreted from mammary 
epithelial cells binds up to 85% of copper in milk (Platonova et al., 2007, 
Tsymbalenko et al., 2009), thus Cp-bound copper is a significant source of 
copper for the neonate. Cp’s ferroxidase activity enables it to oxidise Fe (II) 
to the more inert Fe (III) form. It is likely that Cp helps load iron onto 
lactoferrin, which carries iron in milk (Dorea, 2000, González-Chávez et al., 
2009, Ha-Duong et al., 2010, Kawakami et al., 1990, Sabatucci et al., 2007, 
Sokolov et al., 2006, Zakharova et al., 2000). This suggests Cp also has an 
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important role in the homeostasis of iron. The membrane bound GPI- Cp is 
thought to oxidise iron and facilitate iron efflux (Chang et al., 2007, Jeong 
and David, 2003, Kono et al., 2006a). 
 
The differentiated culture models introduced in chapter 3 that represent the 
resting, lactating and suckled mammary epithelium have been used 
throughout chapter 4 to analyse the forms of Cp found in mammary epithelial 
cells. The impact of copper levels and lactational hormones on the 
expression of the ferroxidase active holo-Cp and its secretion from the cells 
has been investigated. The presence of the membrane bound GPI-Cp as well 
as a direct interaction between ATP7B and Cp was also investigated in this 
chapter. These studies contribute to the elucidation of the role of Cp in 
mammary epithelial cells, further enhancing the understanding of the 
mechanisms controlling copper delivery into milk. 
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4.2 Results 
 
4.2.1 Two forms of Cp transcripts were present in PMC42-LA cells 
RT-PCR was performed to identify the transcripts of two alternatively spiced 
forms of Cp, secreted (sCp) and glycosylphosphatidylinositol-linked (GPI-
Cp), in PMC42-LA cells. Using previously published primer sequences 
(Banha et al., 2008), bands of 157 bp (sCp) and 407 bp (GPI-Cp) were 
identified, which corresponded to the expected size of the PCR products (Fig 
4.1). The lower band in the GPI-Cp lane is an unidentified artifact which 
appears in the original method (Banha et al., 2008). 
 
4.2.2 Copper affected apo and holo-Cp protein levels, but not 
localisation or mRNA levels in undifferentiated PMC42-LA cells 
To determine the effect of copper on total Cp mRNA, Quantitative Real Time 
PCR was performed on undifferentiated PMC42-LA cells. The data showed 
no change in the levels of total Cp mRNA in response to BCS/DPen (102.5 ± 
8.7%), 5 μM copper (100.0 ± 16.1%) and 50 μM copper (81.6 ± 6.4%) 
treatment (p>0.05) (Fig 4.2a). 
 
Western blot analysis of Cp protein revealed bands of 132 kDa, 130 kDa and 
95 kDa corresponding to the non-copper bound apo-ceruloplasmin (apo-Cp), 
unglycosylated ceruloplasmin and the copper bound holo-ceruloplasmin 
(holo-Cp) forms respectively (Fig 4.2b). Densitometric analysis demonstrated 
that apo-Cp protein levels declined with increasing copper concentrations 
(BCS/DPen – 153.5 ± 42.3%, 5 μM copper – 100.0 ± 19.0%, 50 μM copper –
89.1 ± 19.4%) and the difference between the BCS/DPen and 50 μM copper
  
 
Figure 4.1 Detection of sCp and GPI-Cp mRNA in PMC42-LA cells by 
RT-PCR 
This 1.5% agarose gel shows the PCR products of sCp (lane 1), GPI-Cp 
(lane 2 – top band) and the β-actin positive control (lane 3). The no cDNA 
negative control with no PCR product (lane 4). 
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treated cells was statistically significant (p<0.05). Holo-Cp levels increased 
significantly in the presence of 50 μM copper compared with the copper 
depleted BCS/DPen treated cells (p<0.05), however no significant difference 
was observed between these two treatments and the 5 μM copper basal 
control treatment (BCS/DPen – 68.1 ± 21.1%, 5 μM copper – 100.0 ± 20.6%, 
50 μM copper – 113.0 ± 14.8%). The band at 130 kDa has previously been 
identified as an unglycosylated form of Cp (Boivin et al., 2001). 
 
Immunofluorescence confocal microscopy was used to identify the 
distribution of Cp in PMC42-LA cells treated with BCS/DPen (i), 5μM copper 
(ii) or  50μM copper (iii). Cp was distributed throughout the cytoplasm, 
however no differences were observed between treatments (Fig 4.2c). 
 
4.2.3 Copper treatment influenced the levels of secreted apo and holo-
Cp, but not total GPI-Cp levels 
To identify whether Cp was secreted from PMC42-LA cells, culture medium 
was collected from cells grown in BCS/DPen, 5 μM copper and 50 μM copper 
for 3 days. Western blotting analysis of culture medium showed bands of 132 
kDa and 95 kDa corresponding to the apo-Cp and holo-Cp as in the lysates. 
The 130 kDa band was identified as the bovine Cp (Boivin et al., 2001, Patel 
and David, 1997) that is present in the fetal bovine serum of the RPMI culture 
medium and has no relevance to the human model (Fig 4.3a). Apo-Cp levels 
decreased in response to copper in a similar fashion to the apo-Cp in the 
whole cell lysates (BCS/DPen – 270.1 ± 78.7%, 5 μM copper –100.0 ± 
37.7%, 50 μM copper – 93.8 ± 30.1%). There was no significant 
  
 
Figure 4.2 Cp mRNA and protein levels in response to copper 
treatments in undifferentiated PMC42 cells 
(a) Relative Cp mRNA levels of 50 μM copper and BCS/DPen treatments 
compared to that of the 5 μM copper treated cells. The bar graph shows the 
mean percentage of relative mRNA ±SD from three independent experiments 
normalised against β-actin obtained by qRT-PCR. (b) Representative Cp 
Western blot analysis of 60 μg of undifferentiated PMC42-LA cell extracts. 
Lane 1, BCS/DPen treatment; lane 2, 5 μM copper treatment; lane 3, 50 μM 
copper treatment. β-actin was used as a loading control. Desitometric 
analysis show the intensity of the 132 kDa apo-Cp and 95 kDa holo-Cp 
bands expressed as a mean percentage of arbitrary units ±SD compared to 
the 5 μM copper treated sample normalised against β-actin. The 130 kDa 
band is an unglycosylated form of Cp (Ug-Cp). This figure shows 
representative results of three independent experiments. Asterisk indicates 
significant difference between samples (p<0.05). (c) Immunolocalisation of 
Cp (green) in PMC42-LA cells treated with BCS/DPen (i), 5 μM copper (ii) 
and 50 μM copper (iii). Nuclei were stained with ethidium bromide (red). 
Scale bar = 10 μm.  
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difference between the 5 μM and 50 μM copper treatments, however in both 
of these treatments the cells secreted significantly less apo-Cp than the 
BCS/DPen treated cells (p<0.05). The 95 kDa secreted holo-Cp levels 
followed a similar trend to the whole cell lysates, increasing significantly in 
the presence of copper compared to the copper depleted BCS/DPen sample 
(p<0.05) (BCS/DPen – 46.2 ± 18.0%, 5 μM copper – 100.0 ± 14.7%, 50 μM 
copper – 109.2 ± 24.1%). Blood and milk samples were used as positive 
controls to demonstrate the presence of apo-Cp and holo-Cp in extracellular 
fluids. 
 
GPI-Cp was not detected in whole cell lysates possibly due to its lower 
abundance compared with sCp, however surface biotinylation enabled us to 
quantify the amount of plasma membrane bound GPI-Cp. The 135 kDa band 
detected in all samples corresponds to GPI-linked Cp, slightly larger than the 
132 kDa apo-Cp band. (Fig 4.3b). Densitometric analysis revealed that 
copper treatment had no significant effects on the levels of plasma 
membrane bound GPI-Cp (BCS/DPen – 71.7 ± 21.3%, 5 μM copper – 100 ± 
33.3%, 50 μM copper – 101.7 ± 46.2%) (p>0.05). 
 
4.2.4 Copper levels influenced the proportion of apo and holo-Cp in 
differentiated PMC42-LA cells, while lactational hormones affected 
mRNA levels 
The differentiated PMC42-LA culture models representative of the resting, 
lactating and suckled mammary glands described in chapter 3 have been 
used to investigate the effects of copper and lactational hormones upon Cp 
  
 
Figure 4.3 Secreted Cp and GPI-Cp protein levels in response to copper 
in undifferentiated PMC42 cells 
(a) Representative Cp Western blot of 60 μg of protein obtained from the 
growth medium collected at the conclusion of the experiment from cultured 
PMC42-LA cells treated with copper and copper chelators. Lane 1, 
BCS/DPen treatment; lane 2, 5 μM copper treatment; lane 3, 50 μM copper 
treatment. Ponceau stain was used as a loading control. Densitometric 
analysis show the intensity of the 132 kDa apo-Cp and 95 kDa holo-Cp 
bands expressed as a mean percentage of arbitrary units ±SD compared to 
the 5 μM copper treated sample normalised against Ponceau S stain. This 
figure shows representative results of three independent experiments. 
Asterisks indicate significant differences between samples (p<0.05). Milk 
(lane 4) and serum (lane 5) were used as positive controls for identification of 
secreted forms of Cp. RPMI growth medium (lane 6) was used to confirm that 
the 130 kDa band present in all samples is bovine Cp (B-Cp) from the culture 
medium. (b) The graph indicates densitometric values obtained from Western 
blot analysis of biotinylated GPI-Cp protein bands in response to BCS/DPen 
(lane 1), 5 μM copper (lane 2) and 50 μM copper (lane 3). Values are 
expressed as a mean percentage of arbitrary units ±SD compared to the 5 
μM copper treated sample normalised against Na/K ATPase. Results are 
representative of three independent experiments. The BCS/DPen treated 
lysate (lane 4) shows the band size of apo-Cp in comparison to GPI-Cp. 
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to elucidate its role in delivering copper to milk. The elevated copper 
treatment corresponds to maternal serum copper levels in the early stages of 
lactation, while 5 μM copper treatment represents resting conditions. 
Quantitative Real Time PCR was used to analyse the total Cp mRNA levels 
in response to copper in each of the three differentiated PMC42-LA models. 
No significant differences were observed between the various copper 
treatments of the resting model (BCS/DPen – 96.8 ± 27.6%, 5 μM copper - 
100 ± 10.7%, 50 μM copper – 113.7 ± 10.3%), lactating model (BCS/DPen – 
199.6 ± 49.0%, 5 μM copper – 240.6 ± 35.4%, 50 μM copper – 216.7 ± 
64.2%) or the suckled model (BCS/DPen – 203.6 ± 46.5%, 5 μM copper – 
191.1 ± 42.2%, 50 μM copper – 252.7 ± 42.1%) (p>0.05). However 
hormones significantly increased Cp mRNA levels in the lactating and 
suckled model compared to the resting model for all of the copper treatments 
(p<0.05). No significant difference was observed in any of the treatments 
between the lactating and suckled models (p>0.05) (Fig 4.4a).  
 
Total Cp protein levels were also analysed in response to copper and 
hormone treatments (Fig 4.4b). As it was shown in the undifferentiated cells, 
apo-Cp decreased in response to copper in the resting model (BCS/DPen – 
234.3 ± 40.1%, 5 μM copper – 100.0 ± 17.7%, 50 μM copper – 107.0 ± 
21.9%), lactating model (BCS/DPen – 277.4 ± 63.6%, 5 μM copper – 132.0 ± 
21.0%, 50 μM copper – 123.9 ± 35.5%) and suckled model (BCS/DPen – 
295.7 ± 25.4%, 5 μM copper – 101.1 ± 45.0%, 50 μM copper – 105.4 ± 
57.2%), while holo-Cp levels increased in the presence of copper; resting 
model (BCS/DPen – 46.0 ± 19.6%, 5 μM copper – 100.0 ± 22.5%, 50 μM 
copper – 112.9 ± 16.5%), lactating model (BCS/DPen – 68.7 ± 20.6%, 5 μM 
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copper – 151.8 ± 27.7%, 50 μM copper – 143.1 ± 20.6%), suckled model 
(BCS/DPen – 72.6 ± 25.7%, 5 μM copper – 126.1 ± 17.9%, 50 μM copper – 
162.9 ± 44.0%). Significant variation was observed between bands of the 
BCS/DPen and copper treated samples for both apo and holo-Cp in each of 
the cell culture models (p<0.05), however no statistical difference was 
observed between the 5 μM and 50 μM copper treatements (p>0.05). The 
protein levels of both the apo-Cp and holo-Cp were unaffected by the 
presence of lactational hormones (p>0.05). 
 
The distribution of Cp in differentiated PMC42-LA cells treated with 
BCS/DPen, 5 μM copper or 50 μM copper in each of the resting, lactating 
and suckled models, were analysed by immunofluorescent microscopy (Fig 
4.4c). Cp was distributed throughout the cytoplasm and plasma membrane in 
all samples. Variation in copper levels or the addition of lactational hormones 
had no effect upon Cp localisation. The BCS/DPen and 50 μM copper treated 
resting and suckled models are shown here as examples of the distribution of 
Cp within the cells following treatments. 
 
4.2.5 Copper and hormonal treatments influenced Cp secretions, but 
not GPI-Cp levels 
Growth medium was collected from the differentiated cells grown on 
Transwell filters and analysed by Western blot (Fig 4.5a). Similar to the 
differentiated cell lysates, apo-Cp decreased in response to copper in the 
resting model (BCS/DPen – 176.6 ± 26.7%, 5 μM copper – 100.0 ± 11.4%, 
50 μM copper – 95.8 ± 6.8%), lactating model (BCS/DPen – 515.2 ± 92.7%, 
5 μM copper – 250.4 ± 48.7%, 50 μM copper – 254.0 ± 39.8%) and suckled 
  
 
Figure 4.4 Cp mRNA levels and protein expression and localisation in 
differentiated PMC42-LA 
(a) Relative mRNA levels of Cp in response to copper and hormones 
obtained by qRT-PCR. The bar graph indicates the mean percentage 
differences ±SD compared to the 5 μM copper treated cells of the resting 
model. Cp mRNA levels were normalised against β-actin. BCS/DPen = B, 5 
μM copper = 5, 50 μM copper = 50. Statistical variation is indicated by 
different letters above graph bars (p<0.05). (b) Representative Western blots 
of 60μg of protein extract show Cp in the resting breast model (lanes 1-3), 
lactating model (lanes 4-6) and suckled model (lanes 7-9) treated with 
BCS/DPen (lanes 1, 4 and 7), 5 μM copper (lanes 2, 5 and 8) and 50 μM 
copper (lanes 3, 6 and 9). The β-actin blot demonstrates relative loading of 
samples. Desitometric analysis show the intensity of the 132 kDa apo-Cp and 
95 kDa holo-Cp bands expressed as a mean percentage of arbitrary units 
±SD compared to the 5 μM copper treated sample of the resting model 
normalised against β-actin. The 130 kDa band is an unglycosylated form of 
Cp (Ug-Cp). Results are representative of three independent experiments. 
Statistical variation is indicated by different letters above graph bars (p<0.05). 
(c) Immunofluorescence analysis of Cp (green) in differentiated PMC42-LA 
cells. Cp protein localisation in the resting (i and ii) and suckled (iii and iv) 
breast cell model in response to BCS/DPen (i and iii) and 50 μM copper (ii 
and iv). Nuclei were stained with ethidium bromide (red). Scale bar = 10 μm. 
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model (BCS/DPen – 496.2 ± 34.8%, 5 μM copper – 245.3 ± 46.6%, 50 μM 
copper – 258.4 ± 36.5%); the variation between the BCS/DPen samples and 
the copper treated samples was statistically significant (p<0.05). Holo-Cp 
expression was more prominent in the differentiated cultures and followed 
the same trend as the undifferentiated cells, showing a statistically significant 
increase in holo-Cp secretion in the presence of copper (p<0.05); resting 
model (BCS/DPen – 36.1 ± 10.9%, 5 μM copper – 100.0 ± 7.7%, 50 μM 
copper – 101.6 ± 7.8%), lactating model (BCS/DPen – 84.5 ± 26.6%, 5 μM 
copper – 172.6 ± 22.6%, 50 μM copper – 193.5 ± 16.7%), suckled model 
(BCS/DPen – 83.6 ± 11.6%, 5 μM copper – 188.5 ± 30.7%, 50 μM copper – 
185.5 ± 37.3%). The addition of lactational hormones had a significant effect 
on the level of Cp secreted from cells. Both apo-Cp and holo-Cp were 
elevated in secretions from the suckled and lactating models compared to the 
resting model for all copper treatments (p<0.05), however no statistically 
significant difference was observed between the lactating and suckled 
models (p>0.05). 
 
Membrane bound GPI-Cp was isolated from cells using surface biotinylation 
to identify variations in protein levels in response to copper or lactational 
hormones (Fig 4.5b). Data from the resting model (BCS/DPen – 78.3 ± 
14.9%, 5 μM copper – 100.0 ± 16.2%, 50 μM copper – 109.9 ± 21.6%), 
lactating model (BCS/DPen – 107.6 ± 39.5%, 5 μM copper – 129.3 ± 27.7%, 
50 μM copper – 150.0 ± 15.1%) and suckled model (BCS/DPen – 127.6 ± 
44.0%, 5 μM copper – 150.6 ± 52.8%, 50 μM copper – 172.5 ± 59.5%) 
indicated that copper and hormone treatments had no significant influence on 
the expression of GPI-Cp (p>0.05). 
  
 
Figure 4.5 Cp secretion and GPI-Cp expression in differentiated PMC42-
LA cells treated with copper and lactational hormones 
(a) Representative Western blot of 60μg of growth medium collected from 
cultured PMC42-LA cells treated with hormones, copper and copper 
chelators. The resting model (Lane 1-3), lactating model (Lane 4-6) and 
sucked model (Lane 7-9) were each treated with BCS/DPen (Lane 1, 4 and 
7), 5 μM copper (Lane 2, 5 and 8) or 50 μM copper (Lanes 3, 6 and 9). 
Desitometric analysis shows the intensity of the 132 kDa apo-Cp and 95 kDa 
holo-Cp bands expressed as a mean percentage of arbitrary units ±SD 
compared to the 5 μM copper treated sample of the resting model normalised 
against Ponceau S stain. The 130 kDa band is the bovine Cp from the RPMI 
growth medium (B-Cp). Results are representative of three independent 
experiments. The statistical significance of results is indicated by different 
letters above graph bars (p<0.05). (b) Surface biotinylated GPI-Cp protein 
was analysed by Western blot. This representative Western blot of 
extracellularly biotinylated protein extract shows the GPI-Cp band in the 
resting breast model (lanes 1-3), lactating model (lanes 4-6) and suckled 
model (lanes 7-9) treated with BCS/DPen (lanes 1, 4 and 7), 5 μM copper 
(lanes 2, 5 and 8) and 50 μM copper (lanes 3, 6 and 9). Densitometric 
analysis shows mean intensity of the 135 kDa GPI-Cp bands expressed as a 
percentage of arbitrary units ±SD compared to the 5 μM copper treatment of 
the resting model. Densitometric analysis of GPI-Cp bands were normalised 
against the Na/K ATPase. Results are representative of three independent 
experiments. 
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4.2.6 Cp interacted with ATP7B, but not ATP7A in PMC42-LA cells 
To detect whether ATP7A or ATP7B directly interact with Cp in PMC42-LA 
cells both co-immunoprecipitation (Co-Ip) and co-immunofluorescence 
microscopy experiments were performed. 
 
Proteins interacting with ATP7B were immunoprecipitated using ATP7B 
antibody as a bait and then separated by SDS-PAGE. Probing the Western 
blot with human Cp antibody revealed a holo-Cp band of 95 kDa, indicating 
that there was an interaction between Cp and ATP7B (Fig 4.6a). A copper 
treated whole cell lysate (lane 2), human milk (lane 3) and human serum 
(lane 4) were used as positive controls to identify the holo-Cp band. 
 
To establish whether there was an interaction between Cp and ATP7A, 
copper treated PMC42-LA cells were analysed by dual labelled 
immunofluorescence. Pearson’s co-efficient analysis determined that there 
was no co-localisation of Cp and ATP7A in cells treated with BCS/DPen 
(0.15), 5 μM copper (0.13) and 50 μM copper (0.18) (Fig 4.6b). Values close 
to zero indicate no co-localisation. Co-Ip was also performed using the 
ATP7A antibody, however no interaction with Cp was detected (data not 
shown). 
 
  
 
Figure 4.6 Interactions between Cp and the two ATPases; ATP7A and 
ATP7B 
(a) Western blot of co-immunoprecipitation (Co-Ip) of Cp with ATP7B. Holo-
Cp was isolated from whole cell lysates by Co-Ip with ATP7B (lane 1). Whole 
cell lysate (lane 2), human milk (lane 3) and human serum (lane 4) were 
used as positive controls. (b) Co-immunolocalisation of ATP7A (green) and 
Cp (red) in PMC42-LA cells treated with BCS/DPen (i), 5 μM copper (ii) and 
50 μM copper (iii). Pearson’s coefficient values indicate degree of 
colocalisation of the two proteins. Scale bar = 10 μm.  
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4.3 Discussion 
 
Previous studies have focused on ceruloplasmin (Cp) found in the brain, liver 
and blood, but little has been reported in relation to Cp in the mammary gland 
and in the milk secreted during lactation. While Cp is known to be present in 
the mammary gland and secreted in the milk, its complete role is yet to be 
elucidated. 
 
Cp mRNA has previously been detected in HC11 mammary epithelial 
cultured cells (Kluger et al., 2004) as well as lactating and non lactating 
mammary gland tissue (Cerveza et al., 2000, Maia et al., 2007, Platonova et 
al., 2007). This is consistent with the data presented here for the PMC42-LA 
models where the expression of Cp mRNA was detected in the non-lactating 
and lactating models as well as the undifferentiated cultures. Consistent with 
the current study, it has been widely reported that Cp mRNA levels do not 
respond to changing copper conditions in rodents and cultured cells 
(Broderius et al., 2010, Chen et al., 2006, Fosset et al., 2009, Gambling et 
al., 2004, Gitlin et al., 1992, McArdle et al., 1990, Mercer, 2001, Mostad and 
Prohaska, 2011, Ranganathan et al., 2011). 
 
The data showed that soluble Cp (sCp) was synthesised and secreted in the 
apo-Cp form, mainly in copper deficient cells, however there was also a small 
amount of apo-Cp in the lysates and secretions of the copper treated cells. 
Apo-Cp has no bound copper, thus no ferroxidase activity (Carrico et al., 
1969, Holtzman and Gaumnitz, 1970b, Holtzman and Gaumnitz, 1970a, 
Kojimahara et al., 1993, Kono et al., 2006a, Sato and Gitlin, 1991), and a 
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physiological function of apo-Cp, if any, is yet to be determined. Apo-Cp has 
been found in the blood in normal physiological conditions and is the main Cp 
component of the blood in Wilson’s disease patients, as a consequence of 
mutations to the ATP7B gene which prevents the incorporation of copper into 
Cp for the creation of the ferroxidase active holo-Cp. Rats fed copper 
deficient diets have copper depleted plasma as there is not enough copper 
available for the creation of holo-Cp in the liver and so only apo-Cp is 
secreted (Broderius et al., 2010, Hirano et al., 2005, Holtzman and Gaumnitz, 
1970a, Kojimahara et al., 1993, Matsuda et al., 1974, Terada et al., 1995). 
This study further supports the argument that copper does not influence the 
synthesis and secretion of Cp even though it is required for ferroxidase 
activity of the protein (Gitlin et al., 1992, Sato and Gitlin, 1991). 
 
Ferroxidase active holo-Cp was not detected in copper depleted cells, but 
was present in copper treated samples. This result showing a lack of holo-Cp 
in copper deficient cells is consistent with other studies that have shown a 
marked decrease in holo-Cp levels and Cp activity in rodents fed copper 
deficient diets, and cultured cells treated with copper chelators (Broderius et 
al., 2010, Cerklewski, 1979, Evans and Abraham, 1973, Gitlin et al., 1992, 
Hellman et al., 2002a, Ranganathan et al., 2011, Wang and Weinman, 2004). 
The 50 μM copper (representative of lactational copper serum levels) treated 
cells had no more holo-Cp that the 5 μM copper (representative copper 
levels of the resting system) treated cells, indicating that there is a limit to the 
amount of copper that can be incorporated into Cp. This limit is reached at 
levels similar to basal physiological copper levels and so further metal 
increases will not result in a greater efflux of copper loaded Cp. Additional 
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intracellular copper within the cells is likely to be stored in MT, a copper 
chaperone, as described in chapter 3. These mechanisms may prevent 
excess copper being secreted into milk which would be detrimental to a 
suckling infant. This is consistent with previous data where serum holo-Cp 
levels were not elevated in rats fed high copper diets (Bauerly et al., 2005, 
Cerklewski, 1979, Gambling et al., 2004, Jenkins and Hidiroglou, 1989, 
Ranganathan et al., 2011). Cp contains 85% of the copper in milk and as 
lactation progresses, Cp activity and also milk copper levels decline (Albera 
and Kankofer, 2009, Cerveza et al., 2000, Keen et al., 1982, Platonova et al., 
2007, Tsymbalenko et al., 2009). This indicates that Cp plays an important 
role in regulating copper efflux from the mammary epithelial cells into milk. 
 
The addition of lactational hormones had a significant influence on the 
transcription and secretion of apo and holo-Cp, but not the intracellular levels 
of sCp protein. This is likely due to hormones inducing transcription which is 
balanced by a hormonally regulated increase in secretion, thus preventing a 
net change in total sCp within the cells. Potential estrogen and progesterone 
binding sites have been identified in the 5’ region of the Cp gene, although 
functional analysis of these sites has not been performed (Tsymbalenko et 
al., 2009). However, estrogen, dexamethasone and insulin have all been 
shown previously to increase levels of Cp mRNA in rat livers and HepG2 liver 
cells, which led to increased Cp secretion and serum Cp activity (Ani and 
Moshtaghie, 1990, Clemente et al., 1992, Fitch et al., 1999, Middleton and 
Linder, 1993, Seshadri et al., 2002, Weiner and Cousins, 1983). While 
estrogen has been shown previously to affect Cp levels, the likely cause of 
the increased transcription and secretion in the PMC42-LA cells is 
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dexamethasone and/or insulin given that they are part of the final three day 
treatment of the cells whereas estrogen is administered prior to this, along 
with progesterone. It has been shown in vivo that estrogen withdrawal is one 
of the instigating factors, along with the withdrawal of progesterone, involved 
in initiating the secretion of milk during lactation, hence its position in the 
sequence of our treatments (Neville et al., 2002, Pang and Hartmann, 2007, 
Rillema, 1994). The hormonal response observed is likely to be independent 
of prolactin, as there was no difference between the lactational and suckled 
models which differ in the prolactin level. 
 
The observed localisation of Cp is consistent with its vesicular transport to 
the membrane from the TGN via the secretory pathway (Schaefer et al., 
1999a, Yanagimoto et al., 2011). Copper had no effect on the distribution of 
Cp in the cells, which is consistent with secretion of Cp being unresponsive 
to varying copper levels. Hormones also had no effect on the localisation of 
Cp. It is likely that the majority of Cp observed in these cells is sCp, based on 
our whole cell lysate work which did not show a distinct 
glycosylphosphatidylinositol-linked Cp (GPI-Cp) band. Past studies show 
similar distribution of sCp and GPI-Cp in cultured cells (Hida et al., 2010, 
Kono et al., 2006a, Kono et al., 2007, Kono et al., 2010, Mani et al., 2004, 
Patel et al., 2000, Persichini et al., 2010). 
 
Cp has a variety of roles in different cells. It is likely that its role in mammary 
epithelial cells is related to the transport of copper into milk to nourish the 
suckling infant and also to oxidise iron, perhaps enabling the iron to bind to 
lactoferrin. Lactoferrin may have a role in providing iron to the suckling infant 
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for nutrition (Frazer et al., 2011, Leong and Lonnerdal, 2005), however 
lactoferrin has also been shown to have bactericidal activity in milk (Bullen et 
al., 1972, Frazer et al., 2011, Wooten et al., 1996) which occurs as a 
consequence of its sequestration of iron, therefore depriving bacteria of the 
iron they require to survive (Collard, 2009, Dorea, 2000, González-Chávez et 
al., 2009). If host protection is a key role for lactoferrin then it is vitally 
important for Cp to be secreted in its ferroxidase active form so it can convert 
Fe (II) to Fe (III), thus enabling lactoferrin to bind iron. This would inhibit 
bacterial colony formation in the gut of the developing infant, which is known 
to be less acidic and have decreased secretion of proteolytic enzymes which 
creates an ideal environment for bacterial colonisation (Davidson and 
Lonnerdal, 1988, Sokolov et al., 2007). Research has also confirmed an 
interaction between Cp and lactoferrin (Ha-Duong et al., 2010, Sabatucci et 
al., 2007, Sokolov et al., 2006, Zakharova et al., 2000) with one research 
group indicating that the majority of milk Cp is bound to lactoferrin and that 
this binding enhances Cp’s ability to oxidise the redox active ferrous iron and 
scavange superoxide anion free radicals (Goldstein et al., 1979, Sokolov et 
al., 2009, Sokolov et al., 2005). The iron and copper levels in milk are 
considered lower than adequate for neonatal dietary consumption. However 
the levels in milk may still provide vital nutrition so that the infant does not 
need to rely solely on its liver stores of copper and iron in the first months of 
neonatal growth (Dorea, 2000). It has been shown that iron loaded lactoferrin 
binds to the intestinal brush border, presumably for the absorption of iron, 
while the copper from holo-Cp has been detected in the organs of suckling 
infants (Davidson and Lonnerdal, 1988, Kawakami and Lonnerdal, 1991, 
Linder et al., 1998, Platonova et al., 2007, Wooten et al., 1996). These data 
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provide evidence that Cp and lactoferrin are dietary sources of trace 
elements. 
 
The research presented in this chapter has for the first time reported the 
presence of GPI-Cp mRNA and protein in mammary epithelial cells. GPI-Cp 
is a product of Cp mRNA splicing, which enables GPI-Cp to be distinguished 
from the secreted Cp mRNA sequence (Banha et al., 2008, Patel et al., 
2000). GPI-Cp has been previously observed in a number of cell types and 
tissues including lymphocyte, kidney, spleen, liver and also in sertoli, 
leptomeningeal and astrocyte brain cells (Banha et al., 2008, Fortna et al., 
1999, Kono et al., 2010, Mittal et al., 2003, Mostad and Prohaska, 2011, 
Patel and David, 1997), though has not been reported in the mammary 
gland. 
 
GPI-Cp is a 135 kDa membrane bound form of Cp (Kono et al., 2006b, 
Mostad and Prohaska, 2011, Patel et al., 2000) protein which was detected 
by surface biotinylation indicating its presence at the plasma membrane. 
GPI-Cp could not be detected in whole cell lysates suggesting that its levels 
are significantly lower than sCp in mammary epithelial cells. Copper 
treatment had no major influence on the level of GPI-Cp protein found at the 
plasma membrane. A previous study reported a reduction in GPI-Cp protein 
levels in C6 glioma cells in response to BCS (de Domenico et al., 2007). The 
data described here was consistent with the glioma cells, as the GPI-Cp 
levels reduced slightly upon copper depletion, however the differences were 
not statistically significant. A possible reason for the discrepancy is likely due 
to differences in cell type between the brain and mammary gland. 
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Currently no work has been published on the effects of lactation or lactational 
hormones on the levels of GPI-Cp. Previously it was shown that the holo and 
apo forms of GPI-Cp can be distinguished from each other in glioma cells 
and that the levels of each vary in response to copper (di Patti et al., 2009, 
Kono et al., 2006a, Kono et al., 2010) similar to the sCp shown in this 
chapter. Unfortunately the final elution of the biotinylated protein required the 
use of DTT and while no heat was applied, a step required to denature 
human Cp (Kim et al., 2009, Sato and Gitlin, 1991), it appeared that the GPI-
Cp has been completely denatured. Some forms of Cp denature more readily 
than others, as was demonstrated with rat Cp compared to human Cp (Sato 
and Gitlin, 1991, Terada et al., 1995) and perhaps GPI-Cp denatures more 
easily than sCp. Had GPI-Cp not been denatured, it is possible that a similar 
expression pattern to that of the sCp protein may have been observed in 
response to copper. Lactational hormones had no effect upon the expression 
of GPI-Cp in the mammary epithelial cells. 
 
Current roles attributed to GPI-Cp include the oxidation of iron on account of 
its oxidase activity, and a role in iron efflux from cells (Jeong and David, 
2003, Kono et al., 2006a). GPI-Cp was shown to be important in aiding the 
efflux of iron through ferroportin (de Domenico et al., 2007), a protein also 
found to be present in the mammary gland (Leong and Lonnerdal, 2005). 
Perhaps GPI-Cp’s main role is to aid the efflux of iron into the milk secretions 
via ferroportin, which transports Fe (II). GPI-Cp may then oxidise the iron to 
Fe (III) in a similar fashion to sCp, so that the iron is then able to bind to 
lactoferrin. However as this is the first time that GPI-Cp expression has been 
identified in mammary epithelial cells, it is yet to be determined whether there 
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is a direct interaction between GPI-Cp and lactoferrin. This role could be 
particularly useful if the majority of sCp formed a permanent complex with 
lactoferrin (Sokolov et al., 2009) as GPI-Cp would enable more of the 
available lactoferrin in milk, which has been shown to be 75-88% apo-
lactoferrin (Sokolov et al., 2005), to bind additional iron. GPI-Cp may also 
work in conjunction with other enzymes like hephaestin or zyklopen. 
Hephaestin and zyklopen are two other membrane bound multi-copper 
ferroxidases, however only zyklopen has been detected in mammary glands 
(Chen et al 2010). 
 
Analysis of PMC42-LA cells confirmed an interaction between ATP7B and Cp 
in the mammary gland consistent with ATP7B’s role in delivering copper to 
Cp for secretion into milk. No interaction could be identified between ATP7A 
and Cp by co-localisation or co-immunoprecipitation analysis. While this 
suggests that ATP7A is not involved in delivery of copper into milk via Cp, 
this also may be a consequence of ATP7B being fully functional in these 
cells. In previous studies implicating ATP7A in the delivery of copper to Cp, 
ATP7B has not been present (Barnes et al., 2005, White et al., 2009a). A 
fully functioning ATP7B protein may dominate the process leaving any Cp-
ATP7A interaction undetectable by the methods used. If ATP7A does not 
deliver copper to Cp, it does leave open the question as to how copper is 
secreted from the mammary gland in tx mice. However it has been 
suggested that the remaining copper not bound to Cp, may be bound to other 
copper dependent enzymes like superoxide dismutase (Tsymbalenko et al., 
2009). 
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4.4 Conclusion 
 
This research reports for the first time that GPI-Cp is present on the plasma 
membrane of mammary epithelial cells. It also demonstrates that sCp is 
secreted from these cells in both the apo and holo forms. The level of 
ferroxidase active holo-Cp is dependent on the availability of copper and the 
total level of secretion is influenced by the presence of lactational hormones. 
This research also identified a direct interaction between ATP7B and Cp in 
the mammary gland, consistent with ATP7B’s previously ascribed function in 
delivering copper to Cp for secretion into milk. These data provide new 
insight into the role of Cp in mammary epithelial cells, particularly during 
lactation. The knowledge that copper modulates the levels of bioactive holo-
Cp secreted into milk levels could be used to advance research into neonatal 
nutritional supplementation, while the involvement of both sCp and GPI-Cp in 
enabling lactoferrin to sequester iron is also important for improving neonatal 
health.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
 
ATP7A overexpression disrupts copper 
homeostasis in cultured PMC42-LA 
mammary epithelial cells 
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5.1 Introduction 
 
Cellular copper and iron homeostasis is regulated by influx and efflux 
proteins including CTR1, ATP7A, ATP7B, ceruloplasmin (Cp), transferrin 
receptor 1 (TfR) and β2-microglobulin (β2M). To summarise the role of the 
different proteins, CTR1 plays an important role in copper uptake into the 
cells. ATOX1 then delivers it to the ATPases, ATP7A and ATP7B. The 
ATPases distribute copper to other copper dependent enzymes including Cp, 
or efflux excess copper from the cells (Bhatt et al., 2010, Enns, 2001, 
Lutsenko et al., 2007a, Mayle et al., 2012, Prohaska, 2008). Holo-Cp, the 
copper loaded form, has ferroxidase activity and plays an important role in 
the oxidation of Fe (II) to Fe (III) as well as the influx and efflux of iron, 
depending on cell type (Attieh et al., 1999, Chang et al., 2007, de Domenico 
et al., 2007, Harris et al., 1999, Jeong and David, 2003, Qian et al., 2001, 
Sarkar et al., 2003, Terada et al., 1995, Tsymbalenko et al., 2009, Wooten et 
al., 1996). TfR also plays an important role in iron uptake into cells, binding 
and endocytosing iron loaded transferrin with the assistance of β2M (Bhatt et 
al., 2009, Bhatt et al., 2010, Enns, 2001, Vecchi et al., 2010). When copper 
levels are elevated within cells, metallothionein 1 and 2 (MT) are used as 
long term storage molecules, to protect the cells from toxicity (Coyle et al., 
2002, Mehta et al., 2006, Prohaska and Gybina, 2004, Sutherland and 
Stillman, 2011).  
 
Copper transporters have been extensively studied, identifying their 
individual responses to copper. However there are few reports of the analysis 
of copper transporters in the context of a whole system. Copper efflux in 
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most tissues is carried out by ATP7A (Vulpe et al., 1993), while the liver and 
brain express ATP7B in conjunction with Cp to transport copper from the 
cells (Bull et al., 1993, Terada et al., 1998). The mammary gland is unusual 
in that it expresses both ATPases and Cp, thus giving these tissues the 
unusual characteristic of having three copper efflux proteins (Ackland et al., 
1999, Linder et al., 1998, Llanos et al., 2008, Michalczyk et al., 2008, 
Tsymbalenko et al., 2009, Yang et al., 1990). Previously, ATP7A and ATP7B 
have partially been analysed in the PMC42-LA mammary epithelial cell line 
(Ackland et al., 1997, Michalczyk et al., 2008). 
 
In this chapter the mammary epithelial cell line PMC42-LA was used to 
investigate the consequences of overexpression of ATP7A and provide novel 
insight into the copper homeostasis network of proteins. To investigate the 
interactions between the different components of copper homeostasis and 
how these copper proteins are regulated by intracellular copper, the copper 
efflux protein ATP7A was overexpressed in the PMC42-LA cells with the 
intention of reducing intracellular copper levels. The hypothesis is that this 
disruption in copper homeostasis will impact upon the other copper 
transporting proteins and that they may be regulated to maintain intracellular 
copper and maintain an adequate supply of copper to the milk. In this chapter 
the mammary epithelial cell line PMC42-LA was used to investigate the 
consequences of overexpression of ATP7A and provide novel insight into the 
copper homeostasis network of proteins. 
 
It is proposed that the responses of CTR1 and MT occur to maintain copper 
balance in the cells, however the changes to β2M and Cp indicate that 
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disruption of copper homeostasis can have a more widespread impact than 
initially anticipated. While these two proteins are known to be influenced by 
copper, they have roles associated with iron uptake and metabolism. This 
research has demonstrated the capacity of cells to adjust to disruptions in 
homeostasis particularly in a system containing three copper efflux proteins; 
ATP7A, ATP7B and Cp. It shows that the finely tuned homeostatic 
mechanisms operate to balance disturbances to copper fluxes.  
 106 
 
5.2 Results 
 
5.2.1 Copper did not affect mRNA or protein levels, but influenced the 
localisation of endogenous ATP7A protein in PMC42-LA cells 
Undifferentiated PMC42-LA cells were grown in culture flasks and treated 
with varying concentrations of copper to determine the effect on endogenous 
ATP7A expression. qRT-PCR analysis showed that there was no significant 
difference (p>0.05) in mRNA levels between cells grown in the presence of 
copper or copper chelators (Fig 5.1a). This trend was mirrored in the analysis 
of ATP7A protein levels, determined via Western blotting (Fig 5.1b). A single 
band at approximately 180 kDa was detected in cells treated with copper and 
copper chelators, however densitometric analysis confirmed there were no 
significant changes in its intensity (p>0.05). 
 
To determine the effect of copper on ATP7A localisation, PMC42-LA cells 
were grown on glass coverslips and analysed by immunofluorescence 
confocal microscopy (Fig 5.1c). Reducing copper levels with BCS/DPen (i) 
resulted in accumulation of ATP7A in the perinuclear region. With increasing 
copper, ATP7A became more dispersed throughout the cytoplasm. The 5 μM 
copper treatment (ii) caused ATP7A to move towards the plasma membrane, 
with some protein remained in the perinuclear region of the cells. Treatment 
with 50 μM copper (iii) resulted in complete dispersion of ATP7A protein 
throughout the cytoplasm, with no distinct aggregation remaining in the 
perinuclear region.  
 
  
 
Figure 5.1 ATP7A levels and localisation in response to copper in 
undifferentiated PMC42-LA cells 
(a) Relative ATP7A mRNA levels of 50 μM Cu and BCS/Dpen treatments 
compared to that of the 5 μM Cu treatment. The bar graph shows mRNA 
mean percentages ±SD from three independent experiments normalised 
against β-actin obtained by qRT-PCR. (b) Representative Western blot 
analysis of 60μg of undifferentiated PMC42-LA cell extracts. Lane 1, 
BCS/DPen treatment; lane 2, 5 μM copper treatment; lane 3, 50 μM copper 
treatment. β-actin was used as a loading control. Densitometric analysis 
shows the intensity of the ATP7A Western blot bands expressed as a mean 
percentage of arbitrary units ±SD compared to the 5 μM copper treated 
sample normalised against β-actin. This figure shows representative results 
of three independent experiments. (c) Immunolocalisation of ATP7A (green) 
in undifferentiated PMC42-LA cells grown on glass coverslips treated with 
BCS/Dpen (i), 5 μM copper (ii) and 50 μM copper (iii). Nuclei were stained 
with ethidium bromide (red). Scale bar = 10 μm. 
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5.2.2 Overexpression of ATP7A in PMC42-LA cells 
To investigate the interactions between the major copper transporters, a 
previously developed ATP7A overexpression plasmid, pCMB344 (Ke et al., 
2006) was transfected into PMC42-LA cells. ATP7A-transfected cells had a 
435% increase in relative levels of ATP7A mRNA compared with cells 
transfected with an empty vector (Fig 5.2a). The empty vector cells will be 
referred to as “control cells” for the remainder of the thesis.  Western blot 
analysis showed increased levels of ATP7A protein (Fig 5.2b). The addition 
and depletion of copper had no influence on the levels of ATP7A mRNA and 
protein in the ATP7A overexpressing cells (data not shown).To confirm the 
exogenous ATP7A trafficked like the endogenous protein, 
immunolocalisation of ATP7A in the overexpressing cell line was carried out. 
No discernible difference was observed between the overexpressing and 
control cells (Fig 5.1c) under corresponding copper conditions. ATP7A in the 
overexpressing cells was located in the perinuclear region in the presence of 
copper chelators BCS and DPen, while the addition of copper caused the 
protein to disperse throughout the cell towards the membrane (Fig 5.2c) 
which is characteristic of the endogenous protein.  
 
5.2.3 ATP7A overexpression and copper treatment did not affect the 
localisation of copper transporting proteins in PMC42-LA cells 
PMC42-LA cells with and without the ATP7A overexpressing construct were 
grown in culture flasks and treated with copper and copper chelators to 
investigate how copper transporters respond to altered copper homeostasis. 
Responses to copper and copper chelators were measured in ATP7A 
overexpressing cells. Treatment with 5 μM copper was used to simulate 
  
 
Figure 5.2 Confirmation of ATP7A overexpression and functionality in 
PMC42-LA cells 
(a) Relative ATP7A mRNA levels isolated from ATP7A overexpressing cells 
(lane 1) compared to control cells (lane 2). The bar graph shows mean 
percentage of relative mRNA normalised against β-actin obtained by qRT-
PCR. (b) Representative ATP7A Western blot analysis of 60 μg ATP7A 
overexpressing cell extract (lane 1) compared to control (lane 2). β-actin was 
used as a loading control. (c) Immunolocalisation of ATP7A (green) in ATP7A 
overexpressing PMC42-LA cells treated with BCS/DPen (i), 5 μM copper (ii) 
and 50 μM copper (iii). Nuclei were stained with ethidium bromide (red). 
Scale bar = 10 μm. 
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normal copper levels in the exchangeable pool of copper in blood plasma 
which is in the range of 2.7 and 7.7 μM (Linder, 1991, Linder, 2002). The 50 
μM copper treatment demonstrated the effect of high copper levels. Copper 
chelators were added to determine the effect of copper deficiency in the 
mammary epithelial cells. ATP7B was shown to disperse from the perinuclear 
region towards the membrane with the addition of copper, while CTR1 and 
Cp displayed a granular distribution throughout the cells under all conditions. 
The overexpression of ATP7A in these cells had no influence on the 
localisation of ATP7B, CTR1 or Cp in copper depleted or repleted conditions 
(Fig 5.3). 
 
5.2.4 ATP7A overexpression increased the transcription of Cp, but did 
not affect β2M, CTR1, ATOX1, or ATP7B mRNA levels 
To measure the transcriptional responses to altered copper homeostasis, the 
mRNA levels of several copper related genes were analysed by qRT-PCR in 
response to ATP7A overexpression and different copper conditions. There 
was a significant increase in the total Cp mRNA levels in ATP7A 
overexpressing cells (BCS/Dpen – 571.2 ± 81.6%, 5 μM copper – 646.5 ± 
71.6%, 50 μM copper – 765.3 ± 113.5%) compared to the control PMC42-LA 
cells (BCS/DPen – 102.5 ± 8.7%, 5 μM copper – 100.0 ± 16.1% and 50 μM 
copper 81.6 ± 6.4%) for each of the copper treatments (p<0.05) (Fig 5.4a). 
However there was no significant variation in response to copper levels. β2M 
(Fig 5.4b), CTR1 (Fig 5.5a), ATOX1 (Fig 5.5b) and ATP7B (Fig 5.5c) were 
not altered in ATP7A overexpressing cells compared to controls or in 
response to copper levels (p>0.05). 
 
  
 
Figure 5.3 ATP7B, CTR1 and Cp localisation in undifferentiated PMC42-
LA cells 
Immunolocalisation of ATP7B, CTR1 and Cp (green) in ATP7A 
overexpressing PMC42-LA cells (ATP7B (a), CTR1 (c) and Cp (d)) and also 
PMC42-LA control cells (ATP7B (b)) treated with BCS/DPen (i), 5 μM copper 
(ii) and 50 μM copper (iii). Nuclei were stained with ethidium bromide (red). 
Scale bar = 10 μm.  
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Figure 5.4 Cp and β2M mRNA levels in response to ATP7A 
overexpression in undifferentiated PMC42-LA cells 
The relative levels of Cp (a) and β2M (b) mRNA isolated from ATP7A 
overexpressing cells (lanes 1-3) compared to control (lanes 4-6) and treated 
with BCS/DPen (lanes 1 and 4), 5 μM copper (lanes 2 and 5) and 50 μM 
copper (lanes 3 and 6) were measured. The bar graphs show mean 
percentages of relative mRNA ±SD normalised against β-actin obtained by 
qRT-PCR. Statistical variation is indicated by different letters above graph 
bars (p<0.05). 
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Figure 5.5 The levels of CTR1, ATOX1 and ATP7B mRNA in ATP7A 
overexpression cells 
Relative levels of CTR1 (a), ATOX1 (b) and ATP7B (c) mRNA isolated from 
ATP7A overexpressing cells (lanes 1-3) compared to control (lanes 4-6), and 
treated with BCS/DPen (lanes 1 and 4), 5 μM copper (lanes 2 and 5) and 50 
μM copper (lanes 3 and 6). The bar graphs show mean percentage of 
relative mRNA ±SD normalised against β-actin obtained by qRT-PCR. 
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5.2.5 Increased expression of ATP7A influenced the protein levels of 
CTR1, Cp, MT and β2M, while ATOX1 and ATP7B levels remained 
unaltered 
Total protein levels of CTR1, Cp, MT, β2M, ATOX1 and ATP7B were 
measured by Western blot analysis. The 35 kDa CTR1 monomer protein 
levels were reduced by exposure to elevated copper conditions in ATP7A 
overexpressing cells. It was also observed that ATP7A overexpressing cells 
expressed significantly more CTR1 protein in each copper condition 
(BCS/DPen 377.0% ± 39.7%, 5 μM copper 161.5% ± 7.5% and 50 μM 
copper 119.7% ± 6.9%) compared to the corresponding control sample 
(BCS/DPen 239.6 ± 25.6%, 5 μM copper 100.0 ± 15.1% and 50 μM copper 
67.1 ± 12.2%) (p<0.05) (Fig 5.6). Additionally, the amount of CTR1 protein 
present at the plasma membrane as determined by surface biotinylation, 
correlates with the total CTR1 protein levels. The protein levels at the 
membrane decreased in response to high copper treatment, but overall were 
still higher in response to ATP7A overexpression (Fig 5.9). 
 
ATOX1 and ATP7B protein expression were analysed in response to copper 
treatments and ATP7A overexpression. These factors did not have any 
impact on the levels of these two proteins (p>0.05) (Fig 5.7a).  
 
Bands of 132 kDa, 130 kDa and 95 kDa corresponing to apo-Cp, 
unglycosylated Cp (Ug-Cp) and holo-Cp were detected and their intensity 
was significantly altered by ATP7A overexpression (Fig 5.6). Holo-Cp was 
present predominantly in the copper treated samples, and its expression was 
significantly higher in the ATP7A overexpressing cells (BCS/DPen 118.6 ± 
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19.8%, 5 μM copper 261.6 ± 42.5% and 50 μM copper 324.1 ± 51.4%) 
compared to the controls (BCS/DPen 68.1 ± 21.1%, 5 μM copper 100.0 ± 
20.6% and 50 μM copper 113.0 ± 14.8%) (p<0.05) (Fig 5.6). Apo-Cp, present 
mainly in copper chelated cells, was significantly elevated in the ATP7A 
overexpressing cultures (BCS/DPen 253.5 ± 51.7%, 5 μM copper 157.2 ± 
29.8% and 50 μM copper 162.1 ± 37.0%) compared to each respective 
control sample (BCS/DPen 153.5± 42.3%, 5 μM copper 100.0 ± 19.0% and 
50 μM copper 89.1 ± 19.4%) (p<0.05) (Fig 5.6). The differences observed in 
the lysates were strongly reflected in the Cp protein that was secreted from 
these cells. Holo-Cp secretion was shown to increase with copper, while apo-
Cp decreased and while the trends were the same between the two cells 
types, the ATP7A overexpressing cells secreted significantly more apo-Cp 
and holo-Cp in each of the copper conditions (Fig 5.8). 
Glycosylphosphatidylinositol-linked Cp (GPI-Cp) detected by cell surface 
biotinylation also showed a statistically significant increase in response to 
ATP7A overexpression (p<0.05) (Fig 5.9), however was unaltered in 
response to copper levels. 
 
MT was undetected in BCS/DPen and 5 μM copper treated ATP7A 
overexpressing and control PMC42-LA cells, however upon treatment with 50 
μM copper, a MT band became clearly visible. The levels observed in the 
ATP7A overexpressing cells were significantly lower than the control cells 
being only 49.7 ± 10.6% that of the control PMC42-LA cells (100.0 ± 13.0%) 
(p<0.05) (Fig 5.6). 
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β2M showed a significant increase in protein levels in response to ATP7A 
overexpression in each of the BCS/DPen (ATP7A-OE 217.0 ± 45.5%, control 
79.2 ± 17.1%), 5 μM (ATP7A-OE 219.9 ± 74.7%, control 100.0 ± 31.4%) and 
50 μM copper treatments (ATP7A-OE 240.4 ± 89.8%, control 106.9 ± 30.2%) 
(p<0.05) (Fig 5.6). However the addition of copper or copper chelators had 
no influence on the levels of β2M in either cell line (p>0.05). 
 
The role of TfR in iron uptake is influenced by β2M, however unlike β2M, the 
TfR protein showed no significant difference in response to ATP7A 
overexpression. The copper treatments, both supplementation and depletion 
also had no influence on the protein levels of TfR in PMC42-LA cells (Fig 
5.7a). 
 
Surface biotinylation was performed on PMC42-LA cells to determine the 
levels of ATP7A present at the plasma membrane. ATP7A levels increased 
in response to copper in ATP7A overexpressing (BCS/DPen 58.9 ± 35.1%, 5 
μM copper 126.5 ± 70.4% and 50 μM copper 147.9 ± 33.1%) and control 
PMC42-LA cells (BCS/DPen 26.4 ± 16.2%, 5 μM copper 100.0 ± 7.9% and 
50 μM copper 89.4 ± 6.3%). Statistically significant differences were 
observed between the BCS/DPen treated samples and the 50 μM copper 
treated samples in both cell lines (p<0.05), however no difference was 
observed between the 5 μM and 50 μM copper treated samples (p>0.05). 
The level of ATP7A at the membrane in the ATP7A overexpressing cells was 
higher than in the control cells for each of the copper treatments indicating 
that the transgene is functional and moving to the membrane, however these 
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differences were only statistically significant between the 50 μM copper 
treated cells (p<0.05) (Fig 5.9).  
 
Surface biotinylation was also performed on ATP7B, however no protein was 
detected at the membrane in response to any of the variable copper 
conditions in either the ATP7A overexpressing cells or control PMC42-LA 
cells (data not shown). 
 
5.2.6 Cp protein expression was not influenced by iron treatment in 
PMC42-LA cells 
Cp has a role in oxidising iron, enabling it to be transported in and out of 
cells. It has been shown that iron levels can influence the levels of Cp. 
Cultured PMC42-LA cells were treated with iron and Cp protein levels were 
measured. Cells treated with 100, 300, 500 and 1000 μM iron showed no 
significant variation in Cp protein levels compared to that of the non-treated 
control (p>0.05) (Fig 5.7b). 
 
5.2.7 ATP7A overexpression decreased intracellular copper levels of 
copper loaded cells, while iron levels were unaffected 
Atomic absorption spectroscopy (AAS) was performed to determine 
intracellular metal levels in response to copper treatment and ATP7A 
overexpression. ATP7A overexpressing cells had similar levels of copper 
(BCS/DPen – 26.0 ± 1.8 ng/mg protein, 5 μM copper – 34.7 ± 8.8 ng/mg 
protein) as the control cells (BCS/DPen – 32.9 ± 7.0 ng/mg protein, 5 μM 
copper 27.4 ± 6.7 ng/mg protein) when exposed to basal copper levels or 
copper chelators (p>0.05). There was also little variation between these two  
  
 
Figure 5.6 CTR1, MT, Cp and β2M protein levels in response to ATP7A 
overexpression in undifferentiated PMC42-LA cells 
Representative Western blots of 60 μg of undifferentiated PMC42-LA total 
protein extracts showing bands for CTR1, MT, apo-Cp, holo-Cp and β2M 
protein. ATP7A overexpressing cells (lanes 1-3) treated with BCS/DPen, 5 
μM copper and 50 μM copper are compared to control cells (lanes 4-6). β-
actin was used as a loading control. Densitometric analysis of band intensity 
are expressed as a mean percentage of arbitrary units ±SD compared to the 
5 μM copper treated control sample and normalised against β-actin. This 
figure shows representative results of three independent experiments. 
Statistical variation is indicated by different letters above graph bars (p<0.05). 
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Figure 5.7 ATP7B, ATOX1 and TfR protein levels in response to ATP7A 
overexpression and the influence of iron upon sCp protein expression 
in undifferentiated PMC42-LA cells 
(a) Representative Western blots of 60 μg of undifferentiated PMC42-LA total 
protein extracts showing bands for ATP7B, ATOX1 and TfR protein. ATP7A 
overexpressing cells (lanes 1-3) treated with BCS/DPen, 5 μM copper and 50 
μM copper are compared to control cells (lanes 4-6). β-actin was used as a 
loading control. Densitometric analysis of band intensity are expressed as a 
mean percentage of arbitrary units ±SD compared to the 5 μM copper treated 
control sample and normalised against β-actin. This figure shows 
representative results of three independent experiments. (b) Representative 
Cp Western blot analysis of 60 μg of undifferentiated PMC42-LA cell extracts 
treated with 0 μM, 100 μM, 300 μM, 500 μM and 1000 μM iron. Ponceau 
stain was used as a loading control. Densitometric analysis of band intensity 
are expressed as a mean percentage of arbitrary units ±SD compared to the 
0 μM iron treated control sample and normalised against Ponceau. This 
figure shows representative results of three independent experiments. 
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Figure 5.8 Secreted Cp protein levels in response to ATP7A 
overexpression and copper treatments 
Representative Cp Western blot of 60 μg of protein obtained from the growth 
medium collected at the conclusion of the experiment from cultured PMC42-
LA cells treated with copper and copper chelators. Lane 1, BCS/DPen 
treatment; lane 2, 5 μM copper treatment; lane 3, 50 μM copper treatment. 
Ponceau stain was used as a loading control. Densitometric analysis shows 
the intensity of the 132 kDa apo-Cp and 95 kDa holo-Cp bands expressed as 
a mean percentage of arbitrary units ±SD compared to the 5 μM copper 
treated control sample normalised against Ponceau S stain. This figure 
shows representative results of three independent experiments. Statistical 
variation is indicated by different letters above graph bars (p<0.05). 
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Figure 5.9 Plasma membrane bound CTR1, GPI-Cp and ATP7A protein 
levels in undifferentiated PMC42-LA cells 
Representative Western blot of 60 μg of extracellularly biotinylated protein 
extract showing bands for CTR1, GPI-Cp, and ATP7A protein, isolated from 
ATP7A overexpressing (lanes 1-3) and control cells (lanes 4-6) treated with 
BCS/DPen, 5 μM copper and 50 μM copper. Na/K ATPase was used as a 
loading control. Densitometric analysis of band intensity are expressed as a 
mean percentage of arbitrary units ±SD compared to the 5 μM copper treated 
control sample and normalised against Na/K ATPase. This figure shows 
representative results of three independent experiments. Statistical variation 
is indicated by different letters above graph bars (p<0.05). 
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copper conditions. Upon elevation of copper treatment to 50 μM, the cells 
accumulated significantly higher levels of copper (p<0.05). ATP7A 
overexpressing cells (444.6 ± 68.3 ng/mg protein) accumulated significantly 
less copper than the control cells (586.9 ± 33.3 ng/mg protein) consistent 
with the role of ATP7A as a copper efflux protein (p<0.05) (Fig 5.10a). 
 
Copper and iron homeostasis have previously been shown to be linked, with 
the levels of one metal being affected inversely in response to the other. AAS 
was performed on PMC42-LA cells exposed to the various copper conditions 
to determine whether the observed changes in cellular copper levels affected 
intracellular iron levels. Iron levels for each copper treatment was 29.6 ± 5.1 
ng/mg protein (BCS/DPen), 32.1 ± 5.5 ng/mg protein (5 μM copper) and 33.4 
± 7.2 ng/mg protein (50 μM copper) in the control cells. The levels of iron in 
the ATP7A overexpressing cells were not significantly different to the controls 
although there was a trend indicating that there may be slightly more iron in 
the ATP7A overexpressing line; 38.3± 7.6 ng/mg protein (BCS/DPen), 38.0± 
4.9 ng/mg protein (5 μM copper) and 41.2 ± 8.8 ng/mg protein (50 μM 
copper) (p>0.05). No significant variation was detected in iron levels between 
the various copper treatments for both cell types (p>0.05) (Fig 5.10b). 
 
Copper localised predominantly in the central region of wild type PMC42-LA 
cells treated with 50 μM copper as previously described in chapter 3. 
Synchrotron X-ray fluorescence was also used to analyse the metals in 
ATP7A overexpressing cells. Copper localised near the nuclear and 
perinuclear regions of the ATP7A overexpressing cells treated with 50 μM 
copper. Copper levels in the 5 μM copper treated cells were on the fringe of 
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detection like the control cells and so no clear observations of localisation 
could be made. Copper could not be detected in the BCS/DPen treated cells 
(Fig 5.11c). Zinc localisation was used to identify the position of cells. 
Analysis of the images using GeoPIXE software revealed that copper levels 
within the ATP7A overexpressing cells were slightly reduced compared to the 
control cells when treated 50 μM copper (ATP7A overexpressing cells 23.8 
ppm, control cells 27.8 ppm); consistent with the AAS data (Fig 5.10a). 
Measurement of iron levels showed little difference between copper 
treatments or between the two cell lines (Fig 5.11). 
  
 
Figure 5.10 Intracellular copper and iron levels in PMC42-LA cells in 
response to ATP7A overexpression 
The graphs show average values of copper (a) and iron (b) levels in ATP7A 
overexpressing PMC42-LA cells treated with BCS/DPen, 5 μM copper and 
50 μM copper compared to control PMC42-LA cells. Statistical variation is 
indicated by different letters above graph bars (p<0.05).  
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Figure 5.11 Intracellular copper and iron levels and copper and zinc 
localisation in PMC42-LA cells in response to ATP7A overexpression 
Analysis of the total area of each image using GeoPIXE software revealed 
levels of copper (a) and iron (b) in the overexpressing and control PMC42-LA 
cells. Statistical variation is indicated by different letters above graph bars 
(p<0.05). (c) XFM analysis showing the distribution of copper and zinc in 
PMC42-LA cells treated with BCS/DPen (i and iv), 5 μM copper (ii and v) and 
50 μM copper (iii and vi). The colour scale bar shows the relative levels of 
copper from lowest (black) to highest (white). Length scale bar = 30 μm. 
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5.3 Discussion 
 
The mammary gland is one of the few organs that express ATP7A, ATP7B 
and ceruloplasmin (Cp) simultaneously (Ackland et al., 1999, Linder et al., 
1998, Llanos et al., 2008, Michalczyk et al., 2008, Tsymbalenko et al., 2009, 
Yang et al., 1990) however the intracellular relationships between these three 
transporters have not been thoroughly inverstigated. By transfecting the 
pCMB344 ATP7A overexpression plasmid into the PMC42-LA mammary 
gland carcinoma cell line, the homoestatic balance of the efflux proteins was 
disrupted. The impact this had upon copper and iron levels within the cells 
and the proteins involved in their transport was analysed. In conjunction with 
this, the effect of various copper conditions in both the transfected and 
control cells was also analysed to further understand the dynamics of copper 
homeostasis in mammary epithelial cells.  
 
ATP7A overexpressing plasmids have been previously introduced into CHO 
cells, the human skin fibroblast cell line Me32a and in the human ovarian 
carcinoma 2008 cell line (Bellingham et al., 2004, La Fontaine et al., 1998a, 
Petris and Mercer, 1999, Samimi et al., 2004). PMC42-LA cells 
overexpressing ATP7A were analysed by qRT-PCR, Western blot and 
immunofluorescence microscopy to confirm that the plasmid was expressing 
ATP7A and that the ATP7A protein produced was functional, thus making 
these cells an effective model for analysis of copper homeostatic 
disturbance. Analysis of mRNA and protein levels indicated that ATP7A was 
elevated in comparison to the levels observed in control cells. Additionally, 
immunolocalisation confirmed that upon treatment with copper, ATP7A 
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trafficked towards the plasma membrane, away from the TGN where it was 
observed in the presence of copper chelators. There was no clear difference 
in ATP7A localisation between control and ATP7A overexpressing cells 
indicating that the additional protein was trafficking normally and not being 
retained in the endoplasmic reticulum or TGN. Biotinylation revealed that the 
ATP7A overexpressing cells had more protein at the plasma membrane 
compared to controls suggesting that these cells should be able to efflux 
more copper than the controls. No changes to ATP7A mRNA and protein 
levels in response to copper were identified; consistent with previous studies 
which suggest that ATP7A mediated copper efflux is regulated by protein 
trafficking rather than changes in levels (Monty et al., 2005, Petris et al., 
1996). 
 
Previous studies show that increased expression of ATP7A reduces cellular 
copper accumulation by increasing the rate of copper efflux, making cells 
more resistant to copper toxicity (Bellingham et al., 2004, La Fontaine et al., 
1998a, Petris and Mercer, 1999, Samimi et al., 2004). The atomic absorption 
spectroscopy results revealed that ATP7A overexpression in PMC42-LA cells 
reduced intracellular copper compared to control cells; however this effect 
was only observed in cells treated with 50 μM copper which overall had much 
higher intracellular copper levels than those exposed to the basal copper 
treated and copper chelated samples as was also demonstrated in chapter 3. 
This correlated with the biotinylation data which showed a significant 
increase in ATP7A protein at the plasma membrane in 50 μM copper treated 
ATP7A overexpressing cells compared to controls. Intracellular copper levels 
remained at a basal level in either the presence of copper chelators BCS and 
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DPen, or when exposed to a physiological level of copper (5 μM copper) in 
both control and ATP7A overexpressing cells, consistent with the 
experiments of chapter 3 and also previous findings (Hamza et al., 2003, 
McArdle et al., 1990, Meshitsuka et al., 1987, Steinebach and Wolterbeek, 
1994, Urani et al., 2003). 
 
To obtain a greater understanding of how cells respond to high copper loads 
(50 μM copper), biotinylation was used establish whether either of the two 
ATPases were localised at the plasma membrane. The results obtained in 
this study are in agreement with previous research which showed that copper 
treated cells increased the amount of ATP7A protein at the plasma 
membrane compared to copper depleted cells, while not altering the total 
amount of protein in the cells (Nyasae et al., 2006, Pase et al., 2004). This is 
consistent with the mechanism of ATP7A regulating intracellular copper 
levels by inducing protein trafficking, rather than altering expression. 
 
Biotinylation analysis revealed that there was no significant difference in 
ATP7A levels at the plasma membrane between the 5 μM and 50 μM copper 
treated cells. This result suggests that the efflux mechanism may be 
saturated, preventing further export of copper from the cells, thus the cells 
are unable to effectively efflux copper at high concentrations. This is despite 
the fact that there was more protein trafficking towards the plasma 
membrane as indicated by the immunofluorescence microscopy which 
showed a greater amount of protein dispersed throughout the cells in the 50 
μM copper treated cells compared to the 5 μM copper treatment, which still 
had some ATP7A remaining in the TGN. Additionally, the level of holo-Cp 
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within and secreted from the cells, as shown in chapter 4, does not change 
between the 5 μM and 50 μM copper treated cells. This again suggests that 
there is a limit to the rate of copper efflux from the cells. While efflux rates 
may be limited, the uptake of copper does not appear to suffer the same fate 
as there is still some CTR1 at the plasma membrane when cells are exposed 
to high copper. Limited efflux and unlimited uptake may account for the 
overall increase in the intracellular copper levels observed in both parental 
and ATP7A overexpressing PMC42-LA cells treated with 50 μM copper. 
 
Metallothionein 1 and 2 (MT) expression is strongly correlated to the copper 
levels within the ATP7A overexpressing cells, increasing in expression when 
intracellular copper levels were elevated in the 50 μM copper treated cells, a 
result consistent with the observations of the control cells in chapter 3. MT 
has previously been shown to respond to copper supplementation 
(Armendariz et al., 2004, Coyle et al., 2002, Prohaska and Gybina, 2004, 
Urani et al., 2003). It is likely that the copper accumulating within the cells 
has been sequestered by MT, a metallochaperone that is a storage molecule 
for metal ions like copper, zinc and cadmium, that protects cells from metal 
ion toxicity (Mehta et al., 2006, Sutherland and Stillman, 2011, Urani et al., 
2003). Data showed that MT levels were lower in the 50 μM copper treated 
ATP7A overexpressing cells compared to controls, further supporting the 
functionality of the exogenous ATP7A as it is consistent with the ATP7A 
overexpressing cells having lower copper levels compared to the control 
cells. 
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When copper homeostasis is disturbed, the copper uptake and efflux 
mechanisms should adjust accordingly to maintain balance. In support of this 
theory, the data presented in chapter 3 showed that while CTR1 mRNA 
remained unaltered, increased copper levels caused post-translational 
degradation and internalisation of the CTR1 protein from the membrane. 
Degradation and internalisation are important regulatory mechanisms for 
CTR1 to prevent the uptake of toxic levels of copper as reported in various 
cell types (Guo et al., 2004a, Guo et al., 2004b, Holzer and Howell, 2006, 
Holzer et al., 2004a, Liu et al., 2007, Molloy and Kaplan, 2009, Petris et al., 
2003, Safaei et al., 2009). The CTR1 responses observed in ATP7A 
overexpressing cells were no different from those identified previously in wild 
type PMC42-LA cells. Total and plasma membrane bound CTR1 was greatly 
reduced in response to copper, most likely as a result of protein degradation, 
as no changes to the mRNA levels were detected. As demonstrated 
previously in chapter 3, differences in levels observed between the 
biotinylation densitometry and the whole cell lysate densitometry suggested 
some internalisation. This conclusion is drawn from the fact that the 
difference in total levels of CTR1 between the BCS/DPen and 5 μM copper 
treated cells was smaller than the difference in levels present at the plasma 
membrane, indicating that as copper levels rise, CTR1 is internalised from 
the plasma membrane. CTR1 levels were elevated in the ATP7A 
overexpressing cells compared to the control cells in each of the three 
copper treatments, with biotinylation showing more CTR1 at the plasma 
membrane of the ATP7A overexpressing cells compared to the control for 
each copper condition. The explanation for this effect may be that the 
additional ATP7A in the cells is effluxing more copper, and that the cells may 
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be attempting to balance this efflux through reduction of CTR1 degradation 
and moving more protein to the membrane to increase copper uptake into the 
cells. This is supported by the AAS data which showed no difference in levels 
between the control and ATP7A overexpressing cells in the BCS/DPen and 5 
μM copper treated cells. In the 50 μM copper treated cells, the efflux 
mechanisms may be saturated, limiting the rate of copper efflux. For 
intracellular copper levels to remain in equilibrium when exposed to high 
copper loads, most CTR1 protein would need to be degraded or removed 
from the plasma membrane. This does not occur, thus causing the observed 
elevation in intracellular copper levels.  
 
ATOX1 is a copper chaperone that delivers copper from CTR1 to the 
ATPases, ATP7A and ATP7B. Investigation of the levels of ATOX1 mRNA 
and protein in response to copper supplementation and copper deficiency 
has received little attention. However the expression levels of ATOX1 mRNA 
have been analysed in the livers and placentae of rats fed copper deficient 
and iron deficient diets. The iron deficient diet resulted in elevated copper 
levels in the serum, liver and placenta, whereas the copper deficient diet 
caused reduction in copper levels in the serum and liver. The change in 
copper levels in the placenta and liver had no impact upon the ATOX1 mRNA 
levels (Andersen et al., 2007, Gambling et al., 2004). Consistent with this, no 
variations in ATOX1 mRNA or protein levels were observed in response to 
changes in copper concentration or in response to ATP7A overexpression in 
PMC42-LA cells. ATOX1 is thought to be primarily involved in the movement 
of copper from CTR1 to the ATPases in the TGN (Banci et al., 2007, Banci et 
al., 2009, Hussain et al., 2009, Rodriguez-Granillo et al., 2010, Strausak et 
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al., 2003, van Dongen et al., 2004, Walker et al., 2002, Xiao et al., 2004, Xiao 
and Wedd, 2002). It also plays a critical role in copper efflux by influencing 
trafficking of the ATPases; a process that was abolished upon knockout of 
the ATOX1 gene (Hamza et al., 2003). This suggests that ATOX1 could 
become rate limiting for copper efflux if it were not regulated when demand 
was high. However it was noted in PMC42-LA cells that the ATOX1 mRNA 
levels significantly exceeded the levels of transcript of both ATP7A and 
ATP7B (data not shown); a results also observed by Lutsenko et al. (2007b) 
comparing ATOX1 to ATP7B in HepG2 liver cells. If this translates to an 
excess of ATOX1 protein, it would ensure that ATOX1 does not become a 
limiting factor in the movement of copper through the cells. 
 
Upon overexpression of ATP7A in PMC42-LA cells, the response of ATP7B 
was measured. Previous studies have suggested that these ATPases may 
be interchangeable, where one protein can perform the role of the other 
(Barnes et al., 2005, La Fontaine et al., 1998a). However the effect of 
increasing one of the ATPases on the other has not been tested in cultured 
cells. ATP7A overexpression had no influence upon ATP7B expression as 
ATP7B mRNA and protein levels remained unchanged between the 
overexpressing and control cells in the presence and absence of copper. 
This is consistent with previous studies which suggest that ATP7B-mediated 
copper efflux is regulated by protein trafficking rather than changes to mRNA 
and protein levels (Barnes et al., 2009, Schilsky et al., 1998). The addition 
and depletion of copper elicited small changes in ATP7B localisation in both 
control and ATP7A overexpressing cells indicating that ATP7B was behaving 
as previously described (Michalczyk et al., 2008). Similar to ATP7A, ATP7B 
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resides in the TGN when copper levels are low and disperses towards the 
plasma membrane when copper levels are elevated. No clear differences in 
localisation were observed between the ATP7A overexpressing and control 
cells. It is possible that fluctuations in copper between the control and ATP7A 
overexpressing cells are too small to initiate changes in ATP7B that could be 
observable by immunofluorescence microscopy; even in the 50 μM copper 
treated cells which showed statistically significant changes in intracellular 
copper levels. Similarly, ATP7A overexpression in mice also failed to elicit an 
observable change in ATP7B localisation in mammary epithelial cells 
compared to the cells of control mice (Llanos et al., 2008). 
 
ATP7B protein was not detected at the plasma membrane in copper treated 
copper chelated, ATP7A overexpressing and control cells, when subject to 
surface biotinylation. This result is consistent with the notion that ATP7B 
does not travel to the plasma membrane, rather it delivers copper to vesicles 
in the vicinity of the membrane which then proceed to efflux copper from the 
cell following the departure of ATP7B back towards the TGN (Cater et al., 
2006, Hung et al., 1997, Schaefer et al., 1999b, Yang et al., 1997). In chapter 
4, ATP7B was shown to interact with holo-Cp in mammary epithelial cells. It 
is likely that ATP7B delivers its copper to Cp in these vesicles for efflux from 
the cell. 
 
Cp is secreted from mammary epithelial cells and is known to carry up to 
85% of the copper secreted into milk (Platonova et al., 2007, Tsymbalenko et 
al., 2009) and so it is important to understand the effect of copper 
homeostatic disruption on this protein, as inadequate or excessive supply of 
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copper into milk would be detrimental to a suckling infant. Interestingly, the 
current research revealed a dramatic increase in Cp expression in response 
to ATP7A overexpression. This was detected in both the mRNA and protein 
levels. This observation was made for both the apo and holo forms of soluble 
Cp protein that were within and also secreted from the cells, as well as for 
the glycosylphosphatidylinositol-linked Cp (GPI-Cp) protein detected at the 
plasma membrane. This increased expression was not likely a result of 
fluctuating copper levels or changes to copper efflux from the cells, as it was 
shown in chapter 4 that Cp mRNA levels do not change in response to 
copper treatments. This is supported by other studies which have shown that 
copper has no impact on the levels of Cp mRNA in livers of mice and rats 
(McArdle et al., 1990, Mostad and Prohaska, 2011). Copper levels only affect 
the proportion of apo-Cp (non copper bound) to holo-Cp (copper bound) 
(chapter 4). This was also the case in the ATP7A overexpressing cells, 
where the addition of copper resulted in a marked increase in the presence of 
holo-Cp, while apo-Cp was the dominant form present in copper depleted 
cells. The impact of ATP7A overexpression on Cp transcription and 
translation had not been anticipated. There has been limited research 
showing connections between ATP7A and Cp, however it has been reported 
that in the developing brain upon knockout of ATP7B, ATP7A may have 
assumed the role of copper delivery to Cp (Barnes et al., 2005). Further to 
this, macrophages, which do not express ATP7B, were shown to secrete 
holo-Cp, and the incorporation of copper into Cp was impeded by silencing 
ATP7A (White et al., 2009a). A unique hexapeptide sequence in ATP7A 
between transmembrane domain three and four confers its capacity to bind 
to Cp, indicating the possibility of a direct interaction between the two 
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proteins (Tsymbalenko et al., 2000). These three studies suggest that ATP7A 
is a possible source of copper for Cp. While the data presented in chapter 4 
did not reveal a direct interaction between ATP7A and Cp this could be due 
to the presence of a fully functional ATP7B protein in the PMC42 cells. 
Having said this, it is unlikely that an interaction between ATP7A and Cp in 
ATP7A overexpressing cells would be the cause of Cp up-regulation, as this 
would not explain the increase in Cp mRNA levels or the increase in apo-Cp 
levels. 
 
A wide variety of factors are known to influence the transcription of Cp 
including cytokines like IL-6, IL-1β and Interferon γ, and transcription factors 
like FoxO1, HIF-1 and AP-1. The structure of the 3’ untranslated region of Cp 
mRNA, hypoxia, reactive oxygen species/oxidative stress, cancer, pregnancy 
and preeclampsia also influence Cp levels (Das et al., 2007, Guller et al., 
2008, Jaeger et al., 1991, Lee et al., 2004, Mazumder and Fox, 1999, 
Mukhopadhyay et al., 2000, Persichini et al., 2010, Sidhu et al., 2011, Stein 
et al., 2009, Tapryal et al., 2009, Zibzibadze et al., 2009). Therefore it is 
possible that the connection between Cp and ATP7A may involve additional 
factors. At this stage, the literature does not reveal any connection between 
ATP7A expression and the factors that influence Cp mRNA transcription. 
Perhaps future work may be carried out to focus on the Cp promoter using 
luciferase constructs to determine the region that is involved in Cp up-
regulation in the presence of additional ATP7A. This may then shed more 
light on the pathways involved. 
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The effect of iron levels on the transcription of Cp has yielded contradicting 
results. Some researchers have observed changes in Cp expression levels 
(Balusikova et al., 2009, Mukhopadhyay et al., 1998, Qian et al., 2007), while 
others have reported no change (Balusikova et al., 2009, Chang et al., 2007, 
Chen et al., 2006, Chen et al., 2009, Fosset et al., 2009, Gambling et al., 
2004). The observed changes to the protein levels of β2-microglobulin (β2M) 
instigated our interest in the effect of iron upon Cp expression despite these 
conflicting views. β2M protein was significantly elevated in the ATP7A 
overexpressing cells. β2M protein stability is affected by the presence of Cu 
(II) (Deng et al., 2006) and so it is likely that the additional ATP7A is reducing 
the pool of copper that is available for destabilising β2M and preventing its 
degradation rather than influencing transcription levels which were 
unaffected. Interestingly, β2M plays an important role in binding to HFE, a 
protein which impedes the binding of transferrin receptor 1 (TfR) to iron 
loaded plasma transferrin and inhibits iron uptake into the cell (Bhatt et al., 
2009, Bhatt et al., 2010, Enns, 2001, Vecchi et al., 2010). An increase in TfR 
did not accompany the rise in β2M levels, an effect also seen in CHO cells 
overexpressing β2M (Wang et al., 2003). However the increased β2M could 
be binding more HFE, preventing the HFE-TfR complex from being created, 
thus increasing the amount of TfR available to interact with transferrin which 
would enable increased uptake of iron. It has been shown previously that 
CHO cells overexpressing β2M increase their iron uptake (Waheed et al., 
2002). A slight increase in intracellular iron levels was observed in the 
ATP7A overexpressing cells. While the increase in iron was not significant, 
this does not discount that an increase in efflux could be balancing increased 
uptake, similar to the observations of copper in ATP7A overexpressing cells 
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at basal levels. If iron uptake stimulated Cp transcription, Cp could initiate the 
efflux of iron from the cells. However this would not be the case in the copper 
deficient cells as there is no ferroxidase active holo-Cp in these cells which is 
required to mobilise iron. Further to this, incubation of PMC42-LA cells in iron 
had no impact upon the levels of Cp and so it is unlikely that iron played a 
role in elevating Cp transcription in ATP7A overexpressing cells. 
 
Some recent work has identified that β2M has a role in cellular proliferation 
and is up-regulated in some cancers (Huang et al., 2008, Huang et al., 2006, 
Josson et al., 2011, Rowley et al., 1995, Yang et al., 2006). ATP7A and Cp 
have also shown to be up-regulated in tumours (Chen et al., 2012, Nagaraja 
et al., 2006, Owatari et al., 2007, Samimi et al., 2003, Stein et al., 2009, Tye 
et al., 2008, Woo et al., 2009, Youn et al., 2009), while Cp was also reported 
to be elevated in the blood when tumours are present (Cox et al., 2001, 
Geetha et al., 2009, Tye et al., 2008, Zibzibadze et al., 2009). It is possible 
that the overexpression of ATP7A in the PMC42-LA cells has activated some 
linking factors that connect the three proteins. ATP7A may also be initiating 
signalling pathways that are yet to be elucidated. Research has shown that 
changes in ATP7A protein levels have been linked with regulating the 
expression of VEGFR1 and Prnp, independently of a copper effect (Afton et 
al., 2009, Armendariz et al., 2004), similar to the results observed for Cp. 
 
One possible pathway that links ATP7A to Cp could be via MAPK/ERK. 
MAPK/ERK, a pathway involved in cellular growth and proliferation is 
activated by β2M (Huang et al., 2010, Mattie et al., 2008, Yang et al., 2006). 
Cp has activator protein-1 (AP-1) binding sites, and the removal of these 
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sites impedes transcription of Cp (Das et al., 2007, Lee et al., 2004, 
Mukhopadhyay et al., 2000, Tapryal et al., 2010, Tsymbalenko et al., 2009). 
Interestingly, it has been shown that AP-1 is controlled by the MAP kinases 
including ERK (Karin, 1996) and so it is possible that the increase in β2M is 
instigating the changes in Cp expression. 
 
The Cp mRNA results presented here contradict those presented by Llanos 
et al., (2008) in which a mouse model overexpressing ATP7A showed no 
significant difference in Cp mRNA or protein levels. These mice were 
overexpressing human ATP7A and so a logical explanation is that the human 
protein, while capable of trafficking copper and influencing the copper 
secretion into milk, may be different enough from the mouse ATP7A (Qian et 
al., 1998) to be incapable of influencing the Cp mRNA and protein levels as 
found in the human PMC42-LA cell line. 
 
The large increase observed in Cp levels in ATP7A overexpressing cells did 
not correspond to any changes in its localisation within the cells. Cp 
appeared granular throughout the cells, similar to the observations made of 
wild type PMC42-LA cells in chapter 4. 
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5.4 Conclusion 
 
ATP7A is an important component of the cellular copper efflux pathway. 
Overexpressing ATP7A affected the copper uptake protein CTR1, 
intracellular copper levels and copper storage protein MT. In 50 μM copper 
treated cells ATP7A overexpression significantly decreased the level of 
intracellular copper. Intracellular copper levels corresponded with the MT 
protein levels. Less MT was detected in the overexpressing cells when it was 
expressed in the 50 μM copper treated cells, suggesting that there was less 
copper that required storing. CTR1 protein levels increased in response to 
ATP7A overexpression, a response which may accommodate an increased 
rate of efflux caused by ATP7A. This would be particularly important in cells 
treated with copper chelators and those having basal copper levels as 
elevated efflux would leave the cells copper deficient. Interestingly ATP7A 
overexpression influenced iron transport pathways, causing increases in β2M 
and Cp. While the change in β2M is likely copper related, the change in Cp is 
perplexing and perhaps there are signalling mechanisms that ATP7A 
instigates that are yet to be identified. This research has given insight into the 
copper homeostatic mechanisms in a system containing three copper efflux 
proteins and has also revealed some interesting results which opens the door 
for more in depth analysis and the possibility of identifying new roles for 
ATP7A. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6 
 
Copper homeostasis is altered by ATP7A 
overexpression in differentiated PMC42-LA 
mammary epithelial cells 
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6.1 Introduction 
 
ATP7A is a copper transporting protein involved in removing excess copper 
from cells, preventing the accumulation of toxic copper levels. The 
overexpression of ATP7A in undifferentiated PMC42-LA cells influenced 
proteins involved in maintaining copper and iron homeostasis. Ceruloplasmin 
(Cp) and β2-microglobulin (β2M) levels increased, while CTR1 and 
metallothionein 1 and 2 (MT) levels decreased in the presence of additional 
ATP7A protein. The changes in β2M, CTR1 and MT were likely due to 
increased efflux of copper which also caused a decrease in copper 
accumulation in high copper treated cells. 
 
In the physiological conditions of the mammary epithelium, ATP7A’s role in 
copper efflux may be more important than in other cell types. Localising 
basolaterally, ATP7A is hypothesised to increase the return of copper from 
the mammary epithelium back into the maternal bloodstream, thereby 
impeding the movement of copper into the milk and so in addition to 
maintaining cellular copper levels it may also be protecting a suckling infant 
from exposure to toxic copper levels (Llanos et al., 2008). 
 
The aim of this research was to investigate copper homeostasis in mammary 
epithelial cells; a unique system which contains three copper efflux 
molecules. Continuing on from the undifferentiated PMC42-LA cells analysis, 
this current chapter describes the responses associated with differentiated 
PMC42-LA cells overexpressing ATP7A. As described in chapter 3 and 4, 
differentiated cultures were treated with lactational hormones to mimic 
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lactation and the suckling response. This enabled analysis of homeostatic 
disruption in a system more representative of in vivo conditions. 
 
A number of results were similar to those observed throughout chapters 3-5, 
however some variations and novel responses were observed including 
hormonally induced trafficking of ATP7A and copper induced changes in 
ATP7B expression. The data obtained showed that the mammary epithelial 
cells utilise a number of mechanisms in the presence of homeostatic 
disturbances of copper that ensure an adequate flux of copper across the 
apical membrane and enabling a suckling infant to be properly nourished. 
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6.2 Results 
 
6.2.1.1 Copper induces trafficking of ATP7A, but does not affect the 
expression of ATP7A mRNA or protein in differentiated PMC42-LA cells 
ATP7A has been shown previously to be more dispersed in lactating human 
mammary epithelial cells compared to non-lactating cells (Ackland et al., 
1999). Immunocytochemistry and confocal microscopy were used to 
determine whether the distribution of ATP7A in the resting, lactating and 
suckled differentiated culture models was consistent with the localisation in 
tissues. Confocal microscopy enabled protein localisation within three axes of 
individual cells and entire organoids to be determined. The EHS matrix 
surface on which the organoids were grown, is located on the right hand side 
of image ii and the lower side of image iii. 
 
Depleting the resting breast model cells of copper resulted in tight perinuclear 
labelling of ATP7A consistent with a TGN localisation (Fig 6.1a). As copper 
concentrations increased, ATP7A became more dispersed, showing a 
granular cytoplasmic distribution with some perinuclear labelling in cells 
treated with 5 μM copper (Fig 6.1b). Further dispersion of ATP7A into the 
cytoplasm occurred in cells treated with 50 μM copper (Fig 6.1c). No 
perinuclear labelling could be seen with the 50 μM treatment. This pattern of 
distribution was observed in all three cell models (Fig 6.1d-i) of differentiated 
cells. In all models, ATP7A was localised towards the basolateral side of the 
organoids’ cells. 
  
Figure 6.1 Localisation of ATP7A in differentiated PMC42-LA cells 
Localisation of ATP7A (green) in the resting (a, b and c), lactating (d, e and f) 
and suckled (g, h and i) breast cell models in response to BCS/DPen (a, d 
and g), 5 μM copper (b, e and h) and 50 μM copper (c, f and i). Image i of 
each sub-figure is a transverse section through the top of the organoid. 
Image ii and iii show y-z and x-z sagittal sections respectively, cutting 
through the centre of the organoid. Nuclei were stained with ethidium 
bromide (red). Scale bar = 20 μm. 
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ATP7A mRNA and protein was analysed by qRT-PCR and Western blot 
respectively to determine expression levels in response to various copper 
loads. These analyses revealed that copper treatments had no significant 
effect upon the amount of ATP7A mRNA or protein in differentiated PMC42-
LA cells (p>0.05) (Fig 6.2a and b). 
 
Biotinylation of PMC42-LA cells was performed to determine the amount of 
ATP7A present at the plasma membrane. The data revealed that there was 
significantly more ATP7A at the plasma membrane in copper treated cells 
compared to BCS/DPen treated cells (p<0.05), while no difference was 
observed between the 5 μM and 50 μM copper treated samples (p>0.05). 
This pattern was reflected across all three models (Fig 6.2c). 
 
6.2.1.2 ATP7B mRNA levels are reduced in response to copper 
QRT-PCR revealed that ATP7B mRNA was influenced by copper levels in 
differentiated cells. The addition of 50 μM copper caused ATP7B to be 
significantly down regulated compared to the 5 μM copper treated and 
copper chelated mRNA levels in the lactating model (p<0.05). No statistically 
significant difference was observed between any of the copper treatments in 
the resting and suckled models of the control cells (p>0.05) (Fig 6.3a). 
 
A band of approximately 160 kDa was detected by Western blot analysis for 
ATP7B which is consistent for the full length ATP7B protein. The results 
obtained for ATP7B were extremely inconsistent, therefore three of the five 
performed experiments are displayed, each from a separate set of lysates
  
Figure 6.2 ATP7A mRNA and protein expression in differentiated 
PMC42-LA cells 
(a) Relative mRNA levels of ATP7A in response to copper and hormones 
obtained by qRT-PCR. The bar graph indicates the mean percentage 
differences ±SD compared to the 5 μM copper treated cells of the resting 
model. ATP7A mRNA levels were normalised against β-actin. B = 
BCS/DPen, 5 = 5 μM copper, 50 = 50 μM copper. Representative Western 
blots of 60μg of total protein extract (b) as well as surface biotinylated protein 
(c) from differentiated PMC42-LA cells show ATP7A bands in the resting 
breast model (lanes 1-3), lactating model (lanes 4-6) and suckled model 
(lanes 7-9) treated with BCS/DPen (lanes 1, 4 and 7), 5 μM copper (lanes 2, 
5 and 8) and 50 μM copper (lanes 3, 6 and 9). β-actin and Na/K ATPase 
blots demonstrate relative loading of samples. ATP7A densitometry graph 
bars show mean intensity of ATP7A bands expressed as a percentage of 
arbitrary units ±SD compared to the 5 μM copper treatment of the resting 
model, normalised against β-actin or Na/K ATPase for total protein and 
surface biotinylation respectively. These blots are representative of three 
independent experiments. Statistical variation is indicated by different letters 
above graph bars (p<0.05). 
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(Fig 6.3b). Images of Ponceau S stained membranes show even loading for 
each experiment. The lysates utilised for ATP7B analysis were also used for 
detection of the other copper transporters, however these did not show the 
same degree of inconsistency. Obtaining a clear indication of ATP7B’s 
response to copper was difficult due to the highly variable results. When 
compiling the densitometric analysis of all five blots, a slight down-regulation 
in response to elevated copper could be identified in some of the models, 
however due to the large error bars, the results cannot be deemed 
significant. A second, custom made, ATP7B antibody was also used on 
control cells lysates and again detection was difficult and no clear outcome 
could be obtained (data not shown). In spite of the inconsistency, it is 
possible that ATP7B protein levels may be reduced in response to copper in 
these differentiated cells, a result which would be consistent with the mRNA 
data.  
 
6.2.2.1 Lactational hormones increased the dispersion of ATP7A, but 
had little effect on expression in differentiated PMC42-LA cells 
The addition of lactational hormones caused a slight increase to both the 
mRNA and protein levels of ATP7A, however these changes were not 
significant (p>0.05). (Fig 6.2a and b). 
 
Surface biotinylation analysis of ATP7A revealed that addition of lactational 
hormones caused an increase in protein at the plasma membrane for each of 
the copper treatments, however, similar to total cellular ATP7A levels, this 
increase was not significant (p>0.05) (Fig 6.2c). Further to this, 
immunofluorescent confocal microscopy analysis of ATP7A revealed that
  
Figure 6.3 ATP7B mRNA and protein expression in differentiated 
PMC42-LA cells 
(a) Relative mRNA levels of ATP7B in response to copper and hormones 
obtained by qRT-PCR. The bar graph indicates the mean percentage 
differences ±SD compared to the 5 μM copper treated cells of the resting 
model. ATP7A mRNA levels were normalised against β-actin. B = 
BCS/DPen, 5 = 5 μM copper, 50 = 50 μM copper. (b) Western blots depicting 
60μg of protein extract from differentiated PMC42-LA cells show ATP7B 
bands in the resting breast model (lanes 1-3), lactating model (lanes 4-6) and 
suckled model (lanes 7-9) treated with BCS/DPen (lanes 1, 4 and 7), 5 μM 
copper (lanes 2, 5 and 8) and 50 μM copper (lanes 3, 6 and 9). The Ponceau 
image demonstrates the relative loading of samples in each replicate. The 
ATP7B densitometry graph bars show mean intensity of the ATP7B bands 
from five independent experiments expressed as a percentage of arbitrary 
units ±SD compared to the 5 μM copper treatment of the resting model, 
normalised against Ponceau. Blots show three of the five experiments 
performed. 
 148 
 
 
 
 
 
 
 
 149 
exposure to lactational hormones caused ATP7A to disperse. This was 
evident in the presence of copper and also copper chelators. The addition of 
extra prolactin in the suckled model further enhanced the dispersion of 
ATP7A (Fig 6.1). 
 
6.2.2.2 Lactational hormones had no impact upon ATP7B mRNA or 
protein levels 
The addition of lactational hormones had no influence upon ATP7B mRNA in 
differentiated cells (p>0.05) (Fig 6.3a). A similar trend was observed in the 
protein. Densitometric analysis indicated that hormones likely had no 
influence upon ATP7B protein levels, however the blotting was inconsistent 
as stated earlier (Fig 6.3b). 
 
6.2.3.1 Localisation of ATP7A in the overexpressing system does not 
change in comparison to endogenous ATP7A localisation 
ATP7A was overexpressed in differentiated PMC42-LA cells to determine the 
effect of this homeostatic distubance upon copper transporting proteins in a 
system reminiscent of the physiological conditions of mammary epithelial 
cells. Increases in ATP7A expression in vivo could ultimately lead to copper 
deficient milk and provide inadequate nourishment to a suckling infant if the 
imbalance is not corrected by other proteins. 
 
The ATP7A localisation observed in these ATP7A overexpressing cells (Fig 
6.4) did not alter from the pattern observed in control cells (Fig 6.1) only the 
staining intensity was slightly greater. Surface biotinylation suggested there 
was slightly more ATP7A at the plasma membrane compared to control cells 
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in each respective treatment, however this change was not statistically 
significant (p>0.05) (Fig 6.5a, b and c). 
 
6.2.3.2 ATP7B mRNA levels are influenced copper and hormones in 
ATP7A overexpressing PMC42-LA cells 
ATP7A overexpression had no influence upon ATP7B mRNA expression in 
the resting model (p>0.05), however in combination with lactational 
hormones, levels were significantly higher than in the control cells (p<0.05) 
(Fig 6.6a). ATP7B levels were also significantly altered by copper in ATP7A 
overexpressing cells. There was significantly less ATP7B mRNA in 50 μM 
copper treated cells compared to the 5 μM copper treated and copper 
chelated cells in the resting, lactating and suckled models (p<0.05) (Fig 
6.6a). This data is consistent with the trend observed in the parental 
differentiated PMC42-LA cells. These trends were not reflected in protein 
levels due to inconsistencies in blotting with the ATP7B antibody (Fig 6.6b-d). 
 
6.2.3.3 Cp mRNA as well as sCp and GPI-Cp protein levels increased in 
response to ATP7A overexpression 
ATP7A overexpression caused a significant increase in total Cp mRNA levels 
compared to the control for each individual treatment (p<0.05) (Fig 6.7a). 
Protein levels also followed this trend. Apo and holo-Cp detected within and 
also secreted from ATP7A overexpressing cells, strongly exceeded the levels 
of the control cells (p<0.05) (Fig 6.7b-g). The levels of 
Glycosylphosphatidylinositol-linked Cp (GPI-Cp) detected at the plasma 
membrane by surface biotinylation was also increased significantly in 
response to ATP7A overexpression (p<0.05) (Fig 6.7h-j). 
  
Figure 6.4 ATP7A localisation in differentiated ATP7A overexpressing 
PMC42-LA cells 
Localisation of ATP7A (green) in the resting (a, b and c), lactating (d, e and f) 
and suckled (g, h and i) breast cell culture models in response to BCS/DPen 
(a, d and g), 5 μM copper (b, e and h) and 50 μM copper (c, f and i). Image i 
of each sub-figure is a transverse section through the top of the organoid. 
Image ii and iii show y-z and x-z sagittal sections respectively, cutting 
through the centre of the organoid. Nuclei were stained with ethidium 
bromide (red). Scale bar = 20 μm. 
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Figure 6.5 Plasma membrane levels of ATP7A in copper and hormone 
treated PMC42-LA cells 
Surface biotinylated ATP7A protein was analysed by Western blot. These 
representative Western blots of extracellularly biotinylated protein extract 
show the ATP7A band in ATP7A overexpressing and control cells of the 
resting breast model, lactating model and suckled model treated with 
BCS/DPen, 5 μM copper and 50 μM copper. Densitometric analysis showed 
the mean intensity of ATP7A bands expressed as a percentage of arbitrary 
units ±SD compared to the 5 μM copper treatment of the control cells, 
normalised against the Na/K ATPase. The data represents four independent 
experiments. Statistical variation is indicated by different letters above graph 
bars (p<0.05). 
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Figure 6.6 ATP7B mRNA and protein expression levels in response to 
copper, hormones and ATP7A overexpression 
(a) Relative mRNA levels of ATP7B in response to copper and hormones 
obtained by qRT-PCR. The bar graph indicates the mean percentage 
differences ±SD compared to the 5 μM copper treated cells of the control 
resting model. ATP7B mRNA levels were normalised against β-actin. B = 
BCS/DPen, 5 = 5 μM copper, 50 = 50 μM copper. Western blots show 60μg 
of protein extract from ATP7A overexpressing and control cells in each of the 
resting (b), lactating (c) and suckled (d) models treated with BCS/DPen, 5 μM 
copper and 50 μM copper. The Ponceau images demonstrate relative 
loading of samples in each replicate. ATP7B densitometry graph bars show 
mean intensity of ATP7B bands expressed as a percentage of arbitrary units 
±SD compared to the 5 μM copper treatment of the control cells, normalised 
against Ponceau. Blots represent three of the five experiments performed. 
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Cp mRNA was unaltered by copper treatments, but increased significantly in 
response to lactational hormones in ATP7A overexpressing cells (Fig 6.7a). 
This data reflected the results obtained for the parental cells presented in 
chapter 4. The copper and lactational hormone responses of Cp protein in 
ATP7A overexpressing cells also reflected the results obtained in chapter 4. 
Copper increased the level of holo-Cp present within and secreted from the 
ATP7A overexpressing PMC42-LA cells, while in copper chelated cells, apo-
Cp was the predominant form (6.7b-g). The addition of lactational hormones 
had no influence upon the total Cp protein within the cells, however induced 
an increase in protein secretion from the cells. GPI-Cp detected at the 
plasma membrane of overexpressing cells was not altered by the copper or 
hormonal treatments. No variation in Cp localisation was observed by 
immunofluorescent confocal microscopy (data not shown). 
 
6.2.3.4 CTR1 mRNA and protein increased in the presence of additional 
ATP7A 
Overexpression of ATP7A had no effect upon the level of CTR1 mRNA in the 
resting model, however, when lactational hormones were present, CTR1 
mRNA levels were significantly elevated compared to control cells (p<0.05) 
(Fig 6.8a). Contrary to this, CTR1 protein levels in ATP7A overexpressing 
cells were elevated in all three models. Significant differences were detected 
between the control and ATP7A overexpressing cells treated with BCS/DPen 
and 5 μM copper (p<0.05), however no differences were observed between 
the 50 μM copper treated cells (p>0.05) (Fig 6.8b). Plasma membrane bound 
CTR1 protein levels reflected total CTR1 protein, with all samples having 
more protein at the membrane in ATP7A overexpressing cells compared to
  
Figure 6.7 Cp mRNA and protein in differentiated PMC42-LA cells 
(a) Relative mRNA levels of Cp in response to ATP7A overexpression, 
copper and hormones obtained by qRT-PCR. The bar graph indicates the 
mean percentage differences ±SD compared to the 5 μM copper treated cells 
of the control resting model. Cp mRNA levels were normalised against β-
actin. B = BCS/DPen, 5 = 5 μM copper, 50 = 50 μM copper. Representative 
Western blots of 60μg of protein, comparing the levels of apo-Cp and holo-
Cp in whole cell extracts from the resting (b), lactating (c) and suckled (d) 
models as well as the levels of apo and holo-Cp secreted from these cells (e, 
f and g) in ATP7A overexpressing cells to control cells. The β-actin blots 
(lysates) and Ponceau images (secretions) demonstrate relative loading of 
samples. Cp densitometry graph bars show mean intensity of Cp bands 
expressed as a percentage of arbitrary units ±SD compared to the 5 μM 
copper treatment of control cells, normalised against β-actin (lysates) or 
Ponceau (secretions) and is representative of three independent 
experiments. Statistical variation is indicated by different letters above graph 
bars (p<0.05). Surface biotinylated GPI-Cp protein was analysed by Western 
blot. These representative Western blots of extracellularly biotinylated protein 
extract show the GPI-Cp band in ATP7A overexpressing and control cells of 
the resting breast model (h), lactating model (i) and suckled model (j) treated 
with BCS/DPen, 5 μM copper and 50 μM copper. Densitometric analysis 
showed mean intensity of GPI-Cp bands expressed as a percentage of 
arbitrary units ±SD compared to the 5 μM copper treatment of the control 
cells, normalised against the Na/K ATPase representative of four 
independent experiments. Statistical variation is indicated by different letters 
above graph bars (p<0.05). 
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the corresponding treatment in the control cells. However the differences 
were only significant for the BCS/DPen treated cells (p<0.05) and not the 5 
μM or 50 μM copper treated cells for each of the three models (p>0.05) (Fig 
6.8c). 
 
As observed in parental differentiated cells in chapter 3, CTR1 mRNA levels 
were unaltered by copper treatment. However, unlike the parental PMC42-LA 
cells, CTR1 mRNA was influenced by lactational hormones in the ATP7A 
overexpressing cells, increasing significantly in the lactating and suckled 
models (p<0.05). CTR1 protein levels decreased in response to elevated 
copper loads and surface biotinylation revealed a similar trend with more 
CTR1 protein being present at the plasma membrane when copper levels 
were depleted. Lactational hormones increased the levels of total and 
membrane bound CTR1 protein levels in ATP7A overexpressing cells, 
however CTR1 localisation determined by immunofluorescent confocal 
microscopy did not reveal any significant variation between treatment (data 
not shown). These results are consistent with those presented in chapter 3 
for the parental PMC42-LA cells. 
 
6.2.3.5 Intracellular copper levels increase in response to ATP7A 
overexpression in differentiated PMC42-LA cells  
AAS analysis of copper levels revealed that ATP7A overexpression caused 
an increase in intracellular copper in all 50 μM copper treated cells as well as 
the 5 μM copper treated cells of the lactating and suckled models, compared 
to the control cells of corresponding treatment (p<0.05). The BCS/DPen 
treated and 5 μM copper treated resting model cells showed no difference in
  
Figure 6.8 CTR1 mRNA and protein in differentiated PMC42-LA cells 
(a) Relative mRNA levels of CTR1 in response to ATP7A overexpression, 
copper and hormones obtained by qRT-PCR. The bar graph indicates the 
mean percentage differences ±SD compared to the 5 μM copper treated cells 
of the control resting model. CTR1 mRNA levels were normalised against β-
actin. B = BCS/DPen, 5 = 5 μM copper, 50 = 50 μM copper. (b) 
Representative Western blots of 60μg of protein extract from resting, 
lactating and suckled models comparing CTR1 bands in ATP7A 
overexpressing cells to control cells for each respective copper treatment. 
The β-actin blot demonstrates relative loading of samples. The CTR1 
densitometry graph bars show mean intensity of ATP7A bands expressed as 
a percentage of arbitrary units ±SD compared to the 5 μM copper treatment 
of control cells, normalised against β-actin and represents data from three 
independent experiments. Statistical variation is indicated by different letters 
above graph bars (p<0.05). (c) Surface biotinylated CTR1 protein was 
analysed by Western blot. These representative Western blots of 
extracellularly biotinylated protein extract show the CTR1 band in ATP7A 
overexpressing and control cells of the resting breast model, lactating model 
and suckled model treated with BCS/DPen, 5 μM copper and 50 μM copper. 
Densitometric analysis showed mean intensity of CTR1 bands expressed as 
a percentage of arbitrary units ±SD compared to the 5 μM copper treatment 
of the control cells, normalised against Na/K ATPase and is representative of 
four independent experiments. Statistical variation is indicated by different 
letters above graph bars (p<0.05). 
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intracellular copper levels between the control and ATP7A overexpressing 
cells (p>0.05) (Fig 6.9). Analysis of XFM data revealed a similar trend (data 
not shown). 
 
As demonstrated in differentiated parental PMC42-LA cells in chapter 3, the 
ATP7A overexpressing cells showed an accumulation of copper within the 
organoids compared to the surrounding monolayer of cells (Fig 6.10). No 
copper was detected in the BCS/DPen treated samples. The total 
fluorescence images indicate the position of cells and organoidal structures 
in each image. 
 
6.2.4 ATOX1 expression is not influenced by copper, lactational 
hormones or elevated levels of ATP7A 
QRT-PCR analysis revealed copper concentrations had no significant effect 
(p>0.05) on the expression of ATOX1 mRNA in the resting model, lactating 
model or suckled model of wild type PMC42-LA and ATP7A overexpressing 
PMC42-LA cells. The presence of hormones also had no significant effect on 
ATOX1 transcript (p>0.05) in wild type and ATP7A overexpressing cells. Also 
the overexpression of ATP7A had no impact on the mRNA levels of ATOX1 
(p>0.05) (Fig 6.11a). 
 
A single band of approximately 7 kDa corresponding to the ATOX1 protein 
was detected across all samples treated with copper and lactational 
hormones in both the ATP7A overexpressing and control cells. Similar to the 
mRNA results, no differences in protein levels were detected in response to 
copper or lactational hormones. The overexpression of ATP7A also had no
  
Figure 6.9 Intracellular copper within differentiated PMC42-LA cells 
AAS analysis of copper levels within control and ATP7A overexpressing cells 
of the resting, lactating and suckled models treated with BCS/DPen, 5 μM 
copper and 50 μM copper. B = BCS/DPen, 5 = 5 μM copper, 50 = 50 μM 
copper. Data is representative of three independent experiments. Statistical 
variation is indicated by different letters above graph bars (p<0.05). 
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Figure 6.10 Copper localisation within the organoids of ATP7A 
overexpressing cells treated with copper and lactational hormones 
XFM analysis revealed the distribution of copper within the organoids of 
copper and hormonally treated ATP7A overexpressing PMC42-LA cells. No 
copper was detected in the BCS/DPen treated cells of the resting model (a), 
lactating model (d) or suckled model (g), while copper was clearly visible in 
the 5 μM copper (b, e and h) and 50 μM copper (c, f and i) treated cells in 
each respective model. Total X-ray fluorescence images accompany the 
XFM copper images to show the position of each of the organoids. The 
colour scale bar shows the relative levels of copper from lowest (black) to 
highest (white). Length scale bar = 30 μm. 
 161 
 
 
 
 
 
 162 
influence upon the levels of ATOX1 protein present in the cells (p>0.05) (Fig 
6.11b and c). 
 
6.2.5 ATP7A overexpression increased the levels of β2M protein, but 
not mRNA in PMC42-LA cells 
Analysis of β2M mRNA by qRT-PCR revealed that copper, lactational 
hormones and ATP7A overexpression had no influence upon transcription of 
this gene (p>0.05) (Fig 6.12a). However the same cannot be said for the 
protein. While the addition of copper and lactational hormones did not 
influence β2M protein levels (p>0.05), overexpression of ATP7A caused a 
significant elevation in the level of β2M present within the cells (p<0.05). This 
effect was consistent in all three culture models and all three copper 
conditions (Fig 6.12b and c). 
 
 
 
  
Figure 6.11 ATOX1 mRNA and protein expression levels in response to 
copper, lactational hormones and ATP7A overexpression 
(a) Relative mRNA levels of ATOX1 in response to copper, hormones and 
ATP7A overexpression obtained by qRT-PCR. The bar graph indicates the 
mean percentage differences ±SD compared to the 5 μM copper treated cells 
of the control resting model. ATOX1 mRNA levels were normalised against 
β-actin. B = BCS/DPen, 5 = 5 μM copper, 50 = 50 μM copper. (b) 
Representative Western blots of 60μg of protein extract from ATP7A 
overexpressing and control cells showing ATOX1 bands in the resting breast 
model (lanes 1-3), lactating model (lanes 4-6) and suckled model (lanes 7-9) 
treated with BCS/DPen (lanes 1, 4 and 7), 5 μM copper (lanes 2, 5 and 8) 
and 50 μM copper (lanes 3, 6 and 9). (c) Representative Western blots of 60 
μg of protein extract from resting, lactating and suckled models comparing 
ATOX1 bands in ATP7A overexpressing cells to control cells for each 
respective copper treatment. The β-actin blots demonstrate relative loading 
of samples. The ATOX1 densitometry graph bars show the mean intensity of 
ATOX1 bands expressed as a percentage of arbitrary units ±SD compared to 
the 5 μM copper treatment of the resting model (b) and the 5 μM copper 
treatment of the control cells (c), normalised against β-actin and is 
representative of three independent experiments.  
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Figure 6.12 β2M mRNA and protein expression in differentiated PMC42-
LA cells 
(a) Relative mRNA levels of β2M in response to copper, hormones and 
ATP7A overexpression obtained by qRT-PCR. The bar graph indicates the 
mean percentage differences ±SD compared to the 5 μM copper treated cells 
of the control resting model. β2M mRNA levels were normalised against β-
actin. B = BCS/DPen, 5 = 5 μM copper, 50 = 50 μM copper. (b) 
Representative Western blots of 60 μg of protein extract from ATP7A 
overexpressing and control cells show β2M bands in the resting breast model 
(lanes 1-3), lactating model (lanes 4-6) and suckled model (lanes 7-9) treated 
with BCS/DPen (lanes 1, 4 and 7), 5 μM copper (lanes 2, 5 and 8) and 50 μM 
copper (lanes 3, 6 and 9). (c) Representative Western blots of 60μg of 
protein extract from resting, lactating and suckled models comparing β2M 
bands in ATP7A overexpressing cells to control cells for each respective 
copper treatment. The β-actin blot demonstrates relative loading of samples. 
β2M densitometry graph bars show mean intensity of β2M bands expressed 
as a percentage of arbitrary units ±SD compared to the 5 μM copper 
treatment of the resting model (b) and the 5 μM copper treatment of the 
control cells (c), normalised against β-actin and is representative of three 
independent experiments. Statistical variation is indicated by different letters 
above graph bars (p<0.05). 
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6.3 Discussion 
 
The study described in chapter 5 examined the effects of ATP7A 
overexpression on copper levels and copper transporting proteins in 
undifferentiated PMC42-LA mammary cells. To further investigate copper 
homeostasis in human mammary epithelial cells, the differentiated models 
used in chapter 3 and 4 representing the resting, lactating and suckled 
mammary gland, were implemented to ascertain the responses of copper 
transporting proteins to copper, lactational hormones and ATP7A 
overexpression. The study was carried out to establish whether the changes 
observed in the undifferentiated cells, have similar implications in models that 
more closely represent physiological conditions of the resting and lactating 
mammary epithelium. 
 
The results obtained from ATP7A overexpressing differentiated PMC42-LA 
cells, were similar to the data described in the previous three chapters 
showing responses to copper, lactational hormones and ATP7A 
overexpression. However there were still a few novel findings observed in the 
ATP7A overexpressing differentiated cultures that had not been detected in 
the undifferentiated cells. 
 
In differentiated cells, ATP7A mRNA and protein expression levels were not 
responsive to extracellular copper treatments, consistent with the data of 
chapter 5. A slight increase in ATP7A expression was observed in response 
to lactational hormones, however this was not significant. Analysis of ATP7A 
localisation in the PMC42-LA cell models revealed some interesting results. 
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ATP7A responded to copper as it did in undifferentiated cells (Ackland et al., 
1997, chapter 5), moving from a tight perinuclear localisation in depleted 
copper conditions and dispersing as copper concentrations increased. This 
phenomenon was seen in all differentiated PMC42-LA breast models; 
resting, lactating and suckled in both control and ATP7A overexpressing 
cells. However hormones also played a role in the trafficking of ATP7A as 
there was greater dispersion in the lactating model compared to that of the 
resting model, similar to the observations made of ATP7B (Michalczyk et al., 
2008). This result correlates with differences observed in ATP7A localisation 
between resting human mammary tissue where the protein was found to be 
predominantly in the perinuclear region and lactating mammary tissue which 
showed a dispersed, cytoplasmic pattern (Ackland et al., 1999). These data 
suggest that the PMC42-LA resting and lactating models are more 
representative of the human breast than the undifferentiated PMC42-LA cells 
which showed no movement of ATP7A in response to lactational hormones 
(Ackland et al., 1997) and indicates that the full function of ATP7A trafficking 
only occurs in differentiated cells. 
 
Some research has indicated that ATP7A localises apically as well as 
basolaterally in the mammary epithelial cells of hyperprolactinemic rats 
(Kelleher and Lonnerdal, 2006). This is not something that was observed in 
the PMC42-LA cells. The localisation of ATP7A in these cells, while 
dispersed, was more prominent in the basolateral part of the cell. This agrees 
with research which showed that ATP7A is targeted towards the basolateral 
membrane via its dileucine motif (Greenough et al., 2004). The basolateral 
localisation observed in PMC42-LA cells is also more reminiscent of research 
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conducted on ATP7A overexpressing mice which showed predominantly 
basolateral localisation (Llanos et al., 2008). 
 
Surface biotinylation analysis of ATP7A supported the immunolocalisation 
results. A greater amount of ATP7A was observed at the plasma membrane 
in response to copper, while very little was detected in the chelated samples. 
The addition of hormones also increased the presence of ATP7A at the 
plasma membrane. 
 
The results obtained are consistent with the concept that ATP7A is mobilised 
to the basolateral membrane during lactation and functions to transport 
copper back into the maternal bloodstream, protecting a suckling infant from 
receiving high copper levels in milk. The hormonally induced dispersion of 
ATP7A seems counterproductive in relation to the increased presence of 
CTR1 at the plasma membrane in response to hormones observed in 
chapter 3. However the cells may be increasing copper uptake by CTR1 at 
the basal membrane to enhance the movement of copper into the cell and 
then into the milk via ATP7B and ceruloplasmin (Cp), while ATP7A is 
effluxing copper across the basolateral membrane when intracellular copper 
levels become too high or when copper secretion across the apical 
membrane needs to be impeded to prevent the build up of high milk copper 
levels. 
 
Responses of CTR1 in differentiated ATP7A overexpressing cells were 
analysed as described in chapter 3 for PMC42-LA cells expressing only 
endogenous ATP7A and comparisons were made between the two cell 
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types. The addition of copper, hormones or presence of excess ATP7A had 
no observable effect upon the localisation of CTR1 when analysed by 
immunofluorescence microscopy (data not shown); however surface 
biotinylation did indicate that there was less protein at the plasma membrane 
when cells were exposed to elevated copper. This was also reflected in the 
total CTR1 protein levels of the cells. Copper depletion increased CTR1 
protein levels within the cells and at the plasma membrane, while copper 
caused levels to reduce. Like copper chelation, the addition of lactational 
hormones and the overexpression of ATP7A increased the levels of CTR1. 
These data are consistent with the proposed model in which CTR1 enables 
an influx of copper from the basolateral membrane of the cells. The increase 
in CTR1 expression in cells exposed to copper chelation may be induced to 
elevate copper uptake in depleted conditions, while in copper loaded cells, 
CTR1 is down-regulated to prevent the uptake of toxic levels of copper. The 
elevation of CTR1 in response to ATP7A overexpression may occur to 
balance increased copper efflux caused by the additional ATP7A protein. 
However the lactational hormone response of CTR1 may be initiated to 
increase copper uptake into the cell which would allow for the movement of 
additional copper across apical side of the cells into the milk. During lactation 
and suckling, additional copper is required in the lumen of the alveolus to 
supply a suckling infant with adequate copper. For this to occur, the copper 
must first be taken up into the cells from the blood, a role performed by 
CTR1.  
 
Most of the CTR1 responses to copper, lactational hormones and the 
overexpression of ATP7A were similar to those presented previously in 
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chapter 3 and 5. However, the overexpression of ATP7A in combination with 
lactational hormones increased the levels of CTR1 mRNA. This effect was 
not observed previously as individually lactational hormones and ATP7A 
overexpression had no effect on CTR1 mRNA. It is not clear whether the 
increase in mRNA translates into protein changes. While CTR1 protein levels 
were increased in hormonally treated ATP7A overexpressing cells, there was 
also a higher level of CTR1 protein in hormonally treated control cells and in 
non-hormonally treated ATP7A overexpressing cells. This indicates that 
protein levels were influenced by hormones and ATP7A overexpression 
independently, whereas the mRNA required the presence of both to be 
elevated. The increase in CTR1 protein in response to hormones may be a 
consequence of reduced degradation of CTR1 protein rather than increased 
transcription, as this increase was not accompanied by transcriptional 
differences in the control cells. If the increase in CTR1 transcription in ATP7A 
overexpressing cells does translate into protein changes, it is possible that 
the posttranslational degradation has a greater influence and prevents the 
protein levels increasing significantly. Additionally, densitometric analysis of 
western blot bands is rather cruder than the analysis of mRNA by qRT-PCR 
which is more sensitive and subtle changes can be detected more easily. 
 
In this study it was observed that ATP7B mRNA was not affected by 
lactational hormones in PMC42-LA cells. Upon overexpression of ATP7A, 
this trend was altered as ATP7B mRNA increased in the presence of ATP7A 
overexpression and lactational hormones. This change is not solely a 
response to ATP7A overexpression as the ATP7A overexpressing resting 
model which is not exposed to lactational hormones showed no difference in 
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ATP7B expression compared to the control cells. Likewise it is not solely an 
effect of the lactational hormones as ATP7B expression did not respond to 
hormonal treatment in the parental PMC42-LA cells. While there was a clear 
increase in ATP7B mRNA levels in response to ATP7A overexpression in 
conjunction with hormones, it was not possible to determine whether this 
correlated to an increase in protein levels. The ATP7B protein analysis 
results were inconsistent and so a final conclusion as to whether the protein 
levels reflected mRNA levels could not be drawn.  
 
The increases in CTR1 and ATP7B mRNA in response to ATP7A 
overexpression and lactational hormones may be occurring to oppose the 
effect of ATP7A. It is possible that there are non-copper induced signalling 
mechanisms that are initiated by ATP7A overexpression that cause CTR1 
and ATP7B mRNA expression to increase, resulting in enhanced uptake of 
copper across the basolateral membrane into the cell via CTR1, which then 
allows the increased levels of ATP7B to facilitate greater copper efflux across 
the apical membrane for secretion into the milk, thus reducing the effect of 
ATP7A overexpression. 
 
In addition to direct regulation by hormones and ATP7A overexpression, 
copper transporters can also be influenced by varying copper levels. The real 
time PCR data indicated that ATP7B is responsive to copper levels. In spite 
of the ATP7B promoter region containing four metal response elements 
(Cullen et al., 2003), most previous research on human tissue, rats, mice and 
human cultured cells, has shown no change in response to copper (Gambling 
et al., 2004, Llanos et al., 2008, Michalczyk et al., 2008, Michalczyk et al., 
 171 
2000, Prohaska, 2008, Schilsky et al., 1998). However there have been two 
studies which did show some different responses. The first showed increase 
in mRNA but not protein in the livers of pups fed copper supplemented diets 
(Bauerly et al., 2005). The second study showed that during the early phase 
of lactation when breast plasma copper levels were highest, mammary gland 
ATP7B mRNA was at its lowest. As copper levels reduced with the 
progression of lactation, ATP7B levels increased (Kelleher and Lonnerdal, 
2006). The second study correlates with the data presented here and is most 
relevant as it also pertains to the mammary gland. The protein levels of the 
second study did not correlate with the mRNA as they identified a slight, but 
statistically significant down-regulation of ATP7B protein in the latter stages 
of lactation, opposite to the mRNA results (Kelleher and Lonnerdal, 2006). 
The research presented in chapter 5 on PMC42-LA cells grown in flasks 
showed no change in ATP7B mRNA in response to copper in either wild type 
or ATP7A overexpressing cells, however one key difference is that the data 
presented in this chapter was performed on differentiated cultures. It is 
possible that ATP7B’s transcriptional regulation is more sensitive to copper in 
differentiated cells. Increasing copper levels caused significant reduction in 
ATP7B mRNA in all ATP7A overexpressing models, as well as the lactating 
model of the control cells. The resting and suckled control models did not 
show statistically significant down-regulation, however there was a trend 
showing a decrease as copper levels rose. This result appears contrary to 
ATP7B’s role as a copper efflux pump, in which an increase in ATP7B would 
be expected with an increase in elevated copper to assist with the efflux of 
high levels of copper. However, due to ATP7B’s apical localisation, an 
increase would result in the transport of more copper into the milk. This 
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would maintain copper levels in the mammary epithelial cells, but would 
elevate milk copper levels which may have adverse effects upon the suckling 
infant. Reducing the level of ATP7B when copper is elevated would reduce 
this risk, however the cells would need to rely solely on ATP7A to remove 
excess copper from the cells across the basolateral side of the cell. Given 
that most cells types in the human body only use ATP7A as a copper efflux 
pump (Vulpe et al., 1993), this should be sufficient for the mammary gland as 
well. The opposite response was found in copper chelated samples which 
showed elevated ATP7B mRNA levels. While not significant, levels were 
consistently higher than in the 5 μM copper control cells. This would suggest 
that copper deficient cells are increasing ATP7B to maintain copper secretion 
into milk; preventing the suckling infant from receiving inadequate amounts of 
copper. 
 
Unfortunately the ATP7B mRNA changes observed in response to copper 
could not be conclusively confirmed by protein analysis. Some data showed 
distinct changes in ATP7B levels in response to copper, with BCS/DPen 
levels being highest, while the copper treated samples expressed much less, 
almost undetectable levels of protein; this is similar in trend to the mRNA. 
These blots showed a reduction in ATP7B protein in response to copper in all 
cell models (resting, lactating and suckled) in both cell types (ATP7A 
overexpressing and controls). In contrast to this, there were some blots which 
showed fewer differences between copper treatments, or sometimes 
variation which could be considered random, showing no distinct trends at all. 
The densitometric analysis of these inconsistent results did not reveal any 
trend or significant changes that could be correlated with the mRNA data. 
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Two ATP7B antibodies have been used for this work, one custom made, one 
commercially available, and both yielded poor results. The custom made 
antibody produced multiple bands on the blot and so it was difficult to 
determine which band was ATP7B. The band that was closest to the 
predicted ATP7B size was not consistent in intensity and almost 
undetectable in some of the samples. The commercially available ATP7B 
antibody worked effectively for the undifferentiated cells, giving clear results 
which were presented in chapter 5; however this was not the case for 
differentiated cells. Detection of the protein by Western blot was complicated 
by the difficulties of sample preparation for the differentiated cells. These 
cells were grown on a layer of EHS matrix. When the cells were collected, 
some of this matrix contaminated the samples, adding to the total protein 
estimations. This also made it more difficult to lyse and homogenise the cells 
in a small volume of lysis buffer as it increases the viscosity of the sample. 
Once the sample was homogenous, the concentration was lower than 
desired, thus it was difficult to load more than 60 μg of protein, where it may 
be more useful to load 100-120 μg for easier detection of this protein. To 
further analyse ATP7B in these cells, another antibody that is more sensitive 
would be required for analysis of ATP7B protein in differentiated PMC42-LA 
cells. 
 
The ATP7B mRNA demonstrated some unexpected results, however the 
localisation of the protein was consistent with those observed previously 
(Michalczyk et al., 2008, chapter 5). ATP7B resided near the TGN in copper 
depleted samples and dispersed with the addition of copper and lactational 
hormones (data not shown). This is consistent with its role as an efflux pump, 
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receiving copper in the TGN from ATOX1 and trafficking towards the plasma 
membrane where it enables the efflux of copper into milk. 
 
ATOX1, the copper chaperone that delivers copper to, ATP7A and ATP7B, 
showed no variation in response to copper levels or ATP7A overexpression 
in undifferentiated PMC42-LA, as demonstrated in chapter 5. The results 
from the differentiated cultures were no different, with the copper and 
hormonal treatments and also ATP7A overexpression having no influence 
upon the mRNA or protein levels in PMC42-LA cells. There has been little 
research analysing the effect of copper on ATOX1 and none on the effect of 
lactational hormones. However, it has been shown that the altered copper 
status of mice fed iron deficient and also copper deficient diets has little 
impact on ATOX1 expression in the placenta and liver (Andersen et al., 2007, 
Gambling et al., 2004). As stated previously (Lutsenko et al., 2007, chapter 
5), there is an excess of ATOX1 transcript with respect to ATP7A and ATP7B 
and so perhaps alteration of ATOX1 expression is unnecessary as levels are 
always sufficient when the demand for loading copper onto the ATPases is 
high. 
 
The experiments described in chapter 4 and 5 have clearly demonstrated 
that the secreted form of Cp and the membrane bound 
glycosylphosphatidylinositol-linked Cp (GPI-Cp) are influenced by copper and 
lactational hormones in undifferentiated and differentiated cells and by 
ATP7A overexpression in undifferentiated cells. The results obtained from 
differentiated ATP7A overexpressing cultures were consistent with the 
previous data. Increases in Cp transcription and secretion in response to 
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lactational hormones ensures an adequate supply of Cp into the milk when 
demand is high. Additionally, the presence of copper is important as Cp is 
inactive in its apo form (when it does not have copper bound) and unable to 
oxidise iron, therefore copper deficiency would impact upon not only copper, 
but also the supply of iron to a suckling infant as well. A clear understanding 
of the mechanisms causing Cp up-regulation in response to ATP7A 
overexpression has yet to be determined, as discussed in chapter 5. 
However it is possible that similar to the increases in CTR1 and ATP7B, the 
increase in Cp is intended to counteract the effect of additional ATP7A 
moving copper across the basolateral membrane, promoting sufficient copper 
flux in the direction of the milk. The role of GPI-Cp in lactation is unknown. It 
is possible that GPI-Cp aids the efflux of iron, or perhaps the oxidation of iron 
which would enable iron binding to lactoferrin; similar to the role performed 
by sCp (de Domenico et al., 2007, Jeong and David, 2003, Kono et al., 
2006a, Sabatucci et al., 2007, Sokolov et al., 2007, Zakharova et al., 2000). 
Cp localisation in differentiated ATP7A overexpressing cells remained 
unchanged compared to the control cells and was not influenced by copper 
or lactational hormones (data not shown). 
 
The research described in chapter 5 demonstrated that an increase in 
expression of ATP7A resulted in elevated levels of β2-microglobulin (β2M). 
This is likely the result of the ATP7A effluxing more copper ions which would 
normally be available to destabilise the β2M protein (Deng et al., 2006). β2M 
is known to play a role in iron uptake, where it binds to HFE which enhances 
transferrin receptor’s ability to bind and take up iron loaded transferrin (Bhatt 
et al., 2009, Bhatt et al., 2010, Enns, 2001, Vecchi et al., 2010). However, a 
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number of studies have also outlined the impact of copper in destabilisation 
of β2M which causes the formation of the amyloid plaques that aggregate in 
joints and connective tissue causing Dialysis-Related Amyloidosis (Calabrese 
and Miranker, 2009, de Lorenzi et al., 2008, Deng et al., 2006). Additionally, 
some research has implicated β2M in the growth and proliferation of cells 
(Huang et al., 2008, Huang et al., 2006, Josson et al., 2011, Rowley et al., 
1995, Yang et al., 2006) and that this may be the underlying cause of some 
of the unexpected changes. 
 
Copper was observed to accumulate in differentiated ATP7A overexpressing 
cells compared to controls. Strangely, this response contradicts the previous 
data from undifferentiated ATP7A overexpressing PMC42-LA cells described 
in chapter 5 and is not consistent with ATP7A’s role as a copper efflux 
protein, in which overexpression should decrease copper levels in the cell. It 
was noted as the ATP7A overexpressing cells grew in culture, that the colour 
of the medium was different to the controls at the conclusion of the 
experiment, even though the cells for both cultures were seeded at the same 
density and in the same volume of growth medium. The phenol red pH 
indicator in the growth medium was consistently more yellow in the ATP7A 
overexpressing cells compared to the controls, suggesting that these cells 
had lowered the pH of the medium as a result of creating more metabolic 
waste products, which is likely a consequence of increased growth and 
proliferation. This was observed in all three models treated with BCS/DPen, 5 
μM or 50 μM copper. While the culture medium of ATP7A overexpressing 
cells was consistently more yellow than the control medium, there was no 
noticeable difference in colour between the copper or hormonal treatments. 
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The growth medium colour correlated with the β2M protein levels which 
increased in ATP7A overexpressing cells. It has been shown previously that 
copper and also β2M can promote cellular proliferation (Huang et al., 2008, 
Huang et al., 2006, Itoh et al., 2008, Josson et al., 2011, Rowley et al., 1995, 
Yang et al., 2006). It is possible that β2M influences pathways that enable 
increased copper uptake to enhance cellular growth. For example, β2M 
activates the MAPK/ERK and PI3K/Akt pathways (Huang et al., 2010, Yang 
et al., 2006), and influences the levels of cyclin A and cyclin D1 (Huang et al., 
2006); all of these factors are involved in the growth and proliferation of cells. 
MAPK/ERK and PI3K/Akt have also been shown to increase with the addition 
of copper (Barthel et al., 2007, Samet et al., 1998, Veldhuis et al., 2009, 
Walter et al., 2006). However, BCS/DPen treated cells have very little 
available copper that would make copper enhanced proliferation in these 
cells very unlikely.  
 
An alternate proposal to the theory that β2M induces growth and proliferation 
by altering the copper status of the cell is that β2M caused an increase in 
growth and proliferation via non-copper mediated pathways, thus explaining 
the consistency of the colour of the growth medium in all copper treatments. 
It was shown that blocking β2M with a β2M antibody, activated the MAP 
kinase JNK pathway which initiates stress responses, growth arrest and 
apoptosis, while suppressing the MAPK/ERK and PI3K/Akt pathways (Huang 
et al., 2010, Yang et al., 2006). This indicates that under normal 
circumstances, β2M activates the MAPK/ERK and PI3K/Akt pathways, 
promoting growth and prolifteration, while at the same time suppressing 
growth repression and apoptotic MAPK/JNK pathways. Hence, increased 
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expression of β2M in ATP7A overexpressing cells, should lead to an 
increased rate of cellular growth and proliferation. 
 
Differing growth rates between ATP7A overexpressing and control cells 
alters the dynamics of the culturing system which has implications for 
maintaining experimental consistency. It was identified during method 
development of the differentiated cultures, that the degree of organoid 
formation is influenced by the seeding density of the cells. It was also noted 
that the ATP7A overexpressing cultures formed more and also larger 
organoids than the control cultures when seeded at the same density. This is 
likely a result of differing cellular growth and proliferation rates, which change 
the culture density as the experiment progressed. It was also noted that the 
monolayer cells have centrally rather than basally localised nuclei (Ackland et 
al., 2001) and so it is possible that they are not as polarised or differentiated 
as the organoidal cells. If true, the organoidal cells may behave more like 
luminal epithelial cells than the monolayer cells and may take up more 
copper with the intention of secreting it across the apical membrane into the 
lumen of the organoid. As a result, the organoidal cells may have slightly 
higher intracellular copper levels than the monolayer cells. If this occurs, the 
ATP7A overexpressing cells, which have more and also larger organoids 
than the control cultures, would have a higher proportion of organoidal cells 
than the controls. This could lead to the ATP7A overexpressing cultures 
having more cells with a higher concentration of intracellular copper in them; 
masking an observable copper reduction caused by the increased expression 
of ATP7A. The XFM data also showed higher copper levels within the 
organoidal structures. In chapter 3 it was concluded that most of this copper 
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is within the lumen of the organoids. The elevation in luminal copper could 
also be caused by the ATP7A overexpressing cultures having larger 
organoids, which would have more cells that are able to secrete copper into 
the lumen. This would result in the ATP7A overexpressing cultures having 
more copper in the lumen of their organoids than the control cultures. 
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6.4 Conclusions 
 
The overexpression of ATP7A in a differentiated cell culture model has 
facilitated the study of copper homeostatic disturbances in a system more 
reminiscent of the physiological conditions encountered in the mammary 
gland. ATP7A is proposed to have a protective role in the lactating mammary 
gland, moving copper across the basolateral membrane back to the maternal 
bloodstream. The addition of lactational hormones caused ATP7A to 
disperse to the membrane. In conjunction with the overexpression of ATP7A, 
lactational hormones also induced expression of proteins associated with the 
movement of copper towards the apical surface of the mammary epithelial 
cells. It was also shown for the first time that ATP7B levels were altered by 
exposure to increased copper levels, a response thought to help tightly 
regulate copper delivery to milk. These changes which were not observed in 
undifferentiated cultures, suggest that differentiated cells may regulate 
copper more stringently, particularly in the presence of lactational hormones. 
This attribute may be essential to maintain appropriate copper levels in the 
secreted milk, enabling sufficient nourishment of a suckling infant, while at 
the same time preventing exposure to toxic copper levels that may be 
harmful. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 7 
 
Conclusion 
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Maintaining strict copper homeostasis is crucial for proper functioning of all 
types of cells and tissues in the body. Extensive research has been 
conducted to help explain the role of individual copper transporters in a 
variety of cells. However less is known about the copper fluxes in complex 
systems containing more than one copper efflux protein. It is important to 
gain an understanding of these more complex systems as they are present in 
organs essential to the nourishment of developing foetuses and neonates; 
the placenta and mammary gland. The mammary gland produces milk which 
is an important dietary source for neonates. Adequate copper secretion into 
milk is essential for neonatal growth and development. 
 
Copper homeostasis in mammary epithelial cells is controlled by a small 
number of influx and efflux proteins. CTR1 controls copper uptake from the 
maternal blood stream (Kelleher and Lonnerdal, 2003, Kelleher and 
Lonnerdal, 2006, Llanos et al., 2008). Once inside the cells, copper is 
delivered to ATP7A or ATP7B by copper chaperone ATOX1 (Banci et al., 
2007, Banci et al., 2009, Strausak et al., 2003, Tanchou et al., 2004, van 
Dongen et al., 2004). ATP7A and ATP7B are key components of cellular 
copper efflux. ATP7A is important in removing excess copper across the 
basolateral membrane back into the maternal bloodstream, while ATP7B is 
important in the deliverly of copper to Cp for secretion across the apical 
membrane into milk (Kelleher and Lonnerdal, 2006, Llanos et al., 2008, 
Platonova et al., 2007, Tsymbalenko et al., 2009). MT also plays an 
important role in preventing copper toxicity by binding and storing excess 
cellular copper (Mehta et al., 2006, Sutherland and Stillman, 2011, Urani et al., 
2003). The current research has extensively studied the responses of these 
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proteins to various copper levels, to the increases in hormone levels 
experienced during lactational and neonatal suckling and finally in response 
to the overexpression of copper efflux protein ATP7A. 
 
This research has unveiled some interesting findings. Initially, the 
differentiated culture models used previously that represent the resting and 
lactating mammary gland, were further developed to create an environment 
that simulated the suckling of a feeding infant. Analysis of copper levels in 
these culture models revealed that lactational hormones increased copper 
uptake. This was most clearly observed in cells treated with high copper 
representing the levels present in blood during lactation. This result indicates 
that upon hormonal stimulation, the cells are absorbing more copper, 
possibly to enhance the secretion of copper into milk. It was also observed 
that the organoidal structures that are formed in culture were behaving like 
the lobules of a mammary gland; secreting copper into the lumen of the 
organoids. This demonstrates that the model is functional, secreting trace 
metals and milk proteins across the apical membrane of the polarised cells 
into the luminal cavity of the three dimensional organoid structures. 
 
Upon analysis of the individual transporters, CTR1 expression and 
localisation was found to be influenced by copper and lactational hormones. 
Total CTR1 protein levels and its presence at the membrane were reduced 
with the addition of copper which is intended to decrease copper uptake. As 
an uptake molecule, it is important that CTR1 can regulate copper fluxes in 
response to its surroundings. It is crucial for cellular survival to prevent 
excess uptake of copper which can lead to the production of free radicals. 
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However, when intracellular copper levels were elevated, the cells increased 
the expression of metallothionein 1 and 2, which can bind excessive copper 
and protect the cells from copper toxicity. The addition of lactational 
hormones increased total and membrane bound CTR1 levels. This increase 
is likely intended to enhance the movement of copper into milk secretions. 
 
Regulating copper efflux is as important as regulating copper uptake. In the 
mammary epithelial cells copper can be effluxed across the basolateral 
membrane by ATP7A or across the apical membrane by ceruloplasmin (Cp). 
Ceruloplasmin (Cp) is the main carrier of copper in milk and control of its 
release from mammary epithelial cells is an important factor in regulating milk 
copper levels. Copper levels had little influence upon Cp expression and 
secretion, however its presence determined whether the Cp protein was 
copper loaded and ferroxidase active. Lactational hormones initiated an 
increase in Cp transcription and secretion. This could be a response to 
increased demand, as lactation and suckling would require a high rate of Cp 
secretion to maintain adequate copper supply to the milk. 
 
ATP7A binds copper in the TGN and traffics to the plasma membrane where 
it is able to efflux copper from the cell. Its dispersion away from the TGN and 
presence at the plasma membrane is regulated by copper. As copper levels 
rise, more ATP7A moves towards the membrane, helping to maintain 
appropriate cellular copper concentrations. The addition of lactational 
hormones also increased the dispersion of ATP7A and its presence at the 
plasma membrane. In mammary epithelial cells, ATP7A is most likely 
involved in copper efflux across the basolateral membrane. Increasing 
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copper efflux across the basolateral membrane in response to lactational 
hormones is counterproductive to the increased copper flux into the milk 
caused by CTR1 and Cp. It is possible that the response to lactational 
hormones is designed to increase the total flux of copper in and out of the 
cell. This model would suggest that copper is always moving back and forth 
across the basolateral membrane and when required it can be redirected 
towards the apical membrane for secretion into milk. 
 
ATP7B may assist the movement of copper towards the milk. A decline in 
ATP7B mRNA was observed in response to copper which may also be the 
case for protein levels, indicating that ATP7B may be important in regulating 
copper transport across the apical membrane. When copper levels are 
depleted ATP7B expression is increased in an attempt to raise the milk 
copper content, making it more nutritious. Upon copper overload, ATP7B is 
down-regulated to protect the suckling infant from being exposed to high and 
potentially toxic copper levels. ATP7B most likely regulates milk copper in 
conjunction with Cp. ATP7B was not shown to be present at the plasma 
membrane of cells, however it was shown to directly interact with Cp. Figure 
7.1 demonstrates graphically the changes induced by lactational hormones. 
 
These data were further supported by the experiments using ATP7A 
overexpressing cells which caused an up-regulation of Cp, CTR1 and ATP7B 
mRNA in differentiated cells in the presence of lactational hormones. These 
responses were not copper related as these genes did not respond to altered 
copper levels. Results suggest that there are non-copper related pathways 
which are activated by the presence of additional ATP7A. The hypothesised
  
Figure 7.1 Lactational hormone induced changes of copper 
transporting proteins 
This schematic diagram of copper transporting proteins in mammary 
epithelial cells compares non-hormonal to hormonal conditions in the 
presence of 5 μM copper. The diagram shows the localisation of proteins 
with regard to the apical and basolateral membranes of mammary epithelial 
cells. Arrows indicate the movement of copper through the cells. 
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pathways counteract the effect of ATP7A by up-regulating the proteins 
involved in moving copper in the direction of apical membrane. This is 
particularly evident when lactational hormones are present as there is 
increased requirement for copper to be moved into the milk.  
 
Glycosylphosphatidylinositol-linked Cp (GPI-Cp) was detected for the first 
time in mammary epithelial cells. It was detected at the plasma membrane 
and proved unresponsive to copper and lactational hormones, although its 
expression was elevated in response to ATP7A overexpression. The GPI 
linked form of Cp is membrane bound is likely to have a role in oxidation and 
efflux of iron (Jeong and David, 2003, Kono et al., 2006a). sCp has 
ferroxidase activity, delivers iron to transferrin and interacts with lactoferrin. 
GPI-Cp has similar ferroxidase activity and it is possible the both GPI-Cp and 
sCp play an important role in loading lactoferrin with iron. 
 
In future it will be important to verify the ATP7B protein results and determine 
its responsiveness to copper which will help to obtain a more complete 
understanding of the copper transport pathways in mammary epithelial cells 
under physiological conditions. Further analysis of sCp and particularly GPI-
Cp, which has received little attention in the literature, will further elucidate 
their roles and their impact upon the copper and iron composition of milk. In 
particular, it will be beneficial to obtain antibodies specific to apo and holo-Cp 
and also GPI-Cp to identify any potential differences in localisation. It would 
also be worthwhile attempting to isolate GPI-Cp in its non-reduced form 
enabling analysis of the apo and holo forms of this protein. Further mRNA 
analysis by qRT-PCR using specific primers to sCp and GPI-Cp would 
 188 
divulge more information on the relative levels of the two forms of Cp. This 
may help elucidate the importance of GPI-Cp in mammary epithelial cells, to 
determine whether it plays key roles in copper and iron homeostasis or 
merely a supporting role to sCp. 
 
Further analysis identifying the pathways influenced by ATP7A that initiate 
up-regulation of CTR1, ATP7B and Cp should also be performed. It would be 
interesting to see whether these pathways affect other aspects of cellular 
function outside of the copper transport system. In addition it would also be 
interesting to silence ATP7A to determine whether it imposes an inhibitory 
action upon these three genes. 
 
If it is confirmed that ATP7A initiates transcriptional pathways by some 
mechanism, it would be interesting to see if this effect could be replicated in 
other mammary and non-mammary gland cells lines, to determine whether 
these effects are mammary epithelial cell-specific or universal among all 
cells. If these effects occur in other cell lines it would be informative to 
increase the expression of other copper transporting genes, in particular 
ATP7B which has a similar sequence and structure to ATP7A, and determine 
whether overexpression of these genes also influence transcription. 
 
The findings from this research have underlined the importance of copper 
transporting proteins in maintaining cellular copper homoeostasis and 
provided insights into their role in regulating copper delivery into milk. It was 
shown that during lactation there is an emphasis on enhancing the 
movement of copper into the milk by increasing uptake by CTR1 and efflux 
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by Cp, while ATP7A and MT may have protective roles associated with 
preventing the secretion of toxic copper levels into the milk. 
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